Vertex Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Vertex Pharmaceuticals Inc together

Penke I guess you are interested in Vertex Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vertex Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vertex Pharmaceuticals Inc

I send you an email if I find something interesting about Vertex Pharmaceuticals Inc.

Quick analysis of Vertex Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc? (30 sec.)

How much money do you get?

$0.28

When do you have the money?

1 year

How often do you get paid?

32.5%

What is your share worth?

Current worth

$67.38

Expected worth in 1 year

$81.32

How sure are you?

82.5%

+ What do you gain per year?

Total Gains per Share

$14.22

Return On Investment

3.6%

For what price can you sell your share?

Current Price per Share

$399.92

Expected price per share

$346.29 - $437.00

How sure are you?

50%

1. Valuation of Vertex Pharmaceuticals Inc (5 min.)

Live pricePrice per Share (EOD)

$399.92

Book Value per Share

$67.38

Intrinsic Value Per Share

$-13.63 - $113.08

Total Value Per Share

$53.76 - $180.47

My calculation of the intrinsic value of Vertex Pharmaceuticals Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($1.45) 3Y: ($3.08) TTM: ($3.15)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.01) 3Y: ($-0.10) TTM: ($-0.89)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$4.63	$12.20	$4.18 - $12.49
2	$7.50	$24.21	$2.53 - $12.65
3	$8.80	$36.00	$0.89 - $12.81
4	$8.69	$47.60	$-0.76 - $12.97
5	$7.34	$59.00	$-2.40 - $13.13
6	$4.87	$70.21	$-4.04 - $13.29
7	$1.43	$81.21	$-5.69 - $13.45
8	$-2.87	$92.03	$-7.33 - $13.61
9	$-7.92	$102.65	$-8.97 - $13.77
10	$-13.63	$113.08	$-10.62 - $13.93

2. Growth of Vertex Pharmaceuticals Inc (5 min.)

Is Vertex Pharmaceuticals Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$17.5b	$12.4b	$3.5b	22.2%

How much money is Vertex Pharmaceuticals Inc making?

	Current year	Previous year	Grow	Grow %
Making money	$904.9m	$830.5m	$74.4m	8.2%
Net Profit Margin	36.6%	37.2%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Vertex Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#4 / 1009

Most Revenue
#9 / 1009

Most Profit
#6 / 1009

Most Efficient
#39 / 1009

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc? (5 min.)

Welcome investor! Vertex Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Vertex Pharmaceuticals Inc.

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc?

First you should know what it really means to hold a share of Vertex Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Vertex Pharmaceuticals Inc is $399.92. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Vertex Pharmaceuticals Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vertex Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $67.38. Based on the TTM, the Book Value Change Per Share is $3.48 per quarter. Based on the YOY, the Book Value Change Per Share is $3.59 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.07 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Vertex Pharmaceuticals Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	3.71	0.9%	3.47	0.9%	3.20	0.8%	2.53	0.6%	1.35	0.3%
Usd Book Value Change Per Share	4.02	1.0%	3.48	0.9%	3.59	0.9%	2.52	0.6%	1.55	0.4%
Usd Dividend Per Share	0.00	0.0%	0.07	0.0%	0.07	0.0%	0.07	0.0%	0.04	0.0%
Usd Total Gains Per Share	4.02	1.0%	3.55	0.9%	3.66	0.9%	2.59	0.6%	1.59	0.4%
Usd Price Per Share	406.89	-	355.40	-	280.27	-	257.63	-	189.46	-
Price to Earnings Ratio	27.39	-	25.90	-	21.94	-	42.44	-	23.30	-
Price-to-Total Gains Ratio	101.24	-	107.42	-	77.43	-	120.95	-	128.31	-
Price to Book Ratio	6.04	-	5.78	-	5.87	-	7.12	-	13.41	-
Price-to-Total Gains Ratio	101.24	-	107.42	-	77.43	-	120.95	-	128.31	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	399.92
Number of shares	2

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.07	0.07
Usd Book Value Change Per Share	3.48	2.52
Usd Total Gains Per Share	3.55	2.59
Gains per Quarter (2 shares)	7.11	5.17
Gains per Year (2 shares)	28.44	20.69

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	1	28	18	1	20	11
2	1	56	46	1	40	32
3	2	84	74	2	60	53
4	2	111	102	2	81	74
5	3	139	130	3	101	95
6	3	167	158	3	121	116
7	4	195	186	4	141	137
8	5	223	214	5	161	158
9	5	251	242	5	181	179
10	6	279	270	6	201	200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	4.0	0.0	0.0	100.0%	12.0	0.0	0.0	100.0%	20.0	0.0	0.0	100.0%	28.0	12.0	0.0	70.0%	36.0	94.0	0.0	27.7%
Book Value Change Per Share	4.0	0.0	0.0	100.0%	12.0	0.0	0.0	100.0%	20.0	0.0	0.0	100.0%	33.0	7.0	0.0	82.5%	65.0	64.0	1.0	50.0%
Dividend per Share	2.0	0.0	2.0	50.0%	6.0	0.0	6.0	50.0%	10.0	0.0	10.0	50.0%	13.0	0.0	27.0	32.5%	13.0	0.0	117.0	10.0%
Total Gains per Share	4.0	0.0	0.0	100.0%	12.0	0.0	0.0	100.0%	20.0	0.0	0.0	100.0%	33.0	7.0	0.0	82.5%	65.0	64.0	1.0	50.0%

Fundamentals of Vertex Pharmaceuticals Inc

About Vertex Pharmaceuticals Inc

https://www.vrtx.com
Biotechnology
5400
50 Northern Avenue, Boston, MA, United States, 02210
Google Maps Bing Maps

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 21:49:06.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Vertex Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Vertex Pharmaceuticals Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
A Net Profit Margin of 38.5% means that $0.38 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vertex Pharmaceuticals Inc:

The MRQ is 38.5%. The company is making a huge profit. +2
The TTM is 36.6%. The company is making a huge profit. +2

Trends

Current period		Compared to		+/-
MRQ	38.5%	TTM	36.6%	+1.9%
TTM	36.6%	YOY	37.2%	-0.6%
TTM	36.6%	5Y	34.9%	+1.6%
5Y	34.9%	10Y	3.2%	+31.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	38.5%	-200.1%	+238.6%
TTM	36.6%	-216.8%	+253.4%
YOY	37.2%	-288.3%	+325.5%
5Y	34.9%	-449.1%	+484.0%
10Y	3.2%	-605.5%	+608.7%

Measures how much net profit Vertex Pharmaceuticals Inc earns for each $1 of revenue.

Revenue is the amount of profit Vertex Pharmaceuticals Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Vertex Pharmaceuticals Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Vertex Pharmaceuticals Inc makes more profit. This shows the investor how efficiently Vertex Pharmaceuticals Inc is operating in general and compared to other companies in the same industry. Vertex Pharmaceuticals Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Vertex Pharmaceuticals Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Vertex Pharmaceuticals Inc is 0.38. This means that Vertex Pharmaceuticals Inc earned $0.38 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -200.1%.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Vertex Pharmaceuticals Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Vertex Pharmaceuticals Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Vertex Pharmaceuticals Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Vertex Pharmaceuticals Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Vertex Pharmaceuticals Inc = 968,800
Total revenue MRQ Vertex Pharmaceuticals Inc = 2,517,700
$968,800 / $2,517,700 = 0.38 or 38.5%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Vertex Pharmaceuticals Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
4.3% Return on Assets means that Vertex Pharmaceuticals Inc generated $0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vertex Pharmaceuticals Inc:

The MRQ is 4.3%. Using its assets, the company is less efficient in making profit.
The TTM is 4.3%. Using its assets, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	4.3%	TTM	4.3%	0.0%
TTM	4.3%	YOY	5.2%	-0.9%
TTM	4.3%	5Y	4.9%	-0.6%
5Y	4.9%	10Y	2.1%	+2.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	4.3%	-13.3%	+17.6%
TTM	4.3%	-12.8%	+17.1%
YOY	5.2%	-11.7%	+16.9%
5Y	4.9%	-13.9%	+18.8%
10Y	2.1%	-15.7%	+17.8%

Shows how efficient Vertex Pharmaceuticals Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Vertex Pharmaceuticals Inc is using its resources to generate profit. If the return on assets (4.3%) from Vertex Pharmaceuticals Inc are higher than the Biotechnology mean (-13.3%) that means Vertex Pharmaceuticals Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Vertex Pharmaceuticals Inc is 4.3%. This means the company generated $0.04 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Vertex Pharmaceuticals Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Vertex Pharmaceuticals Inc = 968,800
Total assets MRQ (balance sheet) from Vertex Pharmaceuticals Inc = 22,730,200
968,800 / 22,730,200 = 0.04 or 4.3%

ROA is an important ratio as it will tell you how effectively Vertex Pharmaceuticals Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Vertex Pharmaceuticals Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
5.5% Return on Equity means Vertex Pharmaceuticals Inc generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vertex Pharmaceuticals Inc:

The MRQ is 5.5%. Using its investors money, the company is less efficient in making profit.
The TTM is 5.6%. Using its investors money, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	5.5%	TTM	5.6%	-0.1%
TTM	5.6%	YOY	6.7%	-1.1%
TTM	5.6%	5Y	6.6%	-0.9%
5Y	6.6%	10Y	1.9%	+4.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	5.5%	-16.9%	+22.4%
TTM	5.6%	-16.1%	+21.7%
YOY	6.7%	-15.1%	+21.8%
5Y	6.6%	-19.3%	+25.9%
10Y	1.9%	-20.2%	+22.1%

Shows how efficient Vertex Pharmaceuticals Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Vertex Pharmaceuticals Inc is 5.5%. This means Vertex Pharmaceuticals Inc generated $0.06 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if Vertex Pharmaceuticals Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Vertex Pharmaceuticals Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Vertex Pharmaceuticals Inc = 968,800
Shareholders equity (balance sheet) MRQ Vertex Pharmaceuticals Inc = 17,580,400
968,800 / 17,580,400 = 0.06 or 5.5%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Vertex Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Vertex Pharmaceuticals Inc is operating .

Measures how much profit Vertex Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
An Operating Margin of 38.1% means the company generated $0.38 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vertex Pharmaceuticals Inc:

The MRQ is 38.1%. The company is operating very efficient. +2
The TTM is 38.5%. The company is operating very efficient. +2

Trends

Current period		Compared to		+/-
MRQ	38.1%	TTM	38.5%	-0.4%
TTM	38.5%	YOY	48.3%	-9.8%
TTM	38.5%	5Y	40.3%	-1.9%
5Y	40.3%	10Y	3.1%	+37.3%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	38.1%	-296.2%	+334.3%
TTM	38.5%	-232.5%	+271.0%
YOY	48.3%	-298.2%	+346.5%
5Y	40.3%	-492.1%	+532.4%
10Y	3.1%	-632.4%	+635.5%

Measures how efficient Vertex Pharmaceuticals Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Vertex Pharmaceuticals Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Vertex Pharmaceuticals Inc is 38.1%. This means that Vertex Pharmaceuticals Inc earned $0.38 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -296.2%.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Vertex Pharmaceuticals Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Vertex Pharmaceuticals Inc = 958,800
Total revenue MRQ Vertex Pharmaceuticals Inc = 2,517,700
$958,800 / $2,517,700 = 0.38 or 38.1%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Vertex Pharmaceuticals Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.62 means that the operating costs are $0.62 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vertex Pharmaceuticals Inc:

The MRQ is 0.619. The company is efficient in keeping operating costs low. +1
The TTM is 0.563. The company is very efficient in keeping operating costs low. +2

Trends

Current period		Compared to		+/-
MRQ	0.619	TTM	0.563	+0.056
TTM	0.563	YOY	0.511	+0.052
TTM	0.563	5Y	0.594	-0.032
5Y	0.594	10Y	0.944	-0.349

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.619	3.231	-2.612
TTM	0.563	3.310	-2.747
YOY	0.511	3.890	-3.379
5Y	0.594	5.739	-5.145
10Y	0.944	7.876	-6.932

Measures how efficient Vertex Pharmaceuticals Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Vertex Pharmaceuticals Inc is 61.9%. This means that Vertex Pharmaceuticals Inc earned $0.62 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.23.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Vertex Pharmaceuticals Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(368,000 +1,190,900) \ 2,517,700 = 0.62

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Vertex Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Vertex Pharmaceuticals Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 3.99 means the company has $3.99 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vertex Pharmaceuticals Inc:

The MRQ is 3.987. The company is very able to pay all its short-term debts. +2
The TTM is 4.123. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	3.987	TTM	4.123	-0.136
TTM	4.123	YOY	4.996	-0.872
TTM	4.123	5Y	4.543	-0.419
5Y	4.543	10Y	14.561	-10.018

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	3.987	3.890	+0.097
TTM	4.123	4.173	-0.050
YOY	4.996	5.344	-0.348
5Y	4.543	6.126	-1.583
10Y	14.561	6.448	+8.113

Measures if Vertex Pharmaceuticals Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Vertex Pharmaceuticals Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Vertex Pharmaceuticals Inc is 3.99. This means Vertex Pharmaceuticals Inc has $3.99 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.89.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Vertex Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
14,144,200 \ 3,547,400) = 3.99

The current ratio measures if Vertex Pharmaceuticals Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Vertex Pharmaceuticals Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Vertex Pharmaceuticals Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Vertex Pharmaceuticals Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Vertex Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
A Quick Ratio of 3.84 means the company can pay off $3.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vertex Pharmaceuticals Inc:

The MRQ is 3.843. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 5.598. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	3.843	TTM	5.598	-1.754
TTM	5.598	YOY	5.058	+0.540
TTM	5.598	5Y	5.043	+0.555
5Y	5.043	10Y	16.562	-11.519

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	3.843	3.514	+0.329
TTM	5.598	3.998	+1.600
YOY	5.058	5.380	-0.322
5Y	5.043	6.105	-1.062
10Y	16.562	6.404	+10.158

Measures if Vertex Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Vertex Pharmaceuticals Inc can pay off its short term debts. This shows if Vertex Pharmaceuticals Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Vertex Pharmaceuticals Inc is 3.84. This means that Vertex Pharmaceuticals Inc can pay off $3.84 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.51.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Vertex Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Vertex Pharmaceuticals Inc: (11,221,500 + 849,200 +1,563,400) / 3,547,400 = 3.84

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Vertex Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Vertex Pharmaceuticals Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Vertex Pharmaceuticals Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.23 means that Vertex Pharmaceuticals Inc assets are financed with 22.7% credit (debt) and the remaining percentage (100% - 22.7%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Vertex Pharmaceuticals Inc:

The MRQ is 0.227. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.236. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.227	TTM	0.236	-0.010
TTM	0.236	YOY	0.231	+0.006
TTM	0.236	5Y	0.254	-0.017
5Y	0.254	10Y	0.378	-0.124

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.227	0.339	-0.112
TTM	0.236	0.336	-0.100
YOY	0.231	0.271	-0.040
5Y	0.254	0.366	-0.112
10Y	0.378	0.389	-0.011

Measures how much % of Vertex Pharmaceuticals Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Vertex Pharmaceuticals Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Vertex Pharmaceuticals Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Vertex Pharmaceuticals Inc is 0.23. This means means that Vertex Pharmaceuticals Inc is financed with 22.7% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 389.0%.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Vertex Pharmaceuticals Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Vertex Pharmaceuticals Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
5,149,800 \ 22,730,200 = 22.7% or 0.23.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Vertex Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 29.3% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vertex Pharmaceuticals Inc:

The MRQ is 0.293. The company is very able to pay all its debts with equity. +2
The TTM is 0.310. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.293	TTM	0.310	-0.017
TTM	0.310	YOY	0.300	+0.010
TTM	0.310	5Y	0.341	-0.031
5Y	0.341	10Y	0.664	-0.324

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.293	0.388	-0.095
TTM	0.310	0.402	-0.092
YOY	0.300	0.335	-0.035
5Y	0.341	0.426	-0.085
10Y	0.664	0.461	+0.203

Measures if Vertex Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Vertex Pharmaceuticals Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Vertex Pharmaceuticals Inc is 0.29. This means that Vertex Pharmaceuticals Inc can pay off $0.29 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Vertex Pharmaceuticals Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
5,149,800 \ 17,580,400 = 0.29 or 29.3%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Vertex Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vertex Pharmaceuticals Inc generates.

Above 15 is considered overpriced but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
A PE ratio of 27.39 means the investor is paying $27.39 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vertex Pharmaceuticals Inc:

The EOD is 26.925. Based on the earnings, the company is overpriced. -1
The MRQ is 27.394. Based on the earnings, the company is overpriced. -1
The TTM is 25.898. Based on the earnings, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	26.925	MRQ	27.394	-0.469
MRQ	27.394	TTM	25.898	+1.496
TTM	25.898	YOY	21.937	+3.962
TTM	25.898	5Y	42.435	-16.537
5Y	42.435	10Y	23.301	+19.134

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	26.925	-2.264	+29.189
MRQ	27.394	-2.629	+30.023
TTM	25.898	-2.680	+28.578
YOY	21.937	-4.145	+26.082
5Y	42.435	-6.257	+48.692
10Y	23.301	-6.254	+29.555

Measures how much money you pay for each share for every $1 in earnings Vertex Pharmaceuticals Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Vertex Pharmaceuticals Inc is 27.39. This means the investor is paying $27.39 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.63.
What is the trend?
The trend is important because it shows you how Vertex Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vertex Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vertex Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Vertex Pharmaceuticals Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 260,900 = EPS
PE ratio MRQ = 27.39

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vertex Pharmaceuticals Inc:

The EOD is 220.125. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is 223.961. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is 71.908. Based on how much money comes from the company's main activities, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	220.125	MRQ	223.961	-3.836
MRQ	223.961	TTM	71.908	+152.054
TTM	71.908	YOY	18.623	+53.284
TTM	71.908	5Y	29.358	+42.549
5Y	29.358	10Y	30.927	-1.568

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	220.125	-2.973	+223.098
MRQ	223.961	-3.333	+227.294
TTM	71.908	-3.553	+75.461
YOY	18.623	-5.605	+24.228
5Y	29.358	-8.376	+37.734
10Y	30.927	-8.865	+39.792

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Vertex Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 6.04 means the investor is paying $6.04 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vertex Pharmaceuticals Inc:

The EOD is 5.935. Based on the equity, the company is overpriced. -1
The MRQ is 6.038. Based on the equity, the company is overpriced. -1
The TTM is 5.783. Based on the equity, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	5.935	MRQ	6.038	-0.103
MRQ	6.038	TTM	5.783	+0.255
TTM	5.783	YOY	5.866	-0.082
TTM	5.783	5Y	7.119	-1.336
5Y	7.119	10Y	13.409	-6.290

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	5.935	1.896	+4.039
MRQ	6.038	2.115	+3.923
TTM	5.783	2.093	+3.690
YOY	5.866	2.884	+2.982
5Y	7.119	3.542	+3.577
10Y	13.409	3.916	+9.493

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vertex Pharmaceuticals Inc.

3.1. Institutions holding Vertex Pharmaceuticals Inc

Institutions are holding 97.341% of the shares of Vertex Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Vanguard Group Inc	8.6212	0.1981	22282180	298824	1.3593
2023-12-31	BlackRock Inc	8.466	0.227	21881203	-704023	-3.1172
2023-12-31	Capital World Investors	8.4368	1.578	21805770	3824103	21.2667
2023-12-31	FMR Inc	5.0219	0.4057	12979511	-1380926	-9.6162
2023-12-31	State Street Corporation	4.6753	0.2392	12083818	44272	0.3677
2023-12-31	AllianceBernstein L.P.	2.7237	1.1022	7039738	-486718	-6.4668
2023-12-31	T. Rowe Price Associates, Inc.	2.2779	0.3219	5887412	-962654	-14.0532
2023-12-31	Geode Capital Management, LLC	2.1951	0.2409	5673419	77445	1.3839
2023-12-31	JPMorgan Chase & Co	2.1761	0.2199	5624265	-481587	-7.8873
2023-12-31	Wellington Management Company LLP	2.023	0.3966	5228538	-1297313	-19.8796
2023-12-31	Jennison Associates LLC	1.5263	1.1962	3944913	147248	3.8773
2023-12-31	Massachusetts Financial Services Company	1.4029	0.4765	3625802	-265992	-6.8347
2023-12-31	Capital Research Global Investors	1.3804	0.3571	3567664	195080	5.7843
2023-12-31	Loomis, Sayles & Company LP	1.2129	1.9533	3134852	-28616	-0.9046
2023-12-31	NORGES BANK	1.1771	0.2163	3042288	590767	24.098
2023-12-31	Morgan Stanley - Brokerage Accounts	1.1532	0.1069	2980455	110354	3.845
2023-12-31	Goldman Sachs Group Inc	1.1491	0.1085	2969868	1274543	75.1799
2023-12-31	Amundi	1.0517	0.5148	2718117	774696	39.8625
2023-12-31	Northern Trust Corp	1.0371	0.1974	2680597	-132966	-4.7259
2023-12-31	UBS Asset Mgmt Americas Inc	1.0059	0.4162	2599904	-173895	-6.2692
Total		58.7136	10.4727	151750314	+1422642	+0.9%

3.2. Funds holding Vertex Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-02-29	Vanguard Total Stock Mkt Idx Inv	3.1282	0.2194	8085053	-17521	-0.2162
2023-12-31	American Funds Growth Fund of Amer A	2.8714	1.2127	7421474	1353211	22.2998
2023-12-31	Capital Group Growth Fnd of Amer Comp	2.8714	1.2127	7421474	1353211	22.2998
2024-02-29	Vanguard Institutional 500 Index Trust	2.4893	0.2531	6433784	65246	1.0245
2024-03-28	Invesco QQQ Trust	1.8734	0.7796	4841880	5810	0.1201
2023-12-31	American Funds American Balanced A	1.3499	0.6718	3488862	967187	38.3549
2024-02-29	Fidelity Contrafund	1.34	1.101	3463227	-84900	-2.3928
2023-12-31	American Funds New Perspective A	1.2416	1.0306	3209011	160466	5.2637
2023-12-31	Capital Group New Perspective Comp	1.2416	1.0306	3209011	160466	5.2637
2024-03-28	SPDR® S&P 500 ETF Trust	1.2117	0.2436	3131738	18360	0.5897
2024-02-29	Fidelity 500 Index	1.1957	0.2524	3090507	31098	1.0165
2024-03-28	iShares Core S&P 500 ETF	1.0335	0.2438	2671115	19584	0.7386
2023-12-31	American Funds Capital World Gr&Inc A	0.9893	0.885	2556814	445119	21.0788
2023-12-31	Capital Group World Growth & Inc Cmp	0.9893	0.885	2556814	445119	21.0788
2024-02-29	Vanguard Growth Index Investor	0.9267	0.4534	2395219	20658	0.87
2024-03-28	Health Care Select Sector SPDR® ETF	0.7518	1.9672	1943184	-3132	-0.1609
2023-12-31	Capital Group Wash Mutual Invtrs Comp	0.739	0.4621	1910043	120000	6.7037
2023-12-31	American Funds Washington Mutual A	0.739	0.4621	1910043	120000	6.7037
2023-12-31	Vanguard Health Care Inv	0.7191	1.6292	1858518	-840441	-31.1395
2023-12-31	MFS Growth Equity	0.711	1.8734	1837669	18812	1.0343
Total		28.4129	16.8687	73435440	+4358353	+5.9%

3.3. Insider Transactions

Insiders are holding 0.113% of the shares of Vertex Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price
2024-02-26	Ourania Tatsis	SELL	354	425.7
2024-02-20	Ourania Tatsis	SELL	480	420.79
2024-02-12	Amit Sachdev	SELL	3222	420.24
2024-02-12	Jeffrey M Leiden	SELL	2656	419.51
2024-02-12	Kristen Ambrose	SELL	1374	420.24
2024-02-12	Stuart A Arbuckle	SELL	4295	420.24
2024-01-08	Jeffrey M Leiden	SELL	6648	419.07
2023-11-06	Bruce I Sachs	SELL	11250	385
2023-10-31	Carmen Bozic	SELL	5651	355.92
2023-10-17	Carmen Bozic	SELL	5651	373.25
2023-10-17	Sangeeta N Bhatia	SELL	243	375
2023-10-16	Jeffrey M Leiden	SELL	12962	374
2023-10-06	Sangeeta N Bhatia	SELL	242	360
2023-10-03	Carmen Bozic	SELL	5651	345.28
2023-10-02	Jonathan Biller	SELL	610	346.76
2023-09-19	Carmen Bozic	SELL	5651	351
2023-08-23	Ourania Tatsis	SELL	2500	355
2023-08-09	Sangeeta N Bhatia	SELL	242	345.51
2023-08-09	David Altshuler	SELL	63	345.51

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vertex Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	4.019	3.484	+15%	3.593	+12%	2.516	+60%	1.553	+159%
Book Value Per Share	-	-	67.384	61.401	+10%	47.997	+40%	39.041	+73%	22.604	+198%
Current Ratio	-	-	3.987	4.123	-3%	4.996	-20%	4.543	-12%	14.561	-73%
Debt To Asset Ratio	-	-	0.227	0.236	-4%	0.231	-2%	0.254	-11%	0.378	-40%
Debt To Equity Ratio	-	-	0.293	0.310	-5%	0.300	-2%	0.341	-14%	0.664	-56%
Dividend Per Share	-	-	-	0.071	-100%	0.068	-100%	0.071	-100%	0.038	-100%
Eps	-	-	3.713	3.473	+7%	3.203	+16%	2.526	+47%	1.354	+174%
Free Cash Flow Per Share	-	-	0.454	3.147	-86%	3.785	-88%	2.704	-83%	1.455	-69%
Free Cash Flow To Equity Per Share	-	-	-0.005	2.608	-100%	3.720	-100%	2.228	-100%	1.295	-100%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	113.084	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-13.626	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	12.205	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	4.628	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	36.005	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	8.798	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	59.003	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	7.335	-	-	-	-	-	-	-	-
Market Cap	103362926479.360	-3%	106157600593.110	92607182310.300	+15%	72663546079.440	+46%	67205007842.788	+58%	49289757211.282	+115%
Net Profit Margin	-	-	0.385	0.366	+5%	0.372	+4%	0.349	+10%	0.032	+1114%
Operating Margin	-	-	0.381	0.385	-1%	0.483	-21%	0.403	-6%	0.031	+1146%
Operating Ratio	-	-	0.619	0.563	+10%	0.511	+21%	0.594	+4%	0.944	-34%
Pb Ratio	5.935	-2%	6.038	5.783	+4%	5.866	+3%	7.119	-15%	13.409	-55%
Pe Ratio	26.925	-2%	27.394	25.898	+6%	21.937	+25%	42.435	-35%	23.301	+18%
Price Per Share	399.920	-2%	406.890	355.403	+14%	280.270	+45%	257.631	+58%	189.461	+115%
Price To Free Cash Flow Ratio	220.125	-2%	223.961	71.908	+211%	18.623	+1103%	29.358	+663%	30.927	+624%
Price To Total Gains Ratio	99.504	-2%	101.238	107.425	-6%	77.425	+31%	120.948	-16%	128.315	-21%
Quick Ratio	-	-	3.843	5.598	-31%	5.058	-24%	5.043	-24%	16.562	-77%
Return On Assets	-	-	0.043	0.043	-1%	0.052	-17%	0.049	-13%	0.021	+106%
Return On Equity	-	-	0.055	0.056	-2%	0.067	-18%	0.066	-16%	0.019	+196%
Total Gains Per Share	-	-	4.019	3.555	+13%	3.661	+10%	2.587	+55%	1.591	+153%
Usd Book Value	-	-	17580400000.000	15998925000.000	+10%	12445700000.000	+41%	10175947900.000	+73%	5885985050.000	+199%
Usd Book Value Change Per Share	-	-	4.019	3.484	+15%	3.593	+12%	2.516	+60%	1.553	+159%
Usd Book Value Per Share	-	-	67.384	61.401	+10%	47.997	+40%	39.041	+73%	22.604	+198%
Usd Dividend Per Share	-	-	-	0.071	-100%	0.068	-100%	0.071	-100%	0.038	-100%
Usd Eps	-	-	3.713	3.473	+7%	3.203	+16%	2.526	+47%	1.354	+174%
Usd Free Cash Flow	-	-	118500000.000	819725000.000	-86%	981300000.000	-88%	705008949.900	-83%	379123874.925	-69%
Usd Free Cash Flow Per Share	-	-	0.454	3.147	-86%	3.785	-88%	2.704	-83%	1.455	-69%
Usd Free Cash Flow To Equity Per Share	-	-	-0.005	2.608	-100%	3.720	-100%	2.228	-100%	1.295	-100%
Usd Market Cap	103362926479.360	-3%	106157600593.110	92607182310.300	+15%	72663546079.440	+46%	67205007842.788	+58%	49289757211.282	+115%
Usd Price Per Share	399.920	-2%	406.890	355.403	+14%	280.270	+45%	257.631	+58%	189.461	+115%
Usd Profit	-	-	968800000.000	904900000.000	+7%	830500000.000	+17%	658607350.000	+47%	353020125.000	+174%
Usd Revenue	-	-	2517700000.000	2467300000.000	+2%	2232675000.000	+13%	1837142150.000	+37%	1139850500.000	+121%
Usd Total Gains Per Share	-	-	4.019	3.555	+13%	3.661	+10%	2.587	+55%	1.591	+153%
	EOD	+4 -4	MRQ	TTM	+17 -18	YOY	+18 -17	5Y	+19 -16	10Y	+22 -13

4.2. Fundamental Score

Let's check the fundamental score of Vertex Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	26.925
Price to Book Ratio (EOD)	Between	0-1	5.935
Net Profit Margin (MRQ)	Greater than	0	0.385
Operating Margin (MRQ)	Greater than	0	0.381
Quick Ratio (MRQ)	Greater than	1	3.843
Current Ratio (MRQ)	Greater than	1	3.987
Debt to Asset Ratio (MRQ)	Less than	1	0.227
Debt to Equity Ratio (MRQ)	Less than	1	0.293
Return on Equity (MRQ)	Greater than	0.15	0.055
Return on Assets (MRQ)	Greater than	0.05	0.043
Total			6/10 (60.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Vertex Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	43.237
Ma 20	Greater than	Ma 50	404.729
Ma 50	Greater than	Ma 100	413.251
Ma 100	Greater than	Ma 200	409.604
Open	Greater than	Close	397.730
Total			2/5 (40.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	22,730,200
Total Liabilities	5,149,800
Total Stockholder Equity	17,580,400

	As reported
Total Liabilities	5,149,800
Total Stockholder Equity	+ 17,580,400
Total Assets	= 22,730,200

Assets

Total Assets	22,730,200
Total Current Assets	14,144,200
Long-term Assets	8,586,000

Total Current Assets

Total Current Assets (as reported)	14,144,200
Cash And Cash Equivalents	10,372,300
Short-term Investments	849,200
Net Receivables	1,563,400
Inventory	738,800
Other Current Assets	620,500
Total Current Assets (calculated)	14,144,200
+/-	0

Long-term Assets

Long-term Assets (as reported)	8,586,000
Property Plant Equipment	1,452,900
Goodwill	1,088,000
Long Term Investments	2,497,800
Intangible Assets	839,900
Long-term Assets Other	796,700
Long-term Assets (calculated)	6,675,300
+/-	1,910,700

Liabilities & Shareholders' Equity

Total Current Liabilities	3,547,400
Long-term Liabilities	1,602,400
Total Stockholder Equity	17,580,400

Total Current Liabilities

Total Current Liabilities (as reported)	3,547,400
Short-term Debt	83,700
Accounts payable	364,900
Other Current Liabilities	2,928,500
Total Current Liabilities (calculated)	3,377,100
+/-	170,300

Long-term Liabilities

Long-term Liabilities (as reported)	1,602,400
Capital Lease Obligations	808,400
Long-term Liabilities Other	196,300
Long-term Liabilities (calculated)	1,004,700
+/-	597,700

Total Stockholder Equity

Total Stockholder Equity (as reported)	17,580,400
Common Stock	2,600
Retained Earnings	10,142,400
Accumulated Other Comprehensive Income	-14,300
Other Stockholders Equity	7,449,700
Total Stockholder Equity (calculated)	17,580,400
+/-	0

Other

Capital Stock	2,600
Cash and Short Term Investments	11,221,500
Common Stock Shares Outstanding	260,900
Current Deferred Revenue	170,300
Liabilities and Stockholders Equity	22,730,200
Net Debt	-9,563,900
Net Invested Capital	17,580,400
Net Working Capital	10,596,800
Property Plant and Equipment Gross	2,641,800
Short Long Term Debt Total	808,400

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2003-12-31

2003-09-30

2003-06-30

2003-03-31

2002-12-31

2002-09-30

2002-06-30

2002-03-31

2001-12-31

2001-09-30

2001-06-30

2001-03-31

2000-12-31

2000-09-30

2000-06-30

2000-03-31

1999-12-31

1999-09-30

1999-06-30

1999-03-31

1998-12-31

1998-09-30

1998-06-30

1998-03-31

1997-12-31

1997-09-30

1997-06-30

1997-03-31

1996-12-31

1996-09-30

1996-06-30

1996-03-31

1995-12-31

1995-09-30

1995-06-30

1995-03-31

1994-12-31

1994-09-30

1994-06-30

1994-03-31

1993-12-31

1993-09-30

1993-06-30

1993-03-31

1992-12-31

1992-09-30

1992-06-30

1992-03-31

1991-12-31

1991-09-30

1991-06-30

1991-03-31

1990-12-31

1990-09-30

1990-06-30

1990-03-31

> Total Assets

0
0
0
9,200
0
7,300
32,400
57,100
55,500
54,500
52,900
51,000
48,700
51,600
50,800
61,000
113,900
110,400
106,700
116,200
111,800
106,100
98,300
99,000
90,300
73,700
143,500
143,500
289,600
300,700
298,700
295,600
283,300
274,900
277,900
266,300
249,700
238,600
224,800
232,400
396,931
428,322
774,563
772,881
769,544
766,834
922,370
925,131
925,131
860,474
831,069
815,720
840,306
787,456
742,676
724,411
669,188
624,051
574,362
545,453
484,229
596,903
550,575
548,998
524,658
625,478
902,111
921,579
835,095
761,070
655,148
601,477
889,505
970,805
1,067,554
980,479
1,565,883
1,439,876
1,573,491
1,955,488
1,770,302
1,654,202
1,888,829
1,725,446
1,538,487
1,763,100
2,091,998
2,204,280
2,345,843
2,604,856
2,718,823
2,759,288
2,392,234
2,584,329
2,582,755
2,319,041
2,197,108
2,117,820
2,406,086
2,336,309
2,165,827
2,374,073
2,433,993
2,497,045
2,487,906
2,548,982
2,604,838
2,893,785
2,946,703
3,285,594
3,198,325
3,546,014
3,952,974
4,335,386
4,620,840
6,245,898
6,543,114
7,033,471
7,514,553
8,318,465
8,893,201
10,216,367
11,301,633
11,751,808
12,115,059
12,221,686
12,618,745
13,432,500
14,256,100
15,582,200
16,706,400
18,150,900
18,974,200
20,349,200
21,726,200
22,730,200

22,730,200

21,726,200

20,349,200

18,974,200

18,150,900

16,706,400

15,582,200

14,256,100

13,432,500

12,618,745

12,221,686

12,115,059

11,751,808

11,301,633

10,216,367

8,893,201

8,318,465

7,514,553

7,033,471

6,543,114

6,245,898

4,620,840

4,335,386

3,952,974

3,546,014

3,198,325

3,285,594

2,946,703

2,893,785

2,604,838

2,548,982

2,487,906

2,497,045

2,433,993

2,374,073

2,165,827

2,336,309

2,406,086

2,117,820

2,197,108

2,319,041

2,582,755

2,584,329

2,392,234

2,759,288

2,718,823

2,604,856

2,345,843

2,204,280

2,091,998

1,763,100

1,538,487

1,725,446

1,888,829

1,654,202

1,770,302

1,955,488

1,573,491

1,439,876

1,565,883

980,479

1,067,554

970,805

889,505

601,477

655,148

761,070

835,095

921,579

902,111

625,478

524,658

548,998

550,575

596,903

484,229

545,453

574,362

624,051

669,188

724,411

742,676

787,456

840,306

815,720

831,069

860,474

925,131

922,370

766,834

769,544

772,881

774,563

428,322

396,931

232,400

224,800

238,600

249,700

266,300

277,900

274,900

283,300

295,600

298,700

300,700

289,600

143,500

73,700

90,300

99,000

98,300

106,100

111,800

116,200

106,700

110,400

113,900

61,000

50,800

51,600

48,700

51,000

52,900

54,500

55,500

57,100

32,400

7,300

9,200

> Total Current Assets

0
0
0
4,600
0
2,500
27,400
51,700
49,200
48,100
46,800
44,000
40,700
43,700
42,900
53,100
105,800
101,900
97,100
106,900
100,600
95,200
87,700
87,900
78,600
62,200
132,400
132,200
276,800
287,800
285,500
281,600
267,500
257,900
260,900
248,700
226,700
211,300
194,100
195,200
353,751
385,519
722,185
403,186
333,278
330,474
428,418
776,092
776,092
707,608
673,653
656,572
697,975
649,242
610,275
593,806
533,438
474,215
432,832
406,712
350,029
465,310
424,334
385,055
370,048
452,589
742,700
771,406
706,540
637,657
543,279
496,851
783,938
857,628
953,018
867,581
902,173
782,756
914,066
1,307,026
1,126,768
1,004,555
1,226,439
1,057,039
872,974
827,124
1,245,825
1,331,254
1,436,114
1,593,305
1,634,523
1,589,585
1,565,783
1,716,590
1,648,638
1,588,576
1,430,330
1,347,384
1,650,096
1,548,141
1,358,203
1,241,400
1,296,064
1,355,094
1,346,969
1,397,894
1,440,889
1,761,006
1,871,814
2,073,490
2,175,736
2,483,328
2,921,657
3,276,219
3,559,790
3,702,290
4,053,030
4,559,139
4,601,952
4,609,314
5,222,752
6,461,755
7,188,435
7,825,026
8,200,382
7,958,755
8,394,713
9,014,800
9,869,800
10,954,000
11,544,100
12,681,300
12,965,700
13,872,900
14,695,800
14,144,200

14,144,200

14,695,800

13,872,900

12,965,700

12,681,300

11,544,100

10,954,000

9,869,800

9,014,800

8,394,713

7,958,755

8,200,382

7,825,026

7,188,435

6,461,755

5,222,752

4,609,314

4,601,952

4,559,139

4,053,030

3,702,290

3,559,790

3,276,219

2,921,657

2,483,328

2,175,736

2,073,490

1,871,814

1,761,006

1,440,889

1,397,894

1,346,969

1,355,094

1,296,064

1,241,400

1,358,203

1,548,141

1,650,096

1,347,384

1,430,330

1,588,576

1,648,638

1,716,590

1,565,783

1,589,585

1,634,523

1,593,305

1,436,114

1,331,254

1,245,825

827,124

872,974

1,057,039

1,226,439

1,004,555

1,126,768

1,307,026

914,066

782,756

902,173

867,581

953,018

857,628

783,938

496,851

543,279

637,657

706,540

771,406

742,700

452,589

370,048

385,055

424,334

465,310

350,029

406,712

432,832

474,215

533,438

593,806

610,275

649,242

697,975

656,572

673,653

707,608

776,092

428,418

330,474

333,278

403,186

722,185

385,519

353,751

195,200

194,100

211,300

226,700

248,700

260,900

257,900

267,500

281,600

285,500

287,800

276,800

132,200

132,400

62,200

78,600

87,900

87,700

95,200

100,600

106,900

97,100

101,900

105,800

53,100

42,900

43,700

40,700

44,000

46,800

48,100

49,200

51,700

27,400

2,500

4,600

Cash And Cash Equivalents

0
0
0
4,400
0
2,300
7,400
27,600
24,800
16,300
22,700
11,600
15,000
6,500
15,000
28,600
54,300
21,300
48,500
71,600
51,400
44,100
39,400
28,400
20,200
9,300
39,100
34,900
84,900
188,600
177,200
71,500
58,400
36,300
49,700
24,200
19,800
11,200
22,400
31,500
191,750
183,208
471,429
322,090
222,662
168,527
195,951
189,205
189,205
125,268
103,594
108,098
180,773
133,410
77,449
98,159
53,007
63,692
37,037
55,006
37,371
194,695
101,619
78,045
81,827
41,430
483,431
213,171
354,328
168,718
253,979
355,663
490,696
549,632
542,876
389,115
602,199
408,949
559,133
446,658
396,547
337,608
569,901
243,197
446,536
458,195
542,545
475,320
267,923
454,061
436,886
489,407
379,099
531,247
583,181
569,299
424,045
420,558
718,563
625,259
664,879
870,543
756,250
714,768
604,245
605,866
719,692
1,183,945
1,003,679
1,223,130
1,384,966
1,665,412
1,995,893
2,145,359
2,478,302
2,650,134
2,893,885
3,294,684
3,397,941
3,109,322
3,593,412
4,831,332
5,358,087
5,988,187
6,304,330
6,063,678
6,275,698
6,795,000
7,600,100
8,702,200
9,171,500
10,504,000
9,289,900
10,151,100
11,110,200
10,372,300

10,372,300

11,110,200

10,151,100

9,289,900

10,504,000

9,171,500

8,702,200

7,600,100

6,795,000

6,275,698

6,063,678

6,304,330

5,988,187

5,358,087

4,831,332

3,593,412

3,109,322

3,397,941

3,294,684

2,893,885

2,650,134

2,478,302

2,145,359

1,995,893

1,665,412

1,384,966

1,223,130

1,003,679

1,183,945

719,692

605,866

604,245

714,768

756,250

870,543

664,879

625,259

718,563

420,558

424,045

569,299

583,181

531,247

379,099

489,407

436,886

454,061

267,923

475,320

542,545

458,195

446,536

243,197

569,901

337,608

396,547

446,658

559,133

408,949

602,199

389,115

542,876

549,632

490,696

355,663

253,979

168,718

354,328

213,171

483,431

41,430

81,827

78,045

101,619

194,695

37,371

55,006

37,037

63,692

53,007

98,159

77,449

133,410

180,773

108,098

103,594

125,268

189,205

195,951

168,527

222,662

322,090

471,429

183,208

191,750

31,500

22,400

11,200

19,800

24,200

49,700

36,300

58,400

71,500

177,200

188,600

84,900

34,900

39,100

9,300

20,200

28,400

39,400

44,100

51,400

71,600

48,500

21,300

54,300

28,600

15,000

6,500

15,000

11,600

22,700

16,300

24,800

27,600

7,400

2,300

4,400

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
165,700
0
155,498
195,177
241,918
66,509
100,674
151,501
185,915
553,997
553,997
554,577
547,760
526,886
499,316
499,986
518,155
485,005
467,567
396,676
381,390
337,314
296,961
251,911
297,546
283,112
257,632
220,911
211,324
491,455
300,812
424,249
248,571
105,208
258,947
282,430
377,191
442,986
266,987
345,415
297,477
838,255
696,136
641,537
633,110
788,214
376,916
135,296
116,140
493,602
712,944
769,273
861,656
831,808
860,255
899,449
839,469
895,777
900,155
798,603
759,174
761,847
516,255
145,907
249,580
327,694
421,373
465,570
408,749
250,612
405,103
445,520
427,282
423,254
481,124
622,396
577,583
518,108
584,150
656,538
598,390
698,972
596,984
619,437
792,971
670,710
619,638
644,315
685,187
729,900
638,000
551,200
599,200
274,500
1,124,200
11,236,300
11,928,200
849,200

849,200

11,928,200

11,236,300

1,124,200

274,500

599,200

551,200

638,000

729,900

685,187

644,315

619,638

670,710

792,971

619,437

596,984

698,972

598,390

656,538

584,150

518,108

577,583

622,396

481,124

423,254

427,282

445,520

405,103

250,612

408,749

465,570

421,373

327,694

249,580

145,907

516,255

761,847

759,174

798,603

900,155

895,777

839,469

899,449

860,255

831,808

861,656

769,273

712,944

493,602

116,140

135,296

376,916

788,214

633,110

641,537

696,136

838,255

297,477

345,415

266,987

442,986

377,191

282,430

258,947

105,208

248,571

424,249

300,812

491,455

211,324

220,911

257,632

283,112

297,546

251,911

296,961

337,314

381,390

396,676

467,567

485,005

518,155

499,986

499,316

526,886

547,760

554,577

553,997

185,915

151,501

100,674

66,509

241,918

195,177

155,498

165,700

Net Receivables

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,800
5,900
4,506
5,434
7,087
12,262
7,615
8,414
35,925
20,265
20,265
18,056
13,100
13,200
11,925
9,720
7,850
7,324
7,937
9,939
8,480
11,891
10,866
13,941
20,764
20,595
23,779
183,668
42,614
62,923
44,099
37,189
34,658
31,320
24,825
15,365
21,966
23,489
16,702
14,762
32,783
9,601
7,876
3,548
4,964
12,529
5,594
96,016
445,661
183,135
232,228
185,618
139,629
143,250
194,054
164,866
120,281
85,517
59,858
81,842
114,308
72,994
80,332
94,519
165,272
177,639
181,878
189,356
182,229
201,083
207,955
247,949
263,493
281,343
327,294
393,439
379,755
409,688
438,297
464,900
443,315
633,518
845,269
791,768
791,917
885,352
977,551
929,142
1,100,372
1,136,800
1,292,800
1,332,900
1,385,200
1,442,200
1,547,800
1,556,200
1,538,700
1,563,400

1,563,400

1,538,700

1,556,200

1,547,800

1,442,200

1,385,200

1,332,900

1,292,800

1,136,800

1,100,372

929,142

977,551

885,352

791,917

791,768

845,269

633,518

443,315

464,900

438,297

409,688

379,755

393,439

327,294

281,343

263,493

247,949

207,955

201,083

182,229

189,356

181,878

177,639

165,272

94,519

80,332

72,994

114,308

81,842

59,858

85,517

120,281

164,866

194,054

143,250

139,629

185,618

232,228

183,135

445,661

96,016

5,594

12,529

4,964

3,548

7,876

9,601

32,783

14,762

16,702

23,489

21,966

15,365

24,825

31,320

34,658

37,189

44,099

62,923

42,614

183,668

23,779

20,595

20,764

13,941

10,866

11,891

8,480

9,939

7,937

7,324

7,850

9,720

11,925

13,200

13,100

18,056

20,265

35,925

8,414

7,615

12,262

7,087

5,434

4,506

5,900

4,800

Other Current Assets

0
0
0
200
0
200
20,000
24,100
24,400
31,800
24,100
32,400
25,700
37,200
27,900
24,500
51,500
80,600
48,600
35,300
49,200
51,100
48,300
59,500
58,400
52,900
93,300
97,300
191,900
99,200
108,300
210,100
209,100
221,600
211,200
224,500
206,900
200,100
1,200
157,800
1,997
1,700
1,751
2,325
2,327
2,032
7,265
12,625
5,989
5,159
4,946
4,039
1,376
1,801
3,393
3,318
4,927
3,908
5,925
2,501
4,831
4,763
4,405
3,303
6,810
6,580
5,331
3,857
7,301
7,501
6,071
4,660
9,470
10,201
10,985
11,991
16,285
13,630
881,283
12,512
26,209
21,862
18,464
13,099
855,158
678,486
681,930
66,767
1,016,274
1,263,858
1,333,665
24,673
47,835
43,231
41,105
23,836
35,011
34,399
41,298
57,193
62,648
53,289
63,388
12,065
55,866
56,256
61,012
16,780
128,493
107,082
152,238
63,964
109,886
122,694
118,678
74,045
130,009
151,829
175,142
213,515
223,648
232,565
270,021
308,353
338,925
498,759
457,827
187,200
491,500
549,500
726,900
74,400
468,700
476,900
540,200
620,500

620,500

540,200

476,900

468,700

74,400

726,900

549,500

491,500

187,200

457,827

498,759

338,925

308,353

270,021

232,565

223,648

213,515

175,142

151,829

130,009

74,045

118,678

122,694

109,886

63,964

152,238

107,082

128,493

16,780

61,012

56,256

55,866

12,065

63,388

53,289

62,648

57,193

41,298

34,399

35,011

23,836

41,105

43,231

47,835

24,673

1,333,665

1,263,858

1,016,274

66,767

681,930

678,486

855,158

13,099

18,464

21,862

26,209

12,512

881,283

13,630

16,285

11,991

10,985

10,201

9,470

4,660

6,071

7,501

7,301

3,857

5,331

6,580

6,810

3,303

4,405

4,763

4,831

2,501

5,925

3,908

4,927

3,318

3,393

1,801

1,376

4,039

4,946

5,159

5,989

12,625

7,265

2,032

2,327

2,325

1,751

1,700

1,997

157,800

1,200

200,100

206,900

224,500

211,200

221,600

209,100

210,100

108,300

99,200

191,900

97,300

93,300

52,900

58,400

59,500

48,300

51,100

49,200

35,300

48,600

80,600

51,500

24,500

27,900

37,200

25,700

32,400

24,100

31,800

24,400

24,100

20,000

200

> Long-term Assets

0
0
0
4,600
0
4,800
5,000
5,400
6,300
6,400
6,100
7,000
8,000
7,900
7,900
7,900
8,100
8,500
9,600
9,300
11,200
10,900
10,600
11,100
11,700
11,500
11,100
11,300
12,800
12,900
13,200
14,000
15,800
17,000
17,000
17,600
23,000
27,300
30,700
37,200
43,180
42,803
52,378
369,695
436,266
436,360
493,952
149,039
149,039
152,866
157,416
159,148
142,331
138,214
132,401
130,605
135,750
149,836
141,530
138,741
134,200
131,593
126,241
163,943
154,610
172,889
159,411
150,173
128,555
123,413
111,869
104,626
105,567
113,177
114,536
112,898
663,710
657,120
659,425
648,462
643,534
649,647
662,390
668,407
665,513
935,976
846,173
873,026
909,729
1,011,551
1,084,300
1,169,703
826,451
867,739
934,117
730,465
766,778
770,436
755,990
788,168
807,624
1,132,673
1,137,929
1,141,951
1,140,937
1,151,088
1,163,949
1,132,779
1,074,889
1,212,104
1,022,589
1,062,686
1,031,317
1,059,167
1,061,050
2,543,608
2,490,084
2,474,332
2,912,601
3,709,151
3,670,449
3,754,612
4,113,198
3,926,782
3,914,677
4,262,931
4,224,032
4,417,700
4,386,300
4,628,200
5,162,300
5,469,600
6,008,500
6,476,300
7,030,400
8,586,000

8,586,000

7,030,400

6,476,300

6,008,500

5,469,600

5,162,300

4,628,200

4,386,300

4,417,700

4,224,032

4,262,931

3,914,677

3,926,782

4,113,198

3,754,612

3,670,449

3,709,151

2,912,601

2,474,332

2,490,084

2,543,608

1,061,050

1,059,167

1,031,317

1,062,686

1,022,589

1,212,104

1,074,889

1,132,779

1,163,949

1,151,088

1,140,937

1,141,951

1,137,929

1,132,673

807,624

788,168

755,990

770,436

766,778

730,465

934,117

867,739

826,451

1,169,703

1,084,300

1,011,551

909,729

873,026

846,173

935,976

665,513

668,407

662,390

649,647

643,534

648,462

659,425

657,120

663,710

112,898

114,536

113,177

105,567

104,626

111,869

123,413

128,555

150,173

159,411

172,889

154,610

163,943

126,241

131,593

134,200

138,741

141,530

149,836

135,750

130,605

132,401

138,214

142,331

159,148

157,416

152,866

149,039

493,952

436,360

436,266

369,695

52,378

42,803

43,180

37,200

30,700

27,300

23,000

17,600

17,000

15,800

14,000

13,200

12,900

12,800

11,300

11,100

11,500

11,700

11,100

10,600

10,900

11,200

9,300

9,600

8,500

8,100

7,900

8,000

7,000

6,100

6,400

6,300

5,400

5,000

4,800

4,600

Property Plant Equipment

0
0
0
4,400
0
4,200
4,600
5,000
5,800
6,000
5,800
6,900
7,800
7,800
7,700
7,700
8,100
8,200
8,500
8,500
8,000
7,800
7,500
7,800
7,600
7,200
7,000
8,700
10,100
10,000
10,200
11,100
12,400
13,600
13,700
14,500
15,700
19,700
23,600
24,500
25,210
25,080
24,691
28,149
36,063
43,534
75,064
80,377
80,377
86,222
92,391
95,991
87,346
86,081
82,029
80,083
76,170
73,226
68,179
64,225
60,700
58,496
56,127
54,533
55,869
59,971
61,135
61,535
61,423
67,771
68,900
66,509
64,712
66,630
69,713
68,331
66,601
64,358
62,444
62,279
58,109
60,438
65,439
72,333
70,877
84,203
101,268
133,176
170,331
272,561
347,249
433,609
504,232
581,738
648,924
696,911
726,204
730,000
720,878
715,812
708,616
713,378
706,670
697,715
690,521
690,607
687,613
698,362
708,395
740,103
759,978
789,437
800,670
815,928
808,352
812,005
742,559
731,131
733,509
745,080
736,303
728,357
920,913
958,534
986,123
1,021,233
1,042,347
1,094,100
1,107,400
1,100,100
1,118,700
1,108,400
1,448,000
1,446,700
1,434,500
1,452,900

1,452,900

1,434,500

1,446,700

1,448,000

1,108,400

1,118,700

1,100,100

1,107,400

1,094,100

1,042,347

1,021,233

986,123

958,534

920,913

728,357

736,303

745,080

733,509

731,131

742,559

812,005

808,352

815,928

800,670

789,437

759,978

740,103

708,395

698,362

687,613

690,607

690,521

697,715

706,670

713,378

708,616

715,812

720,878

730,000

726,204

696,911

648,924

581,738

504,232

433,609

347,249

272,561

170,331

133,176

101,268

84,203

70,877

72,333

65,439

60,438

58,109

62,279

62,444

64,358

66,601

68,331

69,713

66,630

64,712

66,509

68,900

67,771

61,423

61,535

61,135

59,971

55,869

54,533

56,127

58,496

60,700

64,225

68,179

73,226

76,170

80,083

82,029

86,081

87,346

95,991

92,391

86,222

80,377

75,064

43,534

36,063

28,149

24,691

25,080

25,210

24,500

23,600

19,700

15,700

14,500

13,700

13,600

12,400

11,100

10,200

10,000

10,100

8,700

7,000

7,200

7,600

7,800

7,500

7,800

8,000

8,500

8,200

8,100

7,700

7,800

6,900

5,800

6,000

5,800

5,000

4,600

4,200

4,400

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,883
26,883
26,102
26,102
26,102
26,102
26,102
26,102
26,102
33,501
33,501
30,992
30,992
30,992
30,992
30,992
30,992
30,992
30,992
30,992
30,992
30,992
30,992
39,915
39,915
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
447,525
1,402,158
1,402,158
1,402,158
1,402,158
1,402,158
1,402,158
1,402,158
1,402,158
1,402,200
1,402,200
1,389,200
1,075,200
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000

1,088,000

1,075,200

1,389,200

1,402,200

1,402,158

447,525

50,384

39,915

30,992

33,501

26,102

26,883

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
30,138
33,213
53,314
20,276
20,276
20,252
20,447
20,447
0
0
36,700
13,600
13,600
33,600
40,800
60,800
0
0
0
0
0
0
0
0
0
0
0
112,200
1,081,500
1,357,300
1,700,000
2,497,800

2,497,800

1,700,000

1,357,300

1,081,500

112,200

60,800

40,800

33,600

13,600

36,700

20,447

20,252

20,276

53,314

33,213

30,138

30,000

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
525,900
525,900
525,900
518,700
518,700
518,700
518,700
518,700
518,700
769,300
663,500
663,500
663,500
663,500
663,500
663,500
250,600
250,600
250,600
30,992
30,992
30,992
30,992
29,000
29,000
284,340
284,340
284,340
284,340
284,340
284,340
284,340
284,340
284,340
29,000
29,000
29,000
29,000
29,000
50,384
0
0
0
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
387,000
603,600
603,600
603,600
603,600
603,600
839,900

839,900

603,600

387,000

400,000

50,384

29,000

284,340

29,000

30,992

250,600

663,500

769,300

518,700

525,900

Other Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,970
17,723
27,687
341,546
400,203
392,826
418,888
68,662
67,099
67,099
65,025
63,157
54,985
52,133
50,372
50,522
59,580
76,610
73,351
74,516
73,500
73,097
70,114
109,410
98,741
112,918
98,276
88,638
67,132
55,642
42,969
38,117
40,855
46,547
44,823
44,567
597,109
592,762
596,981
586,183
585,425
589,209
596,951
596,074
594,636
851,773
744,905
739,850
739,398
738,990
737,051
736,094
322,219
286,001
285,193
33,554
40,574
40,436
35,112
72,356
99,008
366,006
367,871
394,007
394,550
404,225
420,127
366,885
366,494
364,919
110,373
107,614
31,804
32,651
9,793
1,526,800
1,506,559
1,449,357
1,454,696
1,199,396
1,531,988
1,344,932
1,499,306
587,027
844,352
4,262,931
845,688
986,900
970,400
8,261,300
1,202,100
1,422,700
1,688,800
1,882,100
0
0

1,882,100

1,688,800

1,422,700

1,202,100

8,261,300

970,400

986,900

845,688

4,262,931

844,352

587,027

1,499,306

1,344,932

1,531,988

1,199,396

1,454,696

1,449,357

1,506,559

1,526,800

9,793

32,651

31,804

107,614

110,373

364,919

366,494

366,885

420,127

404,225

394,550

394,007

367,871

366,006

99,008

72,356

35,112

40,436

40,574

33,554

285,193

286,001

322,219

736,094

737,051

738,990

739,398

739,850

744,905

851,773

594,636

596,074

596,951

589,209

585,425

586,183

596,981

592,762

597,109

44,567

44,823

46,547

40,855

38,117

42,969

55,642

67,132

88,638

98,276

112,918

98,741

109,410

70,114

73,097

73,500

74,516

73,351

76,610

59,580

50,522

50,372

52,133

54,985

63,157

65,025

67,099

68,662

418,888

392,826

400,203

341,546

27,687

17,723

17,970

> Total Liabilities

0
0
0
4,000
0
4,700
4,600
4,900
4,900
5,900
6,400
7,100
8,100
8,400
10,200
11,500
9,400
11,300
12,000
10,700
10,900
13,700
12,700
13,700
11,900
12,000
9,800
12,700
14,400
14,700
17,200
19,600
14,900
15,600
18,800
20,100
20,200
20,000
18,300
23,200
195,194
203,210
547,958
385,984
378,838
385,485
446,083
449,780
449,780
423,794
422,856
437,139
440,037
473,939
511,394
531,566
512,092
513,758
500,042
510,012
492,720
473,945
417,263
309,822
291,746
450,482
394,342
415,644
333,796
346,485
323,113
330,182
585,250
730,880
717,661
741,605
859,032
710,819
964,747
859,142
779,690
827,067
1,238,733
1,221,473
1,146,815
1,198,632
1,361,152
1,238,768
1,240,266
1,361,249
1,454,077
1,524,906
1,415,402
1,035,666
1,096,069
962,636
966,230
945,551
1,250,181
1,240,126
1,168,290
1,325,857
1,357,261
1,404,365
1,371,708
1,380,137
1,406,197
1,555,594
2,946,703
1,418,363
1,395,081
1,503,708
1,522,153
1,620,503
1,686,359
1,810,695
1,819,801
1,963,506
2,261,159
2,233,221
2,431,547
2,697,125
3,168,160
3,064,993
3,134,805
3,025,290
3,088,037
3,332,500
3,349,100
3,648,700
3,676,800
4,238,200
4,541,900
4,879,000
5,213,400
5,149,800

5,149,800

5,213,400

4,879,000

4,541,900

4,238,200

3,676,800

3,648,700

3,349,100

3,332,500

3,088,037

3,025,290

3,134,805

3,064,993

3,168,160

2,697,125

2,431,547

2,233,221

2,261,159

1,963,506

1,819,801

1,810,695

1,686,359

1,620,503

1,522,153

1,503,708

1,395,081

1,418,363

2,946,703

1,555,594

1,406,197

1,380,137

1,371,708

1,404,365

1,357,261

1,325,857

1,168,290

1,240,126

1,250,181

945,551

966,230

962,636

1,096,069

1,035,666

1,415,402

1,524,906

1,454,077

1,361,249

1,240,266

1,238,768

1,361,152

1,198,632

1,146,815

1,221,473

1,238,733

827,067

779,690

859,142

964,747

710,819

859,032

741,605

717,661

730,880

585,250

330,182

323,113

346,485

333,796

415,644

394,342

450,482

291,746

309,822

417,263

473,945

492,720

510,012

500,042

513,758

512,092

531,566

511,394

473,939

440,037

437,139

422,856

423,794

449,780

446,083

385,485

378,838

385,984

547,958

203,210

195,194

23,200

18,300

20,000

20,200

20,100

18,800

15,600

14,900

19,600

17,200

14,700

14,400

12,700

9,800

12,000

11,900

13,700

12,700

13,700

10,900

10,700

12,000

11,300

9,400

11,500

10,200

8,400

8,100

7,100

6,400

5,900

4,900

4,600

4,700

4,000

> Total Current Liabilities

0
0
0
1,600
0
2,200
2,300
2,700
2,600
2,900
3,200
3,900
4,700
4,600
6,200
7,300
5,600
6,900
7,400
6,000
5,900
8,700
7,800
8,800
7,500
7,500
5,400
7,100
9,100
9,300
11,800
13,700
8,700
8,700
11,200
13,100
13,800
14,200
13,100
18,500
16,039
24,591
199,837
38,671
31,872
38,852
91,898
91,553
91,553
62,286
58,788
64,597
56,291
86,521
119,825
139,067
120,840
137,451
134,446
153,745
148,167
137,986
121,810
100,243
82,243
108,735
161,455
251,014
174,588
202,902
185,708
199,279
173,323
182,894
180,463
216,564
179,299
183,680
665,747
284,883
614,998
164,104
634,105
474,783
569,822
616,837
768,574
392,348
840,266
961,249
1,054,077
432,624
407,639
381,652
409,499
397,829
373,500
362,973
372,178
368,254
302,438
373,823
374,959
506,349
552,041
622,855
7,237
7,954
489,796
625,406
710,739
807,260
485,293
562,154
596,389
715,482
615,007
1,146,117
1,266,311
1,204,522
1,358,974
1,646,858
1,811,485
1,560,110
1,659,876
1,610,090
1,712,855
1,873,600
1,894,100
2,317,500
2,391,300
2,430,600
3,026,200
3,352,100
3,599,400
3,547,400

3,547,400

3,599,400

3,352,100

3,026,200

2,430,600

2,391,300

2,317,500

1,894,100

1,873,600

1,712,855

1,610,090

1,659,876

1,560,110

1,811,485

1,646,858

1,358,974

1,204,522

1,266,311

1,146,117

615,007

715,482

596,389

562,154

485,293

807,260

710,739

625,406

489,796

7,954

7,237

622,855

552,041

506,349

374,959

373,823

302,438

368,254

372,178

362,973

373,500

397,829

409,499

381,652

407,639

432,624

1,054,077

961,249

840,266

392,348

768,574

616,837

569,822

474,783

634,105

164,104

614,998

284,883

665,747

183,680

179,299

216,564

180,463

182,894

173,323

199,279

185,708

202,902

174,588

251,014

161,455

108,735

82,243

100,243

121,810

137,986

148,167

153,745

134,446

137,451

120,840

139,067

119,825

86,521

56,291

64,597

58,788

62,286

91,553

91,898

38,852

31,872

38,671

199,837

24,591

16,039

18,500

13,100

14,200

13,800

13,100

11,200

8,700

13,700

11,800

9,300

9,100

7,100

5,400

7,500

8,800

7,800

8,700

5,900

6,000

7,400

6,900

5,600

7,300

6,200

4,600

4,700

3,900

3,200

2,900

2,600

2,700

2,300

2,200

1,600

Short-term Debt

0
0
0
800
0
1,000
1,100
1,200
1,300
1,500
1,700
1,800
1,900
2,000
1,900
1,800
1,600
1,600
1,600
1,700
1,700
1,800
1,900
2,100
2,100
2,300
2,500
2,900
2,800
2,800
2,700
2,500
2,500
2,700
2,800
2,800
2,700
2,600
2,500
2,400
2,272
2,204
163,800
2,377
2,186
2,016
4,562
4,579
4,579
3,519
2,969
2,195
1,374
3,490
4,837
4,660
36
4,688
4,688
94,656
84,054
81,099
79,864
59,596
49,340
0
42,102
103,758
45,229
62,099
19,997
19,997
77,052
89,664
91,284
105,871
97,665
-95,831
175,899
32,071
164,490
-15,442
168,872
136,991
92,100
94,664
98,416
12,075
193,673
228,495
219,889
13,707
8,302
10,664
14,429
16,893
18,323
19,707
18,124
32,012
48,199
56,794
14,153
87,023
163,543
239,022
315,523
319,426
19,270
18,179
19,881
22,531
16,919
15,060
11,511
9,817
7,520
0
0
30,293
0
0
0
42,434
0
0
0
46,900
0
0
0
89,400
0
0
0
83,700

83,700

89,400

46,900

42,434

30,293

7,520

9,817

11,511

15,060

16,919

22,531

19,881

18,179

19,270

319,426

315,523

239,022

163,543

87,023

14,153

56,794

48,199

32,012

18,124

19,707

18,323

16,893

14,429

10,664

8,302

13,707

219,889

228,495

193,673

12,075

98,416

94,664

92,100

136,991

168,872

-15,442

164,490

32,071

175,899

-95,831

97,665

105,871

91,284

89,664

77,052

19,997

62,099

45,229

103,758

42,102

49,340

59,596

79,864

81,099

84,054

94,656

4,688

4,660

4,837

3,490

1,374

2,195

2,969

3,519

4,579

4,562

2,016

2,186

2,377

163,800

2,204

2,272

2,400

2,500

2,600

2,700

2,800

2,700

2,500

2,700

2,800

2,900

2,500

2,300

2,100

1,900

1,800

1,700

1,600

1,800

1,900

2,000

1,900

1,800

1,700

1,500

1,300

1,200

1,100

1,000

800

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,206
0
0
0
71,296
0
239,022
315,523
840,761
19,270
568,544
587,191
606,433
595,125
592,735
0
0
7,520
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

7,520

592,735

595,125

606,433

587,191

568,544

19,270

840,761

315,523

239,022

71,296

14,206

Accounts payable

0
0
0
0
0
900
900
800
1,000
1,200
0
700
2,500
1,900
2,700
3,500
2,800
3,600
4,100
1,400
3,600
5,800
5,700
3,000
4,200
4,100
2,900
1,400
6,300
5,400
8,500
4,200
6,200
6,000
8,300
2,800
11,100
11,700
10,600
3,000
13,767
17,645
31,387
3,847
2,596
6,362
6,377
11,628
11,628
9,764
12,170
16,745
10,000
9,267
8,069
12,306
7,741
7,815
9,504
6,660
8,474
9,429
6,460
6,210
6,259
8,277
7,144
15,368
9,141
17,754
25,757
32,750
31,281
36,345
31,465
51,760
22,700
27,494
19,962
36,989
29,121
46,495
24,644
35,851
34,881
67,275
49,248
74,642
73,226
59,352
83,732
101,292
59,627
48,570
51,533
49,327
49,571
55,363
38,472
71,194
43,524
72,703
78,899
74,942
75,221
51,302
50,914
61,451
63,145
75,941
77,138
73,994
74,062
83,034
92,149
110,987
82,262
77,045
92,528
87,610
100,703
101,451
107,786
155,139
127,839
127,534
127,863
195,000
173,600
198,000
126,900
303,900
323,200
363,000
375,900
364,900

364,900

375,900

363,000

323,200

303,900

126,900

198,000

173,600

195,000

127,863

127,534

127,839

155,139

107,786

101,451

100,703

87,610

92,528

77,045

82,262

110,987

92,149

83,034

74,062

73,994

77,138

75,941

63,145

61,451

50,914

51,302

75,221

74,942

78,899

72,703

43,524

71,194

38,472

55,363

49,571

49,327

51,533

48,570

59,627

101,292

83,732

59,352

73,226

74,642

49,248

67,275

34,881

35,851

24,644

46,495

29,121

36,989

19,962

27,494

22,700

51,760

31,465

36,345

31,281

32,750

25,757

17,754

9,141

15,368

7,144

8,277

6,259

6,210

6,460

9,429

8,474

6,660

9,504

7,815

7,741

12,306

8,069

9,267

10,000

16,745

12,170

9,764

11,628

6,377

6,362

2,596

3,847

31,387

17,645

13,767

3,000

10,600

11,700

11,100

2,800

8,300

6,000

6,200

4,200

8,500

5,400

6,300

1,400

2,900

4,100

4,200

3,000

5,700

5,800

3,600

1,400

4,100

3,600

2,800

3,500

2,700

1,900

2,500

700

1,200

1,000

800

900

Other Current Liabilities

0
0
0
800
0
300
300
700
300
200
1,500
1,400
300
700
1,600
2,000
1,200
1,700
1,700
2,900
600
1,100
200
3,700
1,200
1,100
0
2,800
0
1,100
600
7,000
0
0
100
7,500
0
-100
0
13,100
0
4,742
4,650
32,447
15,916
19,312
27,212
75,346
35,848
27,228
24,617
33,769
30,809
63,844
98,145
114,355
103,712
85,206
79,236
4,688
4,750
2,975
2,975
2,988
2,988
57,527
75,017
97,999
86,118
98,613
115,937
121,004
41,307
21,310
21,310
21,255
21,255
21,255
150,350
140,867
136,324
54,778
163,650
227,322
224,232
255,844
438,994
260,594
426,687
536,034
619,527
290,059
304,177
289,518
312,530
310,099
276,770
260,729
294,372
247,580
194,797
229,396
267,907
328,088
298,572
321,063
-368,447
-452,344
296,550
376,323
410,445
473,165
56,654
59,629
60,357
40,589
532,745
1,069,072
1,173,783
1,024,287
1,258,271
1,545,407
1,703,699
1,171,018
1,532,037
1,482,556
1,584,992
1,460,000
1,720,500
2,119,500
2,264,400
1,877,700
2,703,000
2,989,100
3,223,500
2,928,500

2,928,500

3,223,500

2,989,100

2,703,000

1,877,700

2,264,400

2,119,500

1,720,500

1,460,000

1,584,992

1,482,556

1,532,037

1,171,018

1,703,699

1,545,407

1,258,271

1,024,287

1,173,783

1,069,072

532,745

40,589

60,357

59,629

56,654

473,165

410,445

376,323

296,550

-452,344

-368,447

321,063

298,572

328,088

267,907

229,396

194,797

247,580

294,372

260,729

276,770

310,099

312,530

289,518

304,177

290,059

619,527

536,034

426,687

260,594

438,994

255,844

224,232

227,322

163,650

54,778

136,324

140,867

150,350

21,255

21,310

41,307

121,004

115,937

98,613

86,118

97,999

75,017

57,527

2,988

2,975

4,750

4,688

79,236

85,206

103,712

114,355

98,145

63,844

30,809

33,769

24,617

27,228

35,848

75,346

27,212

19,312

15,916

32,447

4,650

4,742

13,100

-100

7,500

100

7,000

600

1,100

2,800

1,100

1,200

3,700

200

1,100

600

2,900

1,700

1,200

2,000

1,600

700

300

1,400

1,500

200

300

700

300

800

> Long-term Liabilities

0
0
0
2,400
0
2,500
2,300
2,200
2,300
3,000
3,200
3,200
3,400
3,800
4,000
4,200
3,800
4,400
4,600
4,700
5,000
5,000
4,900
4,900
4,400
4,500
4,400
5,600
5,300
5,400
5,400
5,900
6,200
6,900
7,600
7,000
6,400
5,800
5,200
4,700
179,155
178,619
348,121
347,313
346,966
346,633
354,185
358,227
358,227
361,508
364,068
372,542
383,746
387,418
391,569
392,499
391,252
376,307
365,596
356,267
344,553
335,959
295,453
209,579
209,503
341,747
232,887
164,630
159,208
143,583
137,405
130,903
411,927
547,986
537,198
525,041
679,733
527,139
299,000
574,259
164,692
662,963
604,628
746,690
576,993
581,795
592,578
846,420
400,000
400,000
400,000
1,524,906
1,415,402
1,035,666
1,096,069
962,636
966,230
945,551
1,250,181
1,240,126
1,168,290
1,325,857
1,357,261
1,404,365
1,371,708
1,380,137
1,398,960
1,547,640
774,114
1,418,363
1,395,081
1,503,708
1,036,860
1,058,349
1,089,970
1,095,213
1,204,794
817,389
994,848
1,028,699
1,072,573
1,050,267
1,356,675
1,504,883
1,474,929
1,415,200
1,375,182
1,458,900
1,455,000
1,331,200
1,285,500
1,807,600
1,515,700
1,526,900
1,614,000
1,602,400

1,602,400

1,614,000

1,526,900

1,515,700

1,807,600

1,285,500

1,331,200

1,455,000

1,458,900

1,375,182

1,415,200

1,474,929

1,504,883

1,356,675

1,050,267

1,072,573

1,028,699

994,848

817,389

1,204,794

1,095,213

1,089,970

1,058,349

1,036,860

1,503,708

1,395,081

1,418,363

774,114

1,547,640

1,398,960

1,380,137

1,371,708

1,404,365

1,357,261

1,325,857

1,168,290

1,240,126

1,250,181

945,551

966,230

962,636

1,096,069

1,035,666

1,415,402

1,524,906

400,000

846,420

592,578

581,795

576,993

746,690

604,628

662,963

164,692

574,259

299,000

527,139

679,733

525,041

537,198

547,986

411,927

130,903

137,405

143,583

159,208

164,630

232,887

341,747

209,503

209,579

295,453

335,959

344,553

356,267

365,596

376,307

391,252

392,499

391,569

387,418

383,746

372,542

364,068

361,508

358,227

354,185

346,633

346,966

347,313

348,121

178,619

179,155

4,700

5,200

5,800

6,400

7,000

7,600

6,900

6,200

5,900

5,400

5,300

5,600

4,400

4,500

4,400

4,900

5,000

4,700

4,600

4,400

3,800

4,200

4,000

3,800

3,400

3,200

3,000

2,300

2,200

2,300

2,500

2,400

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
400,000
400,000
400,000
411,181
425,474
455,950
494,179
560,291
615,956
683,201
731,576
387,188
431,950
489,691
522,855
518,321
810,112
792,935
785,708
767,673
806,829
739,503
660,951
581,612
504,792
521,335
529,130
550,365
567,310
583,902
578,206
577,675
576,530
581,550
560,381
551,530
541,561
538,576
532,952
522,067
546,514
539,042
0
0
0
0
0
0
0
0
0
0
0
0

539,042

546,514

522,067

532,952

538,576

541,561

551,530

560,381

581,550

576,530

577,675

578,206

583,902

567,310

550,365

529,130

521,335

504,792

581,612

660,951

739,503

806,829

767,673

785,708

792,935

810,112

518,321

522,855

489,691

431,950

387,188

731,576

683,201

615,956

560,291

494,179

455,950

425,474

411,181

400,000

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,201
37,523
37,523
42,755
46,598
55,223
50,131
51,072
59,039
57,792
41,310
30,599
21,270
9,556
962
906
29,482
29,406
161,655
153,242
144,633
139,211
143,583
137,405
130,903
124,427
260,486
249,698
237,541
229,730
220,636
308,038
292,216
282,556
288,006
279,663
186,412
170,342
174,504
181,019
146,763
147,846
158,231
151,924
128,714
124,523
117,120
104,416
75,116
69,875
64,257
67,891
62,263
65,051
71,948
61,613
48,956
46,457
42,860
40,397
110,661
109,582
105,943
106,350
106,205
116,635
115,528
117,321
108,853
89,468
92,323
267,726
275,526
499,657
376,418
617,620
923,407
291,958
294,993
816,249
902,200
296,400
799,600
803,500
685,800
0
0
0
0

685,800

803,500

799,600

296,400

902,200

816,249

294,993

291,958

923,407

617,620

376,418

499,657

275,526

267,726

92,323

89,468

108,853

117,321

115,528

116,635

106,205

106,350

105,943

109,582

110,661

40,397

42,860

46,457

48,956

61,613

71,948

65,051

62,263

67,891

64,257

69,875

75,116

104,416

117,120

124,523

128,714

151,924

158,231

147,846

146,763

181,019

174,504

170,342

186,412

279,663

288,006

282,556

292,216

308,038

220,636

229,730

237,541

249,698

260,486

124,427

130,903

137,405

143,583

139,211

144,633

153,242

161,655

29,406

29,482

906

962

9,556

21,270

30,599

41,310

57,792

59,039

51,072

50,131

55,223

46,598

42,755

37,523

35,201

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
415,142
418,583
410,363
320,327
304,694
394,484
357,405
361,802
357,615
373,089
383,092
376,609
241,961
233,772
227,557
49,459
43,889
38,105
34,723
42,852
39,093
133,432
131,361
120,153
120,749
140,221
139,829
140,695
141,144
140,810
13,599
8,067
9,636
9,335
9,414
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

9,414

9,335

9,636

8,067

13,599

140,810

141,144

140,695

139,829

140,221

120,749

120,153

131,361

133,432

39,093

42,852

34,723

38,105

43,889

49,459

227,557

233,772

241,961

376,609

383,092

373,089

357,615

361,802

357,405

394,484

304,694

320,327

410,363

418,583

415,142

> Total Stockholder Equity

0
0
0
5,200
0
2,600
27,800
52,200
50,600
48,600
46,500
43,900
40,600
43,200
40,600
49,500
104,500
99,100
94,700
105,500
100,900
92,400
85,600
85,300
78,400
61,700
133,700
130,800
275,200
286,000
281,500
276,000
268,400
259,300
259,100
246,200
229,500
218,600
206,500
209,200
201,737
225,112
226,605
386,897
390,706
381,349
476,287
475,351
475,351
436,680
408,213
378,581
400,269
313,517
231,282
192,845
157,096
110,293
74,320
35,441
-8,491
122,958
133,312
239,176
232,912
174,996
507,769
505,935
501,299
414,585
332,035
271,295
304,255
239,925
349,893
238,874
706,851
729,057
608,744
1,096,346
990,612
827,135
650,096
503,973
391,672
307,549
579,762
786,843
930,498
1,037,773
1,027,733
999,180
746,115
1,322,453
1,264,894
1,356,405
1,230,878
1,172,269
1,155,905
1,096,183
997,537
1,048,216
1,076,732
1,092,680
1,116,198
1,168,845
1,198,641
1,338,191
1,682,793
1,867,231
1,803,244
2,042,306
2,430,821
2,714,883
2,934,481
4,435,203
4,723,313
5,069,965
5,253,394
6,085,244
6,461,654
7,519,242
8,133,473
8,686,815
8,980,254
9,196,396
9,530,708
10,100,000
10,907,000
11,933,500
13,029,600
13,912,700
14,432,300
15,470,200
16,512,800
17,580,400

17,580,400

16,512,800

15,470,200

14,432,300

13,912,700

13,029,600

11,933,500

10,907,000

10,100,000

9,530,708

9,196,396

8,980,254

8,686,815

8,133,473

7,519,242

6,461,654

6,085,244

5,253,394

5,069,965

4,723,313

4,435,203

2,934,481

2,714,883

2,430,821

2,042,306

1,803,244

1,867,231

1,682,793

1,338,191

1,198,641

1,168,845

1,116,198

1,092,680

1,076,732

1,048,216

997,537

1,096,183

1,155,905

1,172,269

1,230,878

1,356,405

1,264,894

1,322,453

746,115

999,180

1,027,733

1,037,773

930,498

786,843

579,762

307,549

391,672

503,973

650,096

827,135

990,612

1,096,346

608,744

729,057

706,851

238,874

349,893

239,925

304,255

271,295

332,035

414,585

501,299

505,935

507,769

174,996

232,912

239,176

133,312

122,958

-8,491

35,441

74,320

110,293

157,096

192,845

231,282

313,517

400,269

378,581

408,213

436,680

475,351

476,287

381,349

390,706

386,897

226,605

225,112

201,737

209,200

206,500

218,600

229,500

246,200

259,100

259,300

268,400

276,000

281,500

286,000

275,200

130,800

133,700

61,700

78,400

85,300

85,600

92,400

100,900

105,500

94,700

99,100

104,500

49,500

40,600

43,200

40,600

43,900

46,500

48,600

50,600

52,200

27,800

2,600

5,200

Common Stock

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
300
262
533
546
596
602
605
748
751
751
758
761
764
767
769
775
780
787
799
801
807
812
953
989
1,081
1,081
1,089
1,234
1,244
1,288
1,297
1,304
1,312
1,385
1,392
1,484
1,494
1,707
1,784
1,791
1,982
2,002
2,007
2,012
2,016
2,033
2,055
2,065
2,072
2,087
2,133
2,141
2,149
2,160
2,300
2,311
2,320
2,334
2,347
2,375
2,385
2,399
2,406
2,419
2,427
2,429
2,440
2,446
2,450
2,459
2,479
2,500
2,512
2,541
2,542
2,551
2,546
2,561
2,565
2,571
2,589
2,591
2,601
2,601
2,599
2,588
2,591
2,562
2,500
2,600
2,600
2,600
2,600
2,600
257,800
257,800
2,600

2,600

257,800

2,600

2,500

2,562

2,591

2,588

2,599

2,601

2,591

2,589

2,571

2,565

2,561

2,546

2,551

2,542

2,541

2,512

2,500

2,479

2,459

2,450

2,446

2,440

2,429

2,427

2,419

2,406

2,399

2,385

2,375

2,347

2,334

2,320

2,311

2,300

2,160

2,149

2,141

2,133

2,087

2,072

2,065

2,055

2,033

2,016

2,012

2,007

2,002

1,982

1,791

1,784

1,707

1,494

1,484

1,392

1,385

1,312

1,304

1,297

1,288

1,244

1,234

1,089

1,081

989

953

812

807

801

799

787

780

775

769

767

764

761

758

751

748

605

602

596

546

533

262

300

Retained Earnings Total Equity

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-2,855,054
-3,055,060
-3,264,017
-3,444,409
-3,620,505
-3,794,574
-3,573,464
-3,414,835
-3,323,245
-3,388,176
-3,445,719
-3,521,867
-3,829,883
-3,887,048
-4,011,180
-3,966,895
-4,199,352
-4,358,734
-4,528,794
-4,705,450
-4,904,056
-5,092,904
-5,188,053
-5,261,784
-5,303,415
-5,367,940
-5,406,781
-5,373,836
-5,135,451
-5,117,455
-5,220,407
-5,119,723
-4,876,111
-4,668,751
-4,540,005
-2,989,478
-2,761,157
-2,493,730
-2,436,212
-1,852,978
-1,250,225
-412,955
254,479
858,669
1,511,807
1,578,731
2,430,659
3,200,800
3,962,900
4,773,400
5,703,900
6,522,800
7,222,600
8,138,300
0
0

8,138,300

7,222,600

6,522,800

5,703,900

4,773,400

3,962,900

3,200,800

2,430,659

1,578,731

1,511,807

858,669

254,479

-412,955

-1,250,225

-1,852,978

-2,436,212

-2,493,730

-2,761,157

-2,989,478

-4,540,005

-4,668,751

-4,876,111

-5,119,723

-5,220,407

-5,117,455

-5,135,451

-5,373,836

-5,406,781

-5,367,940

-5,303,415

-5,261,784

-5,188,053

-5,092,904

-4,904,056

-4,705,450

-4,528,794

-4,358,734

-4,199,352

-3,966,895

-4,011,180

-3,887,048

-3,829,883

-3,521,867

-3,445,719

-3,388,176

-3,323,245

-3,414,835

-3,573,464

-3,794,574

-3,620,505

-3,444,409

-3,264,017

-3,055,060

-2,855,054

Accumulated Other Comprehensive Income

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-87,900
-87,900
-20,000
-20,000
-20,000
-20,000
-23,600
-24,600
-25,600
-26,700
-28,100
-29,400
-30,800
-300
-1,100
-1,473
-1,245
376
3,620
8,160
7,716
12,293
-68,899
11,114
6,654
7,894
6,764
4,435
4,684
3,683
1,578
808
-12,330
-11,293
-13,031
-16,947
-14,901
-17,398
-16,281
10,895
8,252
-1,245
-962
-506
-595
309
881
1,993
647
675
3,168
1,143
418
-115
-640
-1,080
-558
-677
-1,067
-633
-707
-945
-1,053
-628
-673
-416
-550
-1,149
-1,230
-550
-306
-297
-23
1,161
917
791
-1,707
1,511
1,824
-4,899
-3,390
-3,845
21,173
16,025
-21,753
-25,129
-11,572
-39,743
-4,605
307
659
6,000
-3,201
18,847
-1,973
13,383
-14,121
-40,982
-68,480
-33,302
-25,159
11,537
15,900
11,300
57,500
97,600
800
-13,100
-39,800
-3,000
-14,300

-14,300

-3,000

-39,800

-13,100

800

97,600

57,500

11,300

15,900

11,537

-25,159

-33,302

-68,480

-40,982

-14,121

13,383

-1,973

18,847

-3,201

6,000

659

307

-4,605

-39,743

-11,572

-25,129

-21,753

16,025

21,173

-3,845

-3,390

-4,899

1,824

1,511

-1,707

791

917

1,161

-23

-297

-306

-550

-1,230

-1,149

-550

-416

-673

-628

-1,053

-945

-707

-633

-1,067

-677

-558

-1,080

-640

-115

418

1,143

3,168

675

647

1,993

881

309

-595

-506

-962

-1,245

8,252

10,895

-16,281

-17,398

-14,901

-16,947

-13,031

-11,293

-12,330

808

1,578

3,683

4,684

4,435

6,764

7,894

6,654

11,114

-68,899

12,293

7,716

8,160

3,620

376

-1,245

-1,473

-1,100

-300

-30,800

-29,400

-28,100

-26,700

-25,600

-24,600

-23,600

-20,000

-87,900

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,844,744
3,880,746
3,912,778
3,947,433
4,010,777
4,100,775
4,152,106
4,200,659
4,252,284
4,424,489
4,471,727
4,519,448
4,574,987
5,208,431
5,274,307
5,321,286
5,428,193
5,528,679
5,681,163
5,777,154
5,877,324
5,987,169
6,106,270
6,197,500
6,262,964
6,350,244
6,429,726
6,506,795
6,616,975
6,808,002
7,034,113
7,157,362
7,314,369
7,357,042
7,443,263
7,421,476
7,475,909
7,564,331
7,668,188
7,937,606
7,695,905
7,943,717
7,917,375
7,894,027
7,499,161
7,640,233
7,085,950
6,880,800
6,930,200
7,100,000
7,225,500
7,386,500
7,220,200
7,369,100
0
0

7,369,100

7,220,200

7,386,500

7,225,500

7,100,000

6,930,200

6,880,800

7,085,950

7,640,233

7,499,161

7,894,027

7,917,375

7,943,717

7,695,905

7,937,606

7,668,188

7,564,331

7,475,909

7,421,476

7,443,263

7,357,042

7,314,369

7,157,362

7,034,113

6,808,002

6,616,975

6,506,795

6,429,726

6,350,244

6,262,964

6,197,500

6,106,270

5,987,169

5,877,324

5,777,154

5,681,163

5,528,679

5,428,193

5,321,286

5,274,307

5,208,431

4,574,987

4,519,448

4,471,727

4,424,489

4,252,284

4,200,659

4,152,106

4,100,775

4,010,777

3,947,433

3,912,778

3,880,746

3,844,744

Treasury Stock

Other Stockholders Equity

0
0
0
11,400
0
11,400
37,800
63,600
63,600
63,500
63,700
63,800
63,800
67,100
67,200
67,300
125,600
125,700
125,200
140,900
141,000
141,500
141,700
142,200
142,800
236,300
314,700
247,700
397,900
410,100
411,500
416,400
418,200
419,900
423,100
424,200
426,300
427,700
431,200
434,100
444,656
457,136
485,533
659,381
672,054
674,801
829,406
0
858,031
862,439
867,421
794,206
797,609
800,534
805,715
810,407
815,859
826,451
828,210
833,832
838,531
1,008,781
1,101,174
1,243,960
1,260,607
1,282,984
1,676,911
1,702,128
1,777,720
1,808,853
1,832,425
1,856,856
1,984,785
2,013,115
2,253,007
2,281,817
2,914,278
3,108,429
3,138,207
3,784,787
3,844,744
3,880,746
3,912,778
3,947,433
4,010,777
4,100,775
4,152,106
4,200,659
4,252,284
4,424,489
4,471,727
4,519,448
4,574,987
5,208,431
5,274,307
5,321,286
5,428,193
5,528,679
5,681,163
5,777,154
5,877,324
5,987,169
6,106,270
6,197,500
6,262,964
6,350,244
6,429,726
6,506,795
6,616,975
6,808,002
7,034,113
7,157,362
7,314,369
7,357,042
7,443,263
7,421,476
7,475,909
7,564,331
7,668,188
7,937,606
7,695,905
7,943,717
7,917,375
7,894,027
7,499,161
7,640,233
7,085,950
6,880,800
6,930,200
7,100,000
7,225,500
7,386,500
7,220,200
7,113,900
7,084,400
7,449,700

7,449,700

7,084,400

7,113,900

7,220,200

7,386,500

7,225,500

7,100,000

6,930,200

6,880,800

7,085,950

7,640,233

7,499,161

7,894,027

7,917,375

7,943,717

7,695,905

7,937,606

7,668,188

7,564,331

7,475,909

7,421,476

7,443,263

7,357,042

7,314,369

7,157,362

7,034,113

6,808,002

6,616,975

6,506,795

6,429,726

6,350,244

6,262,964

6,197,500

6,106,270

5,987,169

5,877,324

5,777,154

5,681,163

5,528,679

5,428,193

5,321,286

5,274,307

5,208,431

4,574,987

4,519,448

4,471,727

4,424,489

4,252,284

4,200,659

4,152,106

4,100,775

4,010,777

3,947,433

3,912,778

3,880,746

3,844,744

3,784,787

3,138,207

3,108,429

2,914,278

2,281,817

2,253,007

2,013,115

1,984,785

1,856,856

1,832,425

1,808,853

1,777,720

1,702,128

1,676,911

1,282,984

1,260,607

1,243,960

1,101,174

1,008,781

838,531

833,832

828,210

826,451

815,859

810,407

805,715

800,534

797,609

794,206

867,421

862,439

858,031

829,406

674,801

672,054

659,381

485,533

457,136

444,656

434,100

431,200

427,700

426,300

424,200

423,100

419,900

418,200

416,400

411,500

410,100

397,900

247,700

314,700

236,300

142,800

142,200

141,700

141,500

141,000

140,900

125,200

125,700

125,600

67,300

67,200

67,100

63,800

63,700

63,500

63,600

37,800

11,400

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31	1993-12-31	1992-12-31	1991-12-31	1990-12-31
Accounts Payable	364,900	303,900	195,000	155,139	87,610	110,987	73,994	61,451	74,942	71,194	49,327	101,292	74,642	35,851	36,989	51,760	32,750	15,368	6,210	6,660	12,306	16,745	11,628	3,847	3,000	2,800	4,200	1,400	3,000	1,400	3,500	700	800	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Other Comprehensive Income	-14,300	800	15,900	-68,480	-1,973	659	-11,572	21,173	1,824	917	-306	-550	-1,053	-1,067	-640	3,168	881	-962	-16,281	-13,031	1,578	6,764	11,114	3,620	-1,100	-28,100	-23,600	-20,000	0	0	0	0	0	-
Additional Paid In Capital	0	0	0	0	0	0	7,157,362	6,506,795	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Lease Obligations	808,400	471,600	556,700	581,476	538,576	19,658	20,496	34,976	42,923	39,293	48,754	15,170	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Stock	2,600	2,600	2,500	2,599	2,589	2,546	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Surpluse	0	7,386,500	6,880,800	7,894,027	7,937,606	7,421,476	7,157,362	6,506,795	6,197,500	5,777,154	5,321,286	4,519,448	4,200,659	3,947,433	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Cash	10,372,300	10,504,000	6,795,000	5,988,187	3,109,322	2,650,134	1,665,412	1,183,945	714,768	625,259	569,299	489,407	475,320	243,197	446,658	389,115	355,663	213,171	78,045	55,006	98,159	108,098	189,205	322,090	31,500	24,200	71,500	34,900	28,400	71,600	28,600	11,600	27,600	4,400
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Cash And Short Term Investments	11,221,500	10,778,500	7,524,900	6,658,897	3,808,294	3,168,242	2,088,666	1,434,557	1,042,462	1,387,106	1,465,076	1,321,215	968,922	1,031,411	1,284,913	832,101	460,871	704,626	361,157	392,320	583,164	634,984	743,202	388,599	31,500	24,200	71,500	34,900	28,400	71,600	28,600	11,600	27,600	4,400
Common Stock	2,600	2,600	2,500	2,599	2,589	2,546	2,512	2,450	2,427	2,385	2,320	2,149	2,072	2,016	1,982	1,494	1,312	1,244	1,081	807	780	764	751	596	300	0	0	0	0	0	0	0	0	-
Common Stock Shares Outstanding	260,500	259,100	259,900	263,396	260,673	259,185	253,225	244,685	241,312	235,307	224,906	211,946	208,807	200,402	173,259	140,556	128,986	113,221	89,241	78,571	77,004	75,749	74,464	67,682	51,036	50,598	48,528	37,383	34,127	31,429	25,000	24,286	14,615	13,030
Common Stock Total Equity	0	2,600	2,500	2,599	2,589	2,546	2,512	2,450	2,427	2,385	2,320	2,149	2,072	2,016	1,982	1,494	1,312	1,244	1,081	807	780	764	751	596	300	0	0	0	0	0	0	0	0	-
Current Deferred Revenue	170,300	159,600	171,700	191,519	62,332	554,089	237,570	79,421	16,296	17,468	21,510	27,566	163,132	74,619	300,531	37,678	25,528	33,889	31,449	47,741	7,746	11,888	39,498	0	0	0	0	0	0	0	0	0	0	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Deferred Long Term Liab	0	0	0	0	0	0	8,067	140,695	120,153	42,852	49,459	376,609	361,802	320,327	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Good Will	1,088,000	1,088,000	1,402,200	1,402,158	1,402,158	50,384	50,384	50,384	50,384	39,915	30,992	30,992	30,992	26,102	26,102	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Intangible Assets	839,900	603,600	400,000	400,000	400,000	50,384	29,000	284,340	284,340	29,000	105,800	663,500	663,500	518,700	518,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Inventory	738,800	460,600	353,100	280,777	167,502	124,360	111,830	77,604	56,083	30,848	14,147	30,464	112,430	0	8	0	0	0	0	0	0	4,349	6,636	0	0	0	0	0	0	0	0	0	0	-
Liabilities And Stockholders Equity	22,730,200	18,150,900	13,432,500	11,751,808	8,318,465	6,245,898	3,546,014	2,893,785	2,497,045	2,336,309	2,319,041	2,759,288	2,204,280	1,725,446	1,955,496	980,479	601,477	921,579	548,998	545,453	724,411	815,720	925,131	772,881	232,400	266,300	295,600	143,500	99,000	116,200	61,000	51,000	57,100	9,200
Long Term Debt	0	0	0	0	0	561,892	563,406	486,359	696,580	753,642	440,937	668,031	455,950	400,000	121,765	287,500	0	19,997	180,097	334,997	333,460	325,944	323,026	347,313	0	0	0	0	0	0	0	0	0	-
Long Term Debt Total	0	0	0	539,042	538,576	581,550	583,902	521,335	739,503	792,935	489,691	683,201	455,950	400,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Long Term Investments	2,497,800	112,200	0	0	60,800	13,600	20,447	20,276	30,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Debt	-9,563,900	-9,943,000	-6,238,300	-5,406,711	-2,531,951	-2,082,971	-1,101,501	-345,696	105,846	200,039	-128,362	183,224	-75,320	293,794	-292,822	-101,615	-335,666	-89,416	102,052	279,991	247,229	220,041	138,400	27,600	-24,400	-14,400	-63,100	-26,400	-21,400	-65,200	-22,600	-6,500	-24,300	-1,200
Net Invested Capital	17,580,400	13,912,700	10,100,000	8,686,815	6,085,244	4,435,203	2,028,579	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Receivables	1,563,400	1,442,200	1,136,800	885,352	633,518	409,688	281,343	201,083	177,639	72,994	85,517	143,250	183,135	12,529	9,601	23,489	31,320	62,923	20,595	11,891	7,324	13,200	20,265	12,262	5,900	0	0	0	0	0	0	0	0	-
Net Tangible Assets	0	12,221,100	8,697,800	7,284,657	4,683,086	4,384,819	1,949,195	821,858	605,243	1,006,091	1,325,413	343,218	129,387	-40,829	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Working Capital	10,596,800	10,250,700	7,141,200	6,255,846	3,488,002	2,722,817	1,841,703	1,753,052	848,745	1,179,887	1,190,747	1,156,961	492,486	582,256	640,527	651,017	297,572	520,392	284,812	252,967	454,739	591,975	684,539	364,515	176,700	235,600	267,900	125,100	79,100	100,900	45,800	40,100	49,000	-
Non Current Assets Total	8,586,000	5,469,600	4,417,700	3,926,782	3,709,151	2,543,608	1,062,686	1,132,779	1,141,951	788,168	730,465	1,169,703	873,026	668,407	648,462	112,898	104,626	150,173	163,943	138,741	130,605	159,148	149,039	369,695	37,200	17,600	14,000	11,300	11,100	9,300	7,900	7,000	5,400	4,600
Non Current Liabilities Other	196,300	1,496,100	902,200	1,187,460	898,394	108,853	104,479	104,029	39,242	34,455	25,657	32,472	28,668	26,363	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Current Liabilities Total	1,602,400	1,807,600	1,458,900	1,504,883	1,028,699	1,095,213	1,503,708	1,547,640	1,404,365	1,240,126	962,636	1,524,906	400,000	746,690	192,043	525,041	130,903	164,630	209,579	356,267	392,499	372,542	358,227	347,313	4,700	7,000	5,900	5,600	4,900	4,700	4,200	3,200	2,200	2,400
Non Currrent Assets Other	796,700	1,323,300	901,100	662,511	326,943	181,547	193,865	99,693	109,512	3,441	2,562	41,602	45,358	51,272	41,381	44,567	38,117	88,638	90,547	55,653	31,659	36,724	68,662	341,546	12,700	3,100	2,900	2,600	3,300	800	200	100	400	200
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	13,727	181,609	153,661	21,177	0	196,672	141,633	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Assets	0	1,422,700	986,900	587,027	1,199,396	1,540,400	28,230	11,885	28,995	3,441	2,562	41,602	45,358	51,272	41,381	44,567	31,192	31,512	44,194	55,653	31,659	36,724	42,229	20,995	0	0	0	0	0	0	0	0	0	-
Other Current Assets	620,500	74,400	187,200	308,353	213,515	74,045	63,964	16,780	12,065	57,193	23,836	24,673	983,811	13,099	12,512	11,991	4,660	3,857	3,303	2,501	3,318	4,039	5,989	2,325	157,800	224,500	210,100	97,300	59,500	35,300	24,500	32,400	24,100	200
Other Current Liab	2,928,500	1,877,700	1,460,000	1,171,018	1,024,287	40,589	473,165	-452,344	328,088	247,580	310,099	290,059	405,616	227,322	296,916	21,255	121,004	97,999	2,988	4,688	114,355	33,769	35,848	32,447	13,100	7,500	7,000	2,800	3,700	2,900	2,000	1,400	700	800
Other Liab	0	685,800	902,200	923,407	275,526	108,853	112,546	244,724	159,395	62,263	75,116	128,714	146,763	186,412	292,216	237,541	130,903	144,633	29,482	21,270	59,039	46,598	35,201	0	0	0	0	0	0	0	0	0	0	-
Other Stockholder Equity	7,449,700	7,386,500	6,880,800	7,894,027	7,937,606	7,421,476	7,157,362	6,506,795	6,197,500	5,777,154	5,321,286	4,519,448	4,200,659	3,947,433	3,784,787	2,281,817	1,856,856	1,702,128	1,243,960	833,832	810,407	794,206	858,031	659,381	434,100	424,200	416,400	247,700	142,200	140,900	67,300	63,800	63,600	11,400
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Property Plant And Equipment Gross	2,641,800	2,483,100	2,320,400	958,534	745,080	812,005	789,437	698,362	697,715	715,812	696,911	433,609	133,176	72,333	62,279	68,331	66,509	61,535	54,533	64,225	80,083	95,991	80,377	28,149	24,500	14,500	11,100	8,700	0	0	0	0	0	-
Property Plant And Equipment Net	1,452,900	1,108,400	1,094,100	958,534	745,080	812,005	789,437	698,362	697,715	715,812	696,911	433,609	133,176	72,333	62,279	68,331	66,509	61,535	54,533	64,225	80,083	95,991	80,377	28,149	24,500	14,500	11,100	8,700	7,800	8,500	7,700	6,900	5,000	4,400
Property Plant Equipment	0	1,455,800	1,094,100	958,534	833,282	812,005	789,437	698,362	697,715	715,812	696,911	433,609	133,176	72,333	62,279	68,331	66,509	61,535	54,533	64,225	80,083	95,991	80,377	28,149	0	0	0	0	0	0	0	0	0	-
Retained Earnings	10,142,400	6,522,800	3,200,800	858,669	-1,852,978	-2,989,478	-5,119,723	-5,373,836	-5,261,784	-4,705,450	-3,966,895	-3,521,867	-3,414,835	-3,444,409	-2,689,783	-2,047,605	-1,587,754	-1,196,475	-989,584	-786,167	-619,920	-423,153	-314,532	-230,485	-190,800	-149,900	-116,800	-96,900	-56,900	-35,400	-17,800	-19,900	-11,400	-6,200
Retained Earnings Total Equity	0	6,522,800	3,200,800	858,669	-1,852,978	-2,989,478	-5,119,723	-5,373,836	-5,261,784	-4,705,450	-3,966,895	-3,521,867	-3,414,835	-3,444,409	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Short Long Term Debt	0	0	0	0	0	0	606,433	300,000	71,296	14,206	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Short Long Term Debt Total	808,400	561,000	556,700	581,476	577,371	567,163	563,911	838,249	820,614	825,298	440,937	672,631	400,000	536,991	153,836	287,500	19,997	123,755	180,097	334,997	345,388	328,139	327,605	349,690	7,100	9,800	8,400	8,500	7,000	6,400	6,000	5,100	3,300	3,200
Short Term Debt	83,700	89,400	46,900	42,434	30,293	9,817	22,531	319,426	87,023	32,012	16,893	13,707	195,378	136,991	32,071	105,871	19,997	103,758	59,596	94,656	4,660	2,195	4,579	2,377	2,400	2,800	2,500	2,900	2,100	1,700	1,800	1,800	1,200	800
Short Term Investments	849,200	274,500	729,900	670,710	698,972	518,108	423,254	250,612	327,694	761,847	895,777	831,808	493,602	788,214	838,255	442,986	105,208	491,455	283,112	337,314	485,005	526,886	553,997	66,509	0	0	0	0	0	0	0	0	0	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Assets	22,730,200	18,150,900	13,432,500	11,751,808	8,318,465	6,245,898	3,546,014	2,893,785	2,497,045	2,336,309	2,319,041	2,759,288	2,204,280	1,725,446	1,955,496	980,479	601,477	921,579	548,998	545,453	724,411	815,720	925,131	772,881	232,400	266,300	295,600	143,500	99,000	116,200	61,000	51,000	57,100	9,200
Total Current Assets	14,144,200	12,681,300	9,014,800	7,825,026	4,609,314	3,702,290	2,483,328	1,761,006	1,355,094	1,548,141	1,588,576	1,589,585	1,331,254	1,057,039	1,307,034	867,581	496,851	771,406	385,055	406,712	593,806	656,572	776,092	403,186	195,200	248,700	281,600	132,200	87,900	106,900	53,100	44,000	51,700	4,600
Total Current Liabilities	3,547,400	2,430,600	1,873,600	1,560,110	1,204,522	715,482	807,260	7,954	506,349	368,254	397,829	432,624	838,768	474,783	666,507	216,564	199,279	251,014	100,243	153,745	139,067	64,597	91,553	38,671	18,500	13,100	13,700	7,100	8,800	6,000	7,300	3,900	2,700	1,600
Total Liab	5,149,800	4,238,200	3,332,500	3,064,993	2,233,221	1,810,695	1,503,708	1,555,594	1,404,365	1,240,126	962,636	1,524,906	1,238,768	1,221,473	858,550	741,605	330,182	415,644	309,822	510,012	531,566	437,139	449,780	385,984	23,200	20,100	19,600	12,700	13,700	10,700	11,500	7,100	4,900	4,000
Total Permanent Equity	0	0	0	0	0	0	2,042,306	1,338,191	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Stockholder Equity	17,580,400	13,912,700	10,100,000	8,686,815	6,085,244	4,435,203	2,042,306	1,338,191	1,092,680	1,096,183	1,356,405	999,180	786,843	503,973	1,096,946	238,874	271,295	505,935	239,176	35,441	192,845	378,581	475,351	386,897	209,200	246,200	276,000	130,800	85,300	105,500	49,500	43,900	52,200	5,200
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31	1993-12-31	1993-09-30	1993-06-30	1993-03-31	1992-12-31	1992-09-30	1992-06-30	1992-03-31	1991-12-31	1991-09-30	1991-06-30	1991-03-31	1990-12-31	1990-09-30	1990-06-30	1990-03-31
Accounts Payable	364,900	375,900	363,000	323,200	303,900	126,900	198,000	173,600	195,000	127,863	127,534	127,839	155,139	107,786	101,451	100,703	87,610	92,528	77,045	82,262	110,987	92,149	83,034	74,062	73,994	77,138	75,941	63,145	61,451	50,914	51,302	75,221	74,942	78,899	72,703	43,524	71,194	38,472	55,363	49,571	49,327	51,533	48,570	59,627	101,292	83,732	59,352	73,226	74,642	49,248	67,275	34,881	35,851	24,644	46,495	29,121	36,989	19,962	27,494	22,700	51,760	31,465	36,345	31,281	32,750	25,757	17,754	9,141	15,368	7,144	8,277	6,259	6,210	6,460	9,429	8,474	6,660	9,504	7,815	7,741	12,306	8,069	9,267	10,000	16,745	12,170	9,764	11,628	11,628	6,377	6,362	2,596	3,847	31,387	17,645	13,767	3,000	10,600	11,700	11,100	2,800	8,300	6,000	6,200	4,200	8,500	5,400	6,300	1,400	2,900	4,100	4,200	3,000	5,700	5,800	3,600	1,400	4,100	3,600	2,800	3,500	2,700	1,900	2,500	700	0	1,200	1,000	800	900	900	-	-	-	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Accumulated Other Comprehensive Income	-14,300	-3,000	-39,800	-13,100	800	97,600	57,500	11,300	15,900	11,537	-25,159	-33,302	-68,480	-40,982	-14,121	13,383	-1,973	18,847	-3,201	6,000	659	307	-4,605	-39,743	-11,572	-25,129	-21,753	16,025	21,173	-3,845	-3,390	-4,899	1,824	1,511	-1,707	791	917	1,161	-23	-297	-306	-550	-1,230	-1,149	-550	-416	-673	-628	-1,053	-945	-707	-633	-1,067	-677	-558	-1,080	-640	-115	418	1,143	3,168	675	647	1,993	881	309	-595	-506	-962	-1,245	8,252	10,895	-16,281	-17,398	-14,901	-16,947	-13,031	-11,293	-12,330	808	1,578	3,683	4,684	4,435	6,764	7,894	6,654	11,114	-68,899	12,293	7,716	8,160	3,620	376	-1,245	-1,473	-1,100	-300	-30,800	-29,400	-28,100	-26,700	-25,600	-24,600	-23,600	-20,000	-20,000	-20,000	-20,000	-87,900	-87,900	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7,443,263	7,357,042	7,314,369	7,157,362	7,034,113	6,808,002	6,616,975	6,506,795	6,429,726	6,350,244	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Lease Obligations	808,400	744,700	767,600	789,200	471,600	824,600	847,300	872,500	556,700	558,933	893,849	572,856	581,476	546,514	522,067	532,952	538,576	604,539	611,963	623,865	19,658	15,141	15,030	16,911	20,496	20,259	25,346	30,355	34,976	31,719	34,317	38,886	42,923	39,273	42,900	46,471	39,293	42,200	45,053	49,495	48,754	39,381	28,088	14,755	15,170	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Stock	2,600	2,600	2,600	2,600	2,600	2,600	2,600	2,600	2,500	2,562	2,591	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Surpluse	0	0	7,369,100	7,220,200	7,386,500	7,225,500	7,100,000	6,930,200	6,880,800	7,085,950	7,640,233	7,499,161	7,894,027	7,917,375	7,943,717	7,695,905	7,937,606	7,668,188	7,564,331	7,475,909	7,421,476	7,443,263	7,357,042	7,314,369	7,157,362	7,034,113	6,808,002	6,616,975	6,506,795	6,429,726	6,350,244	6,262,964	6,197,500	6,106,270	5,987,169	5,877,324	5,777,154	5,681,163	5,528,679	5,428,193	5,321,286	5,274,307	5,208,431	4,574,987	4,519,448	4,471,727	4,424,489	4,252,284	4,200,659	4,152,106	4,100,775	4,010,777	3,947,433	3,912,778	3,880,746	3,844,744	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Cash	10,372,300	11,110,200	10,151,100	9,289,900	10,504,000	9,171,500	8,702,200	7,600,100	6,795,000	6,275,698	6,063,678	6,304,330	5,988,187	5,358,087	4,831,332	3,593,412	3,109,322	3,397,941	3,294,684	2,893,885	2,650,134	2,478,302	2,145,359	1,995,893	1,665,412	1,384,966	1,223,130	1,003,679	1,183,945	719,692	605,866	604,245	714,768	756,250	870,543	664,879	625,259	718,563	420,558	424,045	569,299	583,181	531,247	379,099	489,407	436,886	454,061	267,923	475,320	542,545	458,195	446,536	243,197	569,901	337,608	396,547	446,658	559,133	408,949	602,199	389,115	542,876	549,632	490,696	355,663	253,979	168,718	354,328	213,171	483,431	41,430	81,827	78,045	101,619	194,695	37,371	55,006	37,037	63,692	53,007	98,159	77,449	133,410	180,773	108,098	103,594	125,268	189,205	189,205	195,951	168,527	222,662	322,090	471,429	183,208	191,750	31,500	22,400	11,200	19,800	24,200	49,700	36,300	58,400	71,500	177,200	188,600	84,900	34,900	39,100	9,300	20,200	28,400	39,400	44,100	51,400	71,600	48,500	21,300	54,300	28,600	15,000	6,500	15,000	11,600	22,700	16,300	24,800	27,600	7,400	2,300	-	4,400	-	-	-
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Cash And Short Term Investments	11,221,500	11,928,200	11,236,300	10,414,100	10,778,500	9,770,700	9,253,400	8,238,100	7,524,900	6,960,885	6,707,993	6,923,968	6,658,897	6,151,058	5,450,769	4,190,396	3,808,294	3,996,331	3,951,222	3,478,035	3,168,242	3,055,885	2,767,755	2,477,017	2,088,666	1,812,248	1,668,650	1,408,782	1,434,557	1,128,441	1,071,436	1,025,618	1,042,462	1,005,830	1,016,450	1,181,134	1,387,106	1,477,737	1,219,161	1,324,200	1,465,076	1,422,650	1,430,696	1,239,354	1,321,215	1,298,542	1,223,334	980,867	968,922	658,685	593,491	823,452	1,031,411	1,203,011	979,145	1,092,683	1,284,913	856,610	754,364	869,186	832,101	920,067	832,062	749,643	460,871	502,550	592,967	655,140	704,626	694,755	262,341	339,459	361,157	399,165	446,606	334,332	392,320	418,427	460,368	520,574	583,164	595,604	633,396	680,089	634,984	651,354	679,845	743,202	0	381,866	320,028	323,336	388,599	713,347	378,385	347,248	31,500	188,100	11,200	19,800	24,200	49,700	36,300	58,400	71,500	177,200	188,600	84,900	34,900	39,100	9,300	20,200	28,400	39,400	44,100	51,400	71,600	48,500	21,300	54,300	28,600	15,000	6,500	15,000	11,600	22,700	16,300	24,800	27,600	7,400	2,300	-	4,400	-	-	-
Common Stock	2,600	257,800	257,800	2,600	2,600	2,600	2,600	2,600	2,500	2,562	2,591	2,588	2,599	2,601	2,601	2,591	2,589	2,571	2,565	2,561	2,546	2,551	2,542	2,541	2,512	2,500	2,479	2,459	2,450	2,446	2,440	2,429	2,427	2,419	2,406	2,399	2,385	2,375	2,347	2,334	2,320	2,311	2,300	2,160	2,149	2,141	2,133	2,087	2,072	2,065	2,055	2,033	2,016	2,012	2,007	2,002	1,982	1,791	1,784	1,707	1,494	1,484	1,392	1,385	1,312	1,304	1,297	1,288	1,244	1,234	1,089	1,081	1,081	989	953	812	807	801	799	787	780	775	769	767	764	761	758	751	751	748	605	602	596	546	533	262	300	300	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Common Stock Shares Outstanding	260,900	260,600	260,400	260,300	260,300	259,500	258,700	257,900	257,000	259,707	261,020	261,916	263,106	264,079	263,403	263,515	262,108	260,473	259,822	260,175	259,812	259,788	258,584	258,526	256,804	250,268	251,635	248,700	247,757	244,920	244,482	243,831	242,987	241,969	240,757	239,493	238,272	236,137	233,808	232,887	235,717	230,505	222,053	215,421	214,607	213,767	211,344	219,264	219,264	219,349	204,413	202,329	202,329	200,887	200,397	198,935	198,935	178,735	172,563	155,860	155,860	140,109	138,725	134,471	134,471	130,006	129,269	125,756	125,756	112,803	108,523	107,440	107,440	94,590	82,274	79,428	79,428	78,742	78,807	78,094	78,094	77,067	76,764	76,411	76,411	75,979	75,660	75,161	75,161	74,682	60,337	60,011	60,011	53,843	58,946	51,928	51,928	51,071	50,960	50,286	50,286	46,000	49,000	49,412	49,412	49,167	46,667	44,615	44,615	37,059	34,844	34,091	34,091	34,500	34,615	33,571	33,571	32,500	30,556	29,091	29,091	24,545	26,667	23,571	23,571	24,444	23,750	22,857	22,857	17,143	19,676	19,676	19,676	19,676	19,676	19,676
Common Stock Total Equity	0	0	2,600	2,600	2,600	2,600	2,600	2,600	2,500	2,562	2,591	2,588	2,599	2,601	2,601	2,591	2,589	2,571	2,565	2,561	2,546	2,551	2,542	2,541	2,512	2,500	2,479	2,459	2,450	2,446	2,440	2,429	2,427	2,419	2,406	2,399	2,385	2,375	2,347	2,334	2,320	2,311	2,300	2,160	2,149	2,141	2,133	2,087	2,072	2,065	2,055	2,033	2,016	2,012	2,007	2,002	1,982	1,791	1,784	1,707	1,494	1,484	1,392	1,385	1,312	1,304	1,297	1,288	1,244	1,234	1,089	1,081	1,081	989	953	812	807	801	799	787	780	775	769	767	764	761	758	753	751	748	605	602	596	546	533	262	300	300	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Current Deferred Revenue	170,300	0	0	0	159,600	0	0	0	171,700	0	0	0	191,519	0	0	0	62,332	0	0	0	554,089	432,372	404,431	337,658	237,570	203,275	154,963	110,831	79,421	9,247	11,468	14,705	16,296	14,000	14,930	15,918	17,468	21,210	27,174	28,836	21,510	31,007	32,900	35,533	27,566	130,929	137,368	146,680	45,037	181,916	199,054	218,609	74,619	276,939	78,273	285,063	74,956	319,536	230,762	37,679	37,678	36,404	35,575	23,683	25,528	24,017	24,436	34,100	33,889	37,192	42,931	23,656	31,449	32,511	44,483	50,889	47,741	41,018	39,742	9,351	7,746	8,774	9,920	14,108	11,888	19,032	21,775	39,498	0	53,747	11,162	11,174	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9,414	9,335	9,636	8,067	13,599	140,810	141,144	140,695	139,829	140,221	120,749	120,153	131,361	133,432	39,093	42,852	34,723	38,105	43,889	49,459	227,557	233,772	241,961	376,609	383,092	373,089	357,615	361,802	357,405	394,484	304,694	320,327	410,363	418,583	415,142	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Good Will	1,088,000	1,088,000	1,088,000	1,088,000	1,088,000	1,075,200	1,389,200	1,402,200	1,402,200	1,402,158	1,402,158	1,402,158	1,402,158	1,402,158	1,402,158	1,402,158	1,402,158	447,525	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	50,384	39,915	39,915	30,992	30,992	30,992	30,992	30,992	30,992	30,992	30,992	30,992	30,992	30,992	30,992	33,501	33,501	26,102	26,102	26,102	26,102	26,102	26,102	26,102	26,883	26,883	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Intangible Assets	839,900	603,600	603,600	603,600	603,600	603,600	387,000	400,000	400,000	400,000	400,000	400,000	400,000	400,000	400,000	400,000	400,000	0	0	0	50,384	29,000	29,000	29,000	29,000	29,000	284,340	284,340	284,340	284,340	284,340	284,340	284,340	284,340	284,340	29,000	29,000	30,992	30,992	30,992	30,992	250,600	250,600	250,600	663,500	663,500	663,500	663,500	663,500	663,500	769,300	518,700	518,700	518,700	518,700	518,700	518,700	525,900	525,900	525,900	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Inventory	738,800	688,700	603,500	535,100	460,600	388,200	367,700	338,900	353,100	333,456	321,620	298,863	280,777	245,460	219,218	187,087	167,502	162,306	143,017	136,698	124,360	124,150	115,025	117,346	111,830	98,192	92,263	82,020	77,604	71,799	66,589	63,200	56,083	49,197	42,113	34,089	30,848	16,753	11,982	11,261	14,147	13,543	19,509	21,532	30,464	86,275	87,805	129,595	112,430	67,654	52,622	17,816	0	0	0	0	0	-856,610	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,428	4,325	4,585	4,349	4,253	4,548	6,636	0	3,362	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Liabilities And Stockholders Equity	22,730,200	21,726,200	20,349,200	18,974,200	18,150,900	16,706,400	15,582,200	14,256,100	13,432,500	12,618,745	12,221,686	12,115,059	11,751,808	11,301,633	10,216,367	8,893,201	8,318,465	7,514,553	7,033,471	6,543,114	6,245,898	4,620,840	4,335,386	3,952,974	3,546,014	3,198,325	3,285,594	2,946,703	2,893,785	2,604,838	2,548,982	2,487,906	2,497,045	2,433,993	2,374,073	2,165,827	2,336,309	2,406,086	2,117,820	2,197,108	2,319,041	2,582,755	2,584,329	2,392,234	2,759,288	2,718,823	2,604,856	2,345,843	2,204,280	2,091,998	1,763,100	1,538,487	1,725,446	1,888,829	1,654,202	1,770,302	1,955,488	1,573,491	1,439,876	1,565,883	980,479	1,067,554	970,805	889,505	601,477	655,148	761,070	835,095	921,579	902,111	625,478	524,658	548,998	550,575	596,903	484,229	545,453	574,362	624,051	669,188	724,411	742,676	787,456	840,306	815,720	831,069	860,474	925,131	925,131	922,370	766,834	769,544	772,881	774,563	428,322	396,931	232,400	224,800	238,600	249,700	266,300	277,900	274,900	283,300	295,600	298,700	300,700	289,600	143,500	143,500	73,700	90,300	99,000	98,300	106,100	111,800	116,200	106,700	110,400	113,900	61,000	50,800	51,600	48,700	51,000	52,900	54,500	55,500	57,100	32,400	7,300	-	9,200	-	-	-
Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	63,484	561,892	561,389	562,645	561,295	563,406	547,051	525,019	498,775	486,359	473,073	547,295	622,065	696,580	767,556	724,773	739,237	753,642	767,912	473,268	473,360	440,937	392,569	387,188	716,821	668,031	615,956	560,291	494,179	455,950	425,474	411,181	400,000	400,000	400,000	86,407	125,316	121,765	262,840	144,000	287,500	287,500	287,500	287,500	287,500	0	0	0	19,997	19,997	79,645	180,092	180,097	180,097	294,547	334,997	334,997	334,997	334,997	334,997	333,460	333,460	340,497	337,287	328,523	325,944	321,313	322,331	322,331	323,026	354,185	346,633	346,966	347,313	348,121	178,619	179,155	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	539,042	546,514	522,067	532,952	538,576	541,561	551,530	560,381	581,550	576,530	577,675	578,206	583,902	567,310	550,365	529,130	521,335	504,792	581,612	660,951	739,503	806,829	767,673	785,708	792,935	810,112	518,321	522,855	489,691	431,950	387,188	731,576	683,201	615,956	560,291	494,179	455,950	425,474	411,181	400,000	400,000	400,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Long Term Investments	2,497,800	1,700,000	1,357,300	1,081,500	112,200	0	0	0	0	0	0	0	0	0	0	0	60,800	40,800	33,600	13,600	13,600	36,700	0	0	20,447	20,447	20,252	20,276	20,276	53,314	33,213	30,138	30,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Debt	-9,563,900	-10,365,500	-9,383,500	-8,500,700	-9,943,000	-8,689,500	-8,170,600	-7,055,900	-6,238,300	-5,716,765	-5,493,926	-5,731,474	-5,406,711	-4,770,315	-4,268,858	-3,020,496	-2,531,951	-2,819,317	-2,706,107	-2,297,779	-2,082,971	-1,912,559	-1,575,234	-1,428,400	-1,101,501	-837,426	-697,588	-504,398	-345,696	96,050	215,228	220,695	105,846	64,732	-46,076	169,028	200,039	49,349	52,710	49,315	-128,362	-190,612	-172,147	337,722	183,224	-36,886	-54,061	132,077	-75,320	-142,545	-58,195	-46,536	293,794	-169,901	-251,201	-271,231	-292,822	-415,133	-264,949	-314,699	-101,615	-255,376	-262,132	-203,196	-335,666	-233,982	-106,619	-289,102	-89,416	-381,681	138,662	98,270	102,052	192,928	140,302	297,626	279,991	282,651	258,921	262,029	247,229	267,885	207,367	149,124	220,041	220,688	199,981	138,400	130,374	162,796	180,122	126,490	27,600	40,492	-2,385	-10,323	-24,400	-14,600	-2,800	-10,700	-14,400	-39,300	-26,700	-49,700	-63,100	-169,000	-180,400	-76,800	-26,400	-32,200	-2,400	-13,700	-21,400	-32,600	-37,200	-44,800	-65,200	-42,200	-15,300	-48,800	-22,600	-9,100	-600	-9,700	-6,500	-17,700	-11,900	-21,200	-24,300	-3,900	1,200	-	-1,200	-	-	-
Net Invested Capital	17,580,400	16,512,800	15,470,200	14,432,300	13,912,700	13,029,600	11,933,500	10,907,000	10,100,000	9,530,708	9,196,396	8,980,254	8,686,815	8,133,473	7,519,242	6,461,654	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Receivables	1,563,400	1,538,700	1,556,200	1,547,800	1,442,200	1,385,200	1,332,900	1,292,800	1,136,800	1,100,372	929,142	977,551	885,352	791,917	791,768	845,269	633,518	443,315	464,900	438,297	409,688	379,755	393,439	327,294	281,343	263,493	247,949	207,955	201,083	182,229	189,356	181,878	177,639	165,272	94,519	80,332	72,994	114,308	81,842	59,858	85,517	120,281	164,866	194,054	143,250	139,629	185,618	232,228	183,135	445,661	96,016	5,594	12,529	4,964	3,548	7,876	9,601	32,783	14,762	16,702	23,489	21,966	15,365	24,825	31,320	34,658	37,189	44,099	62,923	42,614	183,668	23,779	20,595	20,764	13,941	10,866	11,891	8,480	9,939	7,937	7,324	7,850	9,720	11,925	13,200	13,100	18,056	20,265	20,265	35,925	8,414	7,615	12,262	7,087	5,434	4,506	5,900	4,800	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Tangible Assets	0	0	13,778,600	12,740,700	12,221,100	11,350,800	10,544,300	9,504,800	8,697,800	8,128,550	7,794,238	7,578,096	7,284,657	6,731,315	6,117,084	5,059,496	4,683,086	4,805,869	5,019,581	4,672,929	4,384,819	2,826,732	2,606,828	2,321,672	1,949,195	1,711,677	1,336,549	1,165,284	821,858	686,822	646,630	622,355	605,243	587,423	560,240	907,543	1,006,091	1,124,913	1,141,277	1,199,886	1,325,413	1,022,920	1,080,075	503,395	343,218	1,035,040	1,044,695	937,002	129,387	-80,543	-458,953	-153,130	-40,829	105,294	282,333	445,810	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Working Capital	10,596,800	11,096,400	10,520,800	9,939,500	10,250,700	9,661,700	8,947,300	8,181,100	7,141,200	6,681,858	6,621,066	6,540,506	6,255,846	5,454,430	4,895,680	3,907,650	3,404,792	3,335,641	3,413,022	3,438,023	2,986,808	2,963,401	2,714,065	2,436,364	1,676,068	1,464,997	1,448,084	1,382,018	1,753,052	1,433,652	775,039	794,928	848,745	921,105	867,577	1,055,765	1,179,887	1,277,918	984,411	1,056,830	1,190,747	1,239,139	1,334,938	1,158,144	1,156,961	580,446	632,056	595,848	938,906	477,251	210,287	303,152	582,256	592,334	840,451	511,770	1,022,143	248,319	599,076	722,874	651,017	772,555	674,734	610,615	297,572	357,571	434,755	531,952	520,392	581,245	343,854	287,805	284,812	302,524	327,324	201,862	252,967	298,386	336,764	412,598	454,739	490,450	562,721	641,684	591,975	614,865	645,322	684,539	684,539	336,520	291,622	301,406	364,515	522,348	360,928	337,712	176,700	181,000	197,100	212,900	235,600	249,700	249,200	258,800	267,900	273,700	278,500	267,700	125,100	127,000	54,700	71,100	79,100	79,900	86,500	94,700	100,900	89,700	95,000	100,200	45,800	36,700	39,100	36,000	40,100	43,600	45,200	46,600	49,000	25,100	-	-	-	-	-	-
Non Current Assets Total	8,586,000	7,030,400	6,476,300	6,008,500	5,469,600	5,162,300	4,628,200	4,386,300	4,417,700	4,224,032	4,262,931	3,914,677	3,926,782	4,113,198	3,754,612	3,670,449	3,709,151	2,912,601	2,474,332	2,490,084	2,543,608	1,061,050	1,059,167	1,031,317	1,062,686	1,022,589	1,212,104	1,074,889	1,132,779	1,163,949	1,151,088	1,140,937	1,141,951	1,137,929	1,132,673	807,624	788,168	755,990	770,436	766,778	730,465	934,117	867,739	826,451	1,169,703	1,084,300	1,011,551	909,729	873,026	846,173	935,976	665,513	668,407	662,390	649,647	643,534	648,462	659,425	657,120	663,710	112,898	114,536	113,177	105,567	104,626	111,869	123,413	128,555	150,173	159,411	172,889	154,610	163,943	126,241	131,593	134,200	138,741	141,530	149,836	135,750	130,605	132,401	138,214	142,331	159,148	157,416	152,866	149,039	149,039	493,952	436,360	436,266	369,695	52,378	42,803	43,180	37,200	30,700	27,300	23,000	17,600	17,000	17,000	15,800	14,000	13,200	12,900	12,800	11,300	11,100	11,500	11,700	11,100	10,600	10,900	11,200	9,300	9,600	8,500	8,100	7,900	7,900	7,900	8,000	7,000	6,100	6,400	6,300	5,400	5,000	4,800	-	4,600	-	-	-
Non Current Liabilities Other	196,300	869,300	1,526,900	1,515,700	1,496,100	1,067,500	1,092,500	1,168,900	902,200	1,173,773	294,993	1,190,755	1,187,460	1,164,134	898,485	892,797	898,394	872,265	704,286	713,333	108,853	107,907	106,193	106,999	104,479	103,433	101,782	103,840	104,029	33,838	35,449	37,967	39,242	44,112	50,929	41,051	34,455	33,168	26,152	25,986	25,657	27,062	33,054	34,226	32,472	48,298	48,159	31,657	28,668	29,324	29,287	25,926	26,363	116,803	116,108	153,008	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Non Current Liabilities Total	1,602,400	1,614,000	1,526,900	1,515,700	1,807,600	1,285,500	1,331,200	1,455,000	1,458,900	1,375,182	1,415,200	1,474,929	1,504,883	1,356,675	1,050,267	1,072,573	1,028,699	994,848	817,389	1,204,794	1,095,213	1,089,970	1,058,349	1,036,860	1,503,708	1,395,081	1,418,363	774,114	1,547,640	1,398,960	1,380,137	1,371,708	1,404,365	1,357,261	1,325,857	1,168,290	1,240,126	1,250,181	945,551	966,230	962,636	1,096,069	1,035,666	1,415,402	1,524,906	400,000	400,000	400,000	846,420	592,578	581,795	576,993	746,690	604,628	662,963	164,692	574,259	299,000	527,139	679,733	525,041	537,198	547,986	411,927	130,903	137,405	143,583	159,208	164,630	232,887	341,747	209,503	209,579	295,453	335,959	344,553	356,267	365,596	376,307	391,252	392,499	391,569	387,418	383,746	372,542	364,068	361,508	358,227	358,227	354,185	346,633	346,966	347,313	348,121	178,619	179,155	4,700	5,200	5,800	6,400	7,000	7,600	6,900	6,200	5,900	5,400	5,400	5,300	5,600	4,400	4,500	4,400	4,900	4,900	5,000	5,000	4,700	4,600	4,400	3,800	4,200	4,000	3,800	3,400	3,200	3,200	3,000	2,300	2,200	2,300	2,500	-	2,400	-	-	-
Non Currrent Assets Other	796,700	475,200	442,700	427,500	1,323,300	1,094,400	892,400	931,200	986,900	845,688	886,732	710,506	683,311	642,311	409,129	384,283	371,098	316,056	267,626	229,623	181,547	173,314	163,855	151,263	193,865	183,227	137,277	11,494	99,693	141,612	125,757	115,692	109,512	96,535	84,571	30,093	3,441	4,120	9,444	9,582	2,562	3,601	4,409	40,627	41,602	42,559	44,498	44,906	45,358	47,904	48,972	49,834	51,272	52,149	44,407	40,623	41,381	44,979	39,979	44,326	44,567	44,823	46,547	40,855	38,117	42,969	55,642	67,132	88,638	98,276	98,069	83,892	109,410	51,251	54,234	54,637	55,653	54,488	57,747	40,717	50,522	31,509	33,270	36,122	36,724	38,592	66,644	68,662	68,662	418,888	392,826	400,203	341,546	27,687	17,723	17,970	12,700	7,100	7,600	7,300	3,100	3,300	3,400	3,400	2,900	3,000	2,900	2,700	2,600	4,100	4,300	4,100	3,300	3,100	3,100	3,200	800	1,100	300	0	200	200	100	200	100	300	400	500	400	400	600	-	200	-	-	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	28,365	28,655	29,765	13,727	12,167	195,958	182,785	181,609	186,795	187,491	159,119	153,661	154,585	153,252	21,079	21,177	0	0	0	0	182,168	186,996	191,845	196,672	198,714	167,920	137,583	141,633	114,388	105,332	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Assets	0	0	1,882,100	1,688,800	1,422,700	1,202,100	8,261,300	970,400	986,900	845,688	4,262,931	844,352	587,027	1,499,306	1,344,932	1,531,988	1,199,396	1,454,696	1,449,357	1,506,559	1,526,800	9,793	32,651	31,804	107,614	110,373	364,919	366,494	366,885	420,127	404,225	394,550	394,007	367,871	366,006	99,008	72,356	35,112	40,436	40,574	33,554	285,193	286,001	322,219	736,094	737,051	738,990	739,398	739,850	744,905	851,773	594,636	596,074	596,951	589,209	585,425	586,183	596,981	592,762	597,109	44,567	44,823	46,547	40,855	38,117	42,969	55,642	67,132	88,638	98,276	112,918	98,741	109,410	70,114	73,097	73,500	74,516	73,351	76,610	59,580	50,522	50,372	52,133	54,985	63,157	65,025	67,099	67,099	68,662	418,888	392,826	400,203	341,546	27,687	17,723	17,970	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Current Assets	620,500	540,200	476,900	468,700	74,400	726,900	549,500	491,500	187,200	457,827	498,759	338,925	308,353	270,021	232,565	223,648	213,515	175,142	151,829	130,009	74,045	118,678	122,694	109,886	63,964	152,238	107,082	128,493	16,780	61,012	56,256	55,866	12,065	63,388	53,289	62,648	57,193	41,298	34,399	35,011	23,836	41,105	43,231	47,835	24,673	1,333,665	1,263,858	1,016,274	66,767	681,930	678,486	855,158	13,099	18,464	21,862	26,209	12,512	881,283	13,630	16,285	11,991	10,985	10,201	9,470	4,660	6,071	7,501	7,301	3,857	5,331	6,580	6,810	3,303	4,405	4,763	4,831	2,501	5,925	3,908	4,927	3,318	3,393	1,801	1,376	4,039	4,946	5,159	5,989	12,625	7,265	2,032	2,327	2,325	1,751	1,700	1,997	157,800	1,200	200,100	206,900	224,500	211,200	221,600	209,100	210,100	108,300	99,200	191,900	97,300	93,300	52,900	58,400	59,500	48,300	51,100	49,200	35,300	48,600	80,600	51,500	24,500	27,900	37,200	25,700	32,400	24,100	31,800	24,400	24,100	20,000	200	-	200	-	-	-
Other Current Liab	2,928,500	3,223,500	2,989,100	2,703,000	1,877,700	2,264,400	2,119,500	1,720,500	1,460,000	1,584,992	1,482,556	1,532,037	1,171,018	1,703,699	1,545,407	1,258,271	1,024,287	1,173,783	1,069,072	532,745	40,589	60,357	59,629	56,654	473,165	410,445	376,323	296,550	-452,344	-368,447	321,063	298,572	328,088	267,907	229,396	194,797	247,580	294,372	260,729	276,770	310,099	312,530	289,518	304,177	290,059	619,527	536,034	426,687	260,594	438,994	255,844	224,232	227,322	163,650	54,778	136,324	140,867	150,350	21,255	21,255	21,255	21,310	21,310	41,307	121,004	115,937	98,613	86,118	97,999	75,017	57,527	2,988	2,988	2,975	2,975	4,750	4,688	79,236	85,206	103,712	114,355	98,145	63,844	30,809	33,769	24,617	27,228	35,848	75,346	27,212	19,312	15,916	32,447	4,650	4,742	0	13,100	0	-100	0	7,500	100	0	0	7,000	600	1,100	0	2,800	0	1,100	1,200	3,700	200	1,100	600	2,900	1,700	1,700	1,200	2,000	1,600	700	300	1,400	1,500	200	300	700	300	300	-	800	-	-	-
Other Liab	0	0	0	0	685,800	803,500	799,600	296,400	902,200	816,249	294,993	291,958	923,407	617,620	376,418	499,657	275,526	267,726	92,323	89,468	108,853	117,321	115,528	116,635	106,205	106,350	105,943	109,582	110,661	40,397	42,860	46,457	48,956	61,613	71,948	65,051	62,263	67,891	64,257	69,875	75,116	104,416	117,120	124,523	128,714	151,924	158,231	147,846	146,763	181,019	174,504	170,342	186,412	279,663	288,006	282,556	292,216	308,038	220,636	229,730	237,541	249,698	260,486	124,427	130,903	137,405	143,583	139,211	144,633	153,242	161,655	29,406	29,482	906	962	9,556	21,270	30,599	41,310	57,792	59,039	51,072	50,131	55,223	46,598	42,755	37,523	37,523	35,201	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Stockholder Equity	7,449,700	7,084,400	7,113,900	7,220,200	7,386,500	7,225,500	7,100,000	6,930,200	6,880,800	7,085,950	7,640,233	7,499,161	7,894,027	7,917,375	7,943,717	7,695,905	7,937,606	7,668,188	7,564,331	7,475,909	7,421,476	7,443,263	7,357,042	7,314,369	7,157,362	7,034,113	6,808,002	6,616,975	6,506,795	6,429,726	6,350,244	6,262,964	6,197,500	6,106,270	5,987,169	5,877,324	5,777,154	5,681,163	5,528,679	5,428,193	5,321,286	5,274,307	5,208,431	4,574,987	4,519,448	4,471,727	4,424,489	4,252,284	4,200,659	4,152,106	4,100,775	4,010,777	3,947,433	3,912,778	3,880,746	3,844,744	3,784,787	3,138,207	3,108,429	2,914,278	2,281,817	2,253,007	2,013,115	1,984,785	1,856,856	1,832,425	1,808,853	1,777,720	1,702,128	1,676,911	1,282,984	1,260,607	1,243,960	1,101,174	1,008,781	838,531	833,832	828,210	826,451	815,859	810,407	805,715	800,534	797,609	794,206	867,421	862,439	858,031	0	829,406	674,801	672,054	659,381	485,533	457,136	444,656	434,100	431,200	427,700	426,300	424,200	423,100	419,900	418,200	416,400	411,500	410,100	397,900	247,700	314,700	236,300	142,800	142,200	141,700	141,500	141,000	140,900	125,200	125,700	125,600	67,300	67,200	67,100	63,800	63,800	63,700	63,500	63,600	63,600	37,800	11,400	-	11,400	-	-	-
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Property Plant And Equipment Gross	2,641,800	1,434,500	1,446,700	1,448,000	2,483,100	1,461,400	0	0	0	0	1,338,107	1,308,442	958,534	920,913	728,357	736,303	745,080	794,438	789,162	803,132	812,005	808,352	815,928	800,670	789,437	759,978	740,103	708,395	698,362	687,613	690,607	690,521	697,715	706,670	713,378	708,616	715,812	720,878	730,000	726,204	696,911	648,924	581,738	504,232	433,609	347,249	272,561	170,331	133,176	101,268	84,203	70,877	72,333	65,439	60,438	58,109	62,279	62,444	64,358	66,601	68,331	69,713	66,630	64,712	66,509	68,900	67,771	61,423	61,535	61,135	59,971	55,869	54,533	56,127	58,496	60,700	64,225	68,179	73,226	76,170	80,083	82,029	86,081	87,346	95,991	92,391	86,222	84,628	80,377	75,064	43,534	36,063	28,149	24,691	25,080	25,210	24,500	23,600	19,700	15,700	14,500	13,700	13,600	12,400	11,100	10,200	10,000	10,100	8,700	7,000	7,200	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Property Plant And Equipment Net	1,452,900	1,434,500	1,446,700	1,448,000	1,108,400	1,118,700	1,100,100	1,107,400	1,094,100	1,042,347	1,021,233	986,123	958,534	920,913	728,357	736,303	745,080	733,509	731,131	742,559	812,005	808,352	815,928	800,670	789,437	759,978	740,103	708,395	698,362	687,613	690,607	690,521	697,715	706,670	713,378	708,616	715,812	720,878	730,000	726,204	696,911	648,924	581,738	504,232	433,609	347,249	272,561	170,331	133,176	101,268	84,203	70,877	72,333	65,439	60,438	58,109	62,279	62,444	64,358	66,601	68,331	69,713	66,630	64,712	66,509	68,900	67,771	61,423	61,535	61,135	59,971	55,869	54,533	56,127	58,496	60,700	64,225	68,179	73,226	76,170	80,083	82,029	86,081	87,346	95,991	92,391	86,222	80,377	0	75,064	43,534	36,063	28,149	24,691	25,080	25,210	24,500	23,600	19,700	15,700	14,500	13,700	13,600	12,400	11,100	10,200	10,000	10,100	8,700	7,000	7,200	7,600	7,800	7,500	7,800	8,000	8,500	8,500	8,200	8,100	7,700	7,700	7,800	7,800	6,900	5,800	6,000	5,800	5,000	4,600	4,200	-	4,400	-	-	-
Property Plant Equipment	0	0	0	0	1,455,800	1,118,700	1,100,100	1,436,400	1,094,100	1,042,347	1,338,107	1,308,442	958,534	920,913	728,357	736,303	833,282	733,509	731,131	742,559	812,005	808,352	815,928	800,670	789,437	759,978	740,103	708,395	698,362	687,613	690,607	690,521	697,715	706,670	713,378	708,616	715,812	720,878	730,000	726,204	696,911	648,924	581,738	504,232	433,609	347,249	272,561	170,331	133,176	101,268	84,203	70,877	72,333	65,439	60,438	58,109	62,279	62,444	64,358	66,601	68,331	69,713	66,630	64,712	66,509	68,900	67,771	61,423	61,535	61,135	59,971	55,869	54,533	56,127	58,496	60,700	64,225	68,179	73,226	76,170	80,083	82,029	86,081	87,346	95,991	92,391	84,628	84,628	80,377	75,064	43,534	36,063	28,149	24,691	25,080	25,210	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Retained Earnings	10,142,400	9,173,600	8,138,300	7,222,600	6,522,800	5,703,900	4,773,400	3,962,900	3,200,800	2,430,659	1,578,731	1,511,807	858,669	254,479	-412,955	-1,250,225	-1,852,978	-2,436,212	-2,493,730	-2,761,157	-2,989,478	-4,540,005	-4,668,751	-4,876,111	-5,119,723	-5,220,407	-5,117,455	-5,135,451	-5,373,836	-5,406,781	-5,367,940	-5,303,415	-5,261,784	-5,188,053	-5,092,904	-4,904,056	-4,705,450	-4,528,794	-4,358,734	-4,199,352	-3,966,895	-4,011,180	-3,887,048	-3,829,883	-3,521,867	-3,445,719	-3,388,176	-3,323,245	-3,414,835	-3,573,464	-3,794,574	-3,620,505	-3,444,409	-3,264,017	-3,055,060	-2,855,054	-2,689,783	-2,531,139	-2,381,574	-2,210,277	-2,047,605	-1,905,273	-1,775,229	-1,683,908	-1,587,754	-1,502,003	-1,394,970	-1,277,203	-1,196,475	-1,169,131	-1,117,329	-1,039,671	-989,584	-951,453	-871,875	-830,887	-786,167	-743,398	-704,627	-660,358	-619,920	-578,891	-492,470	-402,542	-423,153	-391,070	-357,618	-314,532	-314,532	-311,272	-251,462	-239,355	-230,485	-219,231	-194,373	-206,986	-190,800	-192,500	-178,300	-167,400	-149,900	-137,300	-135,000	-125,200	-116,800	-110,000	-104,100	-102,700	-96,900	-93,100	-86,700	-64,400	-56,900	-56,100	-49,100	-40,100	-35,400	-30,500	-26,600	-21,100	-17,800	-26,600	-23,900	-23,200	-19,900	-17,200	-14,900	-13,000	-11,400	-10,000	-8,800	-	-6,200	-	-	-
Retained Earnings Total Equity	0	0	8,138,300	7,222,600	6,522,800	5,703,900	4,773,400	3,962,900	3,200,800	2,430,659	1,578,731	1,511,807	858,669	254,479	-412,955	-1,250,225	-1,852,978	-2,436,212	-2,493,730	-2,761,157	-2,989,478	-4,540,005	-4,668,751	-4,876,111	-5,119,723	-5,220,407	-5,117,455	-5,135,451	-5,373,836	-5,406,781	-5,367,940	-5,303,415	-5,261,784	-5,188,053	-5,092,904	-4,904,056	-4,705,450	-4,528,794	-4,358,734	-4,199,352	-3,966,895	-4,011,180	-3,887,048	-3,829,883	-3,521,867	-3,445,719	-3,388,176	-3,323,245	-3,414,835	-3,573,464	-3,794,574	-3,620,505	-3,444,409	-3,264,017	-3,055,060	-2,855,054	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7,520	0	0	592,735	595,125	606,433	587,191	568,544	19,270	840,761	315,523	239,022	0	71,296	0	0	0	14,206	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Short Long Term Debt Total	808,400	744,700	767,600	789,200	561,000	482,000	531,600	544,200	556,700	558,933	569,752	572,856	581,476	587,772	562,474	572,916	577,371	578,624	588,577	596,106	567,163	565,743	570,125	567,493	563,911	547,540	525,542	499,281	838,249	815,742	821,094	824,940	820,614	820,982	824,467	833,907	825,298	767,912	473,268	473,360	440,937	392,569	359,100	716,821	672,631	400,000	400,000	400,000	400,000	400,000	400,000	400,000	536,991	400,000	86,407	125,316	153,836	144,000	144,000	287,500	287,500	287,500	287,500	287,500	19,997	19,997	62,099	65,226	123,755	101,750	180,092	180,097	180,097	294,547	334,997	334,997	334,997	319,688	322,613	315,036	345,388	345,334	340,777	329,897	328,139	324,282	325,249	327,605	319,579	358,747	348,649	349,152	349,690	511,921	180,823	181,427	7,100	7,800	8,400	9,100	9,800	10,400	9,600	8,700	8,400	8,200	8,200	8,100	8,500	6,900	6,900	6,500	7,000	6,800	6,900	6,600	6,400	6,300	6,000	5,500	6,000	5,900	5,900	5,300	5,100	5,000	4,400	3,600	3,300	3,500	3,500	-	3,200	-	-	-
Short Term Debt	83,700	0	0	0	89,400	0	0	0	46,900	0	0	0	42,434	0	0	0	30,293	0	0	7,520	9,817	11,511	15,060	16,919	22,531	19,881	18,179	19,270	319,426	315,523	239,022	163,543	87,023	14,153	56,794	48,199	32,012	18,124	19,707	18,323	16,893	14,429	10,664	8,302	13,707	219,889	228,495	193,673	12,075	98,416	94,664	92,100	136,991	168,872	-15,442	164,490	32,071	175,899	-95,831	97,665	105,871	91,284	89,664	77,052	19,997	19,997	62,099	45,229	103,758	42,102	0	49,340	59,596	79,864	81,099	84,054	94,656	4,688	4,688	36	4,660	4,837	3,490	1,374	2,195	2,969	3,519	4,579	4,579	4,562	2,016	2,186	2,377	163,800	2,204	2,272	2,400	2,500	2,600	2,700	2,800	2,800	2,700	2,500	2,500	2,700	2,800	2,800	2,900	2,500	2,300	2,100	2,100	1,900	1,800	1,700	1,700	1,600	1,600	1,600	1,800	1,900	2,000	1,900	1,800	1,700	1,500	1,300	1,200	1,100	1,000	-	800	-	-	-
Short Term Investments	849,200	11,928,200	11,236,300	1,124,200	274,500	599,200	551,200	638,000	729,900	685,187	644,315	619,638	670,710	792,971	619,437	596,984	698,972	598,390	656,538	584,150	518,108	577,583	622,396	481,124	423,254	427,282	445,520	405,103	250,612	408,749	465,570	421,373	327,694	249,580	145,907	516,255	761,847	759,174	798,603	900,155	895,777	839,469	899,449	860,255	831,808	861,656	769,273	712,944	493,602	116,140	135,296	376,916	788,214	633,110	641,537	696,136	838,255	297,477	345,415	266,987	442,986	377,191	282,430	258,947	105,208	248,571	424,249	300,812	491,455	211,324	220,911	257,632	283,112	297,546	251,911	296,961	337,314	381,390	396,676	467,567	485,005	518,155	499,986	499,316	526,886	547,760	554,577	553,997	553,997	185,915	151,501	100,674	66,509	241,918	195,177	155,498	0	165,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Assets	22,730,200	21,726,200	20,349,200	18,974,200	18,150,900	16,706,400	15,582,200	14,256,100	13,432,500	12,618,745	12,221,686	12,115,059	11,751,808	11,301,633	10,216,367	8,893,201	8,318,465	7,514,553	7,033,471	6,543,114	6,245,898	4,620,840	4,335,386	3,952,974	3,546,014	3,198,325	3,285,594	2,946,703	2,893,785	2,604,838	2,548,982	2,487,906	2,497,045	2,433,993	2,374,073	2,165,827	2,336,309	2,406,086	2,117,820	2,197,108	2,319,041	2,582,755	2,584,329	2,392,234	2,759,288	2,718,823	2,604,856	2,345,843	2,204,280	2,091,998	1,763,100	1,538,487	1,725,446	1,888,829	1,654,202	1,770,302	1,955,488	1,573,491	1,439,876	1,565,883	980,479	1,067,554	970,805	889,505	601,477	655,148	761,070	835,095	921,579	902,111	625,478	524,658	548,998	550,575	596,903	484,229	545,453	574,362	624,051	669,188	724,411	742,676	787,456	840,306	815,720	831,069	860,474	925,131	925,131	922,370	766,834	769,544	772,881	774,563	428,322	396,931	232,400	224,800	238,600	249,700	266,300	277,900	274,900	283,300	295,600	298,700	300,700	289,600	143,500	143,500	73,700	90,300	99,000	98,300	106,100	111,800	116,200	106,700	110,400	113,900	61,000	50,800	51,600	48,700	51,000	52,900	54,500	55,500	57,100	32,400	7,300	-	9,200	-	-	-
Total Current Assets	14,144,200	14,695,800	13,872,900	12,965,700	12,681,300	11,544,100	10,954,000	9,869,800	9,014,800	8,394,713	7,958,755	8,200,382	7,825,026	7,188,435	6,461,755	5,222,752	4,609,314	4,601,952	4,559,139	4,053,030	3,702,290	3,559,790	3,276,219	2,921,657	2,483,328	2,175,736	2,073,490	1,871,814	1,761,006	1,440,889	1,397,894	1,346,969	1,355,094	1,296,064	1,241,400	1,358,203	1,548,141	1,650,096	1,347,384	1,430,330	1,588,576	1,648,638	1,716,590	1,565,783	1,589,585	1,634,523	1,593,305	1,436,114	1,331,254	1,245,825	827,124	872,974	1,057,039	1,226,439	1,004,555	1,126,768	1,307,026	914,066	782,756	902,173	867,581	953,018	857,628	783,938	496,851	543,279	637,657	706,540	771,406	742,700	452,589	370,048	385,055	424,334	465,310	350,029	406,712	432,832	474,215	533,438	593,806	610,275	649,242	697,975	656,572	673,653	707,608	776,092	776,092	428,418	330,474	333,278	403,186	722,185	385,519	353,751	195,200	194,100	211,300	226,700	248,700	260,900	257,900	267,500	281,600	285,500	287,800	276,800	132,200	132,400	62,200	78,600	87,900	87,700	95,200	100,600	106,900	97,100	101,900	105,800	53,100	42,900	43,700	40,700	44,000	46,800	48,100	49,200	51,700	27,400	2,500	-	4,600	-	-	-
Total Current Liabilities	3,547,400	3,599,400	3,352,100	3,026,200	2,430,600	2,391,300	2,317,500	1,894,100	1,873,600	1,712,855	1,610,090	1,659,876	1,560,110	1,811,485	1,646,858	1,358,974	1,204,522	1,266,311	1,146,117	615,007	715,482	596,389	562,154	485,293	807,260	710,739	625,406	489,796	7,954	7,237	622,855	552,041	506,349	374,959	373,823	302,438	368,254	372,178	362,973	373,500	397,829	409,499	381,652	407,639	432,624	1,054,077	961,249	840,266	392,348	768,574	616,837	569,822	474,783	634,105	164,104	614,998	284,883	665,747	183,680	179,299	216,564	180,463	182,894	173,323	199,279	185,708	202,902	174,588	251,014	161,455	108,735	82,243	100,243	121,810	137,986	148,167	153,745	134,446	137,451	120,840	139,067	119,825	86,521	56,291	64,597	58,788	62,286	91,553	91,553	91,898	38,852	31,872	38,671	199,837	24,591	16,039	18,500	13,100	14,200	13,800	13,100	11,200	8,700	8,700	13,700	11,800	9,300	9,100	7,100	5,400	7,500	7,500	8,800	7,800	8,700	5,900	6,000	7,400	6,900	5,600	7,300	6,200	4,600	4,700	3,900	3,200	2,900	2,600	2,700	2,300	2,200	-	1,600	-	-	-
Total Liab	5,149,800	5,213,400	4,879,000	4,541,900	4,238,200	3,676,800	3,648,700	3,349,100	3,332,500	3,088,037	3,025,290	3,134,805	3,064,993	3,168,160	2,697,125	2,431,547	2,233,221	2,261,159	1,963,506	1,819,801	1,810,695	1,686,359	1,620,503	1,522,153	1,503,708	1,395,081	1,418,363	2,946,703	1,555,594	1,406,197	1,380,137	1,371,708	1,404,365	1,357,261	1,325,857	1,168,290	1,240,126	1,250,181	945,551	966,230	962,636	1,096,069	1,035,666	1,415,402	1,524,906	1,454,077	1,361,249	1,240,266	1,238,768	1,361,152	1,198,632	1,146,815	1,221,473	1,238,733	827,067	779,690	859,142	964,747	710,819	859,032	741,605	717,661	730,880	585,250	330,182	323,113	346,485	333,796	415,644	394,342	450,482	291,746	309,822	417,263	473,945	492,720	510,012	500,042	513,758	512,092	531,566	511,394	473,939	440,037	437,139	422,856	423,794	449,780	449,780	446,083	385,485	378,838	385,984	547,958	203,210	195,194	23,200	18,300	20,000	20,200	20,100	18,800	15,600	14,900	19,600	17,200	14,700	14,400	12,700	9,800	12,000	11,900	13,700	12,700	13,700	10,900	10,700	12,000	11,300	9,400	11,500	10,200	8,400	8,100	7,100	6,400	5,900	4,900	4,900	4,600	4,700	-	4,000	-	-	-
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,934,481	2,714,883	2,430,821	2,042,306	1,803,244	1,867,231	1,682,793	1,338,191	1,208,341	1,168,845	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Stockholder Equity	17,580,400	16,512,800	15,470,200	14,432,300	13,912,700	13,029,600	11,933,500	10,907,000	10,100,000	9,530,708	9,196,396	8,980,254	8,686,815	8,133,473	7,519,242	6,461,654	6,085,244	5,253,394	5,069,965	4,723,313	4,435,203	2,934,481	2,714,883	2,430,821	2,042,306	1,803,244	1,867,231	1,682,793	1,338,191	1,198,641	1,168,845	1,116,198	1,092,680	1,076,732	1,048,216	997,537	1,096,183	1,155,905	1,172,269	1,230,878	1,356,405	1,264,894	1,322,453	746,115	999,180	1,027,733	1,037,773	930,498	786,843	579,762	307,549	391,672	503,973	650,096	827,135	990,612	1,096,346	608,744	729,057	706,851	238,874	349,893	239,925	304,255	271,295	332,035	414,585	501,299	505,935	507,769	174,996	232,912	239,176	133,312	122,958	-8,491	35,441	74,320	110,293	157,096	192,845	231,282	313,517	400,269	378,581	408,213	436,680	475,351	475,351	476,287	381,349	390,706	386,897	226,605	225,112	201,737	209,200	206,500	218,600	229,500	246,200	259,100	259,300	268,400	276,000	281,500	286,000	275,200	130,800	133,700	61,700	78,400	85,300	85,600	92,400	100,900	105,500	94,700	99,100	104,500	49,500	40,600	43,200	40,600	43,900	46,500	48,600	50,600	52,200	27,800	2,600	-	5,200	-	-	-
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31	1993-12-31	1992-12-31	1991-12-31
Begin Period Cash Flow	10,512,000	6,800,100	5,988,900	3,120,681	2,658,253	1,667,526	1,183,945	714,768	625,259	569,299	489,407	475,320	243,197	446,658	389,115	355,663	213,171	78,045	55,006	98,159	108,098	189,205	346,659	31,548	24,200	71,500	34,900	28,400	71,600	28,600	11,600	27,600	4,400
Capital Expenditures	258,400	204,700	235,000	259,800	75,451	95,524	259,421	56,563	45,302	51,201	51,393	71,140	94,595	38,054	23,496	32,180	32,415	32,417	16,959	12,495	17,351	41,219	53,899	11,913	16,200	7,900	6,000	4,000	5,400	1,900	1,800	1,500	1,200
Cash And Cash Equivalents Changes	0	3,741,100	824,600	2,847,612	460,785	990,727	481,467	469,177	89,509	55,960	79,892	14,087	232,123	-203,461	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	-453,200	-263,500	-332,158	5,230	-1,366,365	-231,576	8,262	-5,977	-15,490	-297,114	24,401	-9,218	-631	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-139,700	3,711,900	811,200	2,868,164	462,428	990,727	481,467	469,177	89,509	55,960	79,892	14,087	232,123	-203,461	57,543	33,452	142,492	135,126	23,039	-43,153	-9,939	-81,107	-157,454	290,542	7,300	4,200	164,800	87,100	1,700	71,900	1,600	-1,200	50,900
Change In Working Capital	-265,700	340,800	-105,200	-54,454	-66,101	238,020	15,264	-2,070	-85,950	-11,063	-5,051	-13,788	-193,064	-63,777	61,424	138,783	47,300	123,054	-52,073	-12,741	68,944	867	41,090	9,789	1,500	-1,900	6,900	-3,300	1,900	-600	2,700	400	800
Change Receivables	0	-358,600	-274,700	-223,444	-225,587	-108,152	-71,759	-33,027	-104,847	7,428	53,363	39,912	-170,606	-2,923	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-84,100	-358,600	-274,700	-223,444	-225,587	-108,152	-71,759	-33,027	-104,847	7,428	53,363	39,912	-170,606	-2,923	13,900	7,831	31,603	-42,328	-8,704	-4,567	1,574	13,641	13,641	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-322,900	-136,400	-92,800	-132,014	-64,047	-31,965	-44,984	-16,450	-23,146	-16,469	7,142	-29,925	-111,388	6,191	9,524	-3,152	19,535	48,249	0	0	70,753	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	1,162,200	354,100	598,566	188,093	232,177	243,070	56,106	51,303	13,749	-53,495	-9,545	91,547	-60,254	0	0	0	0	0	0	0	0	10,059	9,568	0	0	0	0	0	0	0	0	0
Change To Netincome	0	445,600	452,700	521,393	381,890	385,068	797,159	243,845	243,073	177,071	877,719	255,942	248,771	138,944	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	715,000	230,400	249,728	246,318	341,583	123,254	65,220	68,245	-61,452	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	181,300	148,300	125,600	109,515	106,941	72,420	61,397	61,398	62,343	63,257	48,365	38,191	35,041	30,459	30,107	32,196	27,459	25,868	27,289	29,640	23,438	25,432	17,964	9,095	6,300	4,500	3,600	3,200	3,700	3,500	3,900	2,800	1,800
Dividends Paid	0	0	102,000	264,946	10,046	20,840	0	0	0	0	0	0	0	0	290,557	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	10,372,300	10,512,000	6,800,100	5,988,845	3,120,681	2,658,253	1,665,412	1,183,945	714,768	625,259	569,299	489,407	475,320	243,197	446,658	389,115	355,663	213,171	78,045	55,006	98,159	108,098	189,205	322,090	31,500	75,700	199,700	115,500	73,300	100,500	13,200	26,400	55,300
Exchange Rate Changes	0	0	0	0	0	-6,182	5,802	-4,666	-2,834	-2,176	4,708	-141	214	-377	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	3,278,900	3,925,200	2,408,500	2,993,705	1,493,879	1,174,762	745,521	179,540	-410,734	-624,313	-170,490	196,701	49,140	-673,496	-451,082	-258,662	-284,891	-54,892	-189,013	-154,655	-184,974	-120,758	-61,973	-28,557	-48,000	-39,000	-15,400	-44,300	-21,400	-16,600	6,800	-6,800	-3,700
Investments	-2,079,600	227,300	-28,900	378,513	33,664	-15,342	-163,367	120,937	404,402	133,766	-64,123	-337,902	294,495	50,087	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	343,244	289,293	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	-85,500	-24,400	-29,024	-35,005	-7,086	-284,129	-9,527	3,708	280,850	-16,215	-2,615	-250,000	391,623	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	3,619,600	3,322,000	2,342,100	2,711,647	1,176,810	2,087,103	91,635	-84,031	-588,181	-742,745	-687,550	-51,135	41,179	-754,626	-642,178	-459,851	-391,279	-206,891	-203,417	-166,247	-196,767	-108,621	-66,233	-39,658	-41,000	-33,100	-19,800	-40,000	-21,500	-17,600	2,000	-8,500	-5,100
Other Cashflows From Financing Activities	-224,300	3,500	130,300	276,401	24,775	43,759	42,900	158,070	23,662	304,453	-1,252	1,971	900	391,645	149,902	278,607	-42,155	-170	165,251	-17,368	25,509	515	-23,635	501,593	-2,700	1,400	-100	1,600	600	-1,900	-2,000	-1,300	-1,000
Other Cashflows From Investing Activities	0	-343,700	-77,000	-19,327	-1,193,531	-91,292	-174,893	40,095	-90,244	-8,606	61,386	-16,775	-47,488	-4,732	624	0	0	29,766	8,306	0	98,780	200	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-42,600	103,400	-5,800	-220,005	-176,196	60,021	506,423	6,140	12,048	-471	750,416	143,628	141,329	-31	38,564	-622	63,747	46,583	56,147	7,188	-63,238	2,783	-895	4,130	1,400	-600	-100	-200	-100	0	0	0	0
Sale Purchase Of Stock	-427,600	-172,000	-1,561,300	-739,407	-192,015	-350,043	344,840	68,230	185,592	274,615	265,878	191,721	124,862	33,434	290,557	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	581,200	491,300	441,400	429,461	360,489	325,047	290,736	237,705	231,025	177,542	127,303	114,285	126,751	97,676	86,722	63,012	59,407	39,137	7,530	4,165	3,146	1,501	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-562,200	-67,700	-1,478,000	-505,281	126,773	-71,219	68,404	133,271	188,919	497,376	180,884	172,204	-124,238	425,057	999,006	620,738	-10,190	365,865	197,456	-8,626	37,468	13,842	-3,982	544,031	2,800	4,200	164,800	87,100	1,700	71,900	1,600	-1,200	50,900
Total Cash From Operating Activities	3,537,300	4,129,900	2,643,500	3,253,505	1,569,330	1,270,286	844,942	236,103	-365,432	-513,199	-51,570	267,841	143,735	-635,442	-427,586	-226,482	-252,476	-22,475	-172,054	-142,160	-167,623	-79,539	-8,074	-16,644	-31,800	-31,100	-9,400	-40,300	-16,000	-14,700	8,600	-5,300	-2,500
Total Cashflows From Investing Activities	0	-321,100	-340,900	99,388	-1,235,318	-202,158	-437,681	104,469	268,856	73,959	-54,130	-425,817	212,412	7,301	0	0	405,166	0	0	107,428	119,585	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31	1993-12-31	1993-09-30	1993-06-30	1993-03-31	1992-12-31	1992-09-30	1992-06-30	1992-03-31	1991-12-31	1991-09-30
Begin Period Cash Flow	11,116,600	10,153,400	9,295,600	10,512,000	9,177,000	8,704,100	7,604,000	6,800,100	6,280,213	6,071,068	6,312,907	5,988,845	5,360,985	4,835,700	3,601,964	3,120,681	3,404,591	3,301,646	2,901,532	2,658,253	2,487,051	2,154,068	2,005,728	1,667,526	1,384,966	1,223,130	1,003,679	1,183,945	719,692	605,866	604,245	714,768	756,250	870,543	664,879	625,259	718,563	420,558	424,045	569,299	583,181	531,247	379,099	489,407	436,886	454,061	267,923	475,320	542,545	458,195	446,536	243,197	569,901	337,608	396,547	446,658	559,133	408,949	602,199	389,115	542,876	549,632	490,696	355,663	253,979	168,718	354,328	213,171	483,431	41,430	81,827	78,045	101,619	194,695	37,371	55,006	37,037	63,692	53,007	98,159	77,449	133,410	180,773	108,098	103,594	125,268	176,229	195,951	195,951	168,527	222,662	322,090	471,429	183,208	191,750	31,548	22,400	11,200	24,800	24,200	1,500	1,300	72,800	71,500	1,100	12,000	185,000	34,900	78,100	6,000	28,800	28,400	0	600	72,000	71,600	0	0	86,100	28,600	0	2,900	11,200	11,600	0	0	27,300	27,600	26,000	0
Capital Expenditures	116,100	40,600	59,600	42,100	33,600	54,200	53,300	63,600	61,800	52,400	49,900	70,900	47,691	174,795	17,864	19,450	16,761	24,291	16,358	18,041	15,721	20,912	29,612	29,279	42,604	187,951	17,707	11,159	14,788	13,883	15,918	11,974	12,527	8,797	13,420	10,558	14,676	9,298	11,701	15,526	14,471	18,514	1,801	16,607	28,046	21,396	15,543	6,155	9,329	9,985	70,431	4,850	14,428	10,830	9,686	3,110	7,578	4,753	4,586	6,579	6,612	10,506	9,568	5,494	5,199	7,929	13,154	6,133	7,188	6,997	10,779	7,453	5,142	4,434	4,144	3,239	3,804	1,831	3,984	2,876	3,850	1,381	7,943	6,939	10,562	12,399	8,446	11,728	11,728	21,968	10,157	10,046	5,811	1,670	1,778	2,654	2,700	5,700	5,300	2,500	2,200	1,200	2,300	2,200	1,900	1,100	700	2,300	2,300	600	500	600	3,700	700	500	500	400	300	100	1,300	300	400	100	1,200	1,200	400	200	900	600	0
Cash And Cash Equivalents Changes	0	0	847,800	-1,228,400	1,294,200	511,100	1,126,000	809,800	524,760	217,606	-245,858	328,092	610,087	519,127	1,230,464	487,934	-289,562	106,146	400,544	243,657	166,446	333,538	154,197	336,546	280,446	161,836	219,451	-180,266	464,253	113,826	1,621	-110,523	-41,482	-114,293	205,664	39,620	-93,304	298,005	-3,487	-145,254	297,516	-92,054	-15,262	-110,308	52,521	-17,175	186,138	-207,397	-67,225	84,350	11,659	203,339	-326,704	232,293	-58,939	-50,111	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-195,800	-73,600	-130,400	-326,200	-127,500	130,900	-38,181	6,077	-327,415	96,019	8,507	-255,589	-169,441	84,365	3,626	31,904	-73,798	43,498	-1,401,757	-1,532	7,855	29,069	-27,601	-160,753	2,744	-45,966	-6,303	-322	20,152	-5,265	9,967	-6,893	6,182	-15,233	3,620	-1,572	399	-17,937	-143,425	0	0	-153,689	11,340	21,930	13,953	-22,822	19,079	-28,712	13,598	-13,183	5,565	3,204	4,267	-13,667	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-744,300	963,200	857,800	-1,216,400	1,335,000	472,900	1,100,100	803,900	519,887	209,145	-241,839	324,062	627,860	525,285	1,233,736	481,283	-283,910	102,945	400,114	243,279	171,202	332,983	148,340	338,202	280,446	161,836	219,451	-180,266	464,253	113,826	1,621	-110,523	-41,482	-114,293	205,664	39,620	-93,304	298,005	-3,487	-145,254	-13,882	51,934	152,148	-110,308	52,521	-17,175	186,138	-207,397	-67,225	84,350	11,659	203,339	-326,704	232,293	-58,939	-50,111	-112,475	150,184	-193,250	213,084	-153,761	-6,756	58,936	135,033	101,684	85,261	-185,610	141,157	-270,260	442,001	-40,397	3,782	-23,574	-93,076	157,324	-17,635	17,969	-26,655	10,685	-45,152	20,710	-55,961	-47,363	72,675	4,504	-21,674	-50,961	-6,746	-6,746	27,424	-54,135	-99,428	-149,339	288,221	-8,542	160,202	9,100	11,200	400	600	100	1,500	1,300	1,300	1,600	1,100	12,000	150,100	2,600	78,100	6,000	400	700	-4,600	600	400	14,900	-300	-200	57,500	-400	-500	2,900	-400	-300	-300	-300	-300	25,300	26,000
Change In Working Capital	-838,900	188,900	245,400	138,900	-90,900	80,800	383,700	-32,800	134,684	-91,565	-164,458	16,139	-307,161	95,872	179,260	-22,425	-222,016	135,042	83,094	-62,221	83,185	80,082	61,451	13,302	33,894	-2,737	49,801	-65,694	41,971	33,069	-27,963	-49,147	-12,152	-27,636	36,691	-82,853	1,433	18,353	-25,349	-5,500	11,247	63,872	601	-80,771	19,863	77,637	9,949	-121,237	256,146	-313,956	-74,301	-60,953	-29,518	3,903	26,100	-64,262	12,981	99,550	4,447	-55,554	21,416	-20,604	168,720	-30,749	11,819	22,689	19,402	-6,610	4,462	144,117	-908	-24,617	10,048	-21,742	-21,782	-18,597	9,983	-14,274	13,169	-21,619	6,030	34,688	36,812	-8,586	10,604	6,940	-3,606	38,849	348,019	-2,442	6,646	-1,963	-8,653	11,946	7,989	-1,493	4,100	-600	-3,400	1,400	1,000	2,100	-200	-4,800	2,300	2,100	300	2,200	500	-1,400	-700	-1,700	300	1,900	900	-1,200	-1,400	500	1,400	-1,100	400	1,900	-300	700	500	100	100	-300	400	100
Change Receivables	0	0	-2,900	-90,500	10,200	-119,500	-84,100	-165,200	-43,534	-185,318	52,525	-98,373	-72,253	12,948	59,533	-223,672	-184,143	14,426	-25,734	-30,136	-32,985	12,999	-74,693	-13,473	-17,304	-13,005	-36,332	-5,118	-23,267	3,194	-10,442	-2,512	-16,112	-67,538	-15,334	-5,863	14,743	-9,833	-22,719	25,237	102,197	0	0	-48,834	-3,626	46,021	46,610	-49,093	262,526	-349,418	-90,636	6,922	-7,564	-1,404	4,331	1,714	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	15,400	-6,100	-2,900	-90,500	10,200	-119,500	-84,100	-165,200	-43,534	-185,318	52,525	-98,373	-72,253	12,948	59,533	-223,672	-184,143	14,426	-25,734	-30,136	-32,985	12,999	-74,693	-13,473	-17,304	-13,005	-36,332	-5,118	-23,267	3,194	-10,442	-2,512	-16,112	-67,538	-15,334	-5,863	14,743	-9,833	-22,719	25,237	32,626	39,199	30,372	-48,834	-3,626	46,021	46,610	-49,093	262,526	-349,418	-90,636	6,922	-7,564	-1,404	4,331	1,714	572	4,584	1,959	6,785	7,831	9,354	15,955	6,495	31,603	28,265	25,734	18,824	-42,328	0	1,927	-3,184	-8,704	0	0	1,025	0	0	0	-613	1,574	7,020	5,152	2,792	7,065	7,365	5,923	5,923	13,641	0	3,848	4,647	0	0	522	1,450	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-70,000	-97,500	-72,800	-82,600	-78,300	-26,800	-33,300	2,000	-26,973	-18,335	-24,707	-22,785	-37,107	-30,521	-36,936	-27,450	-18,767	-20,106	-12,035	-13,139	-7,504	-15,095	-1,158	-8,208	-16,414	-6,542	-18,378	-3,650	-4,914	-3,757	-3,008	-4,771	-7,019	-6,701	-6,791	-2,635	-11,568	-6,095	-1,294	2,488	1,930	-1,408	-2,611	9,231	2,494	1,869	-17,373	-16,915	-44,564	-14,738	-34,424	-17,662	9,184	23,815	15,736	-42,544	14,367	13,731	5,878	-24,452	4,419	0	0	-27,795	0	0	0	-14,170	47,093	0	0	-12,370	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	340,700	265,800	261,700	354,300	483,400	62,800	189,319	127,573	-13,701	150,616	-165,148	349,431	188,376	225,907	-78,255	146,851	182,067	-62,570	9,511	83,789	129,376	9,501	88,669	58,968	105,181	-9,748	69,872	34,640	-13,867	-34,539	-3,498	54,943	58,980	-59,122	-5,081	35,853	-1,735	-15,288	-37,313	0	0	-16,182	11,430	24,149	-10,663	-34,461	30,748	51,561	46,472	-37,234	-27,309	1,862	17,502	-52,309	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,059	0	1,954	0	9,568	17,235	3,493	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Netincome	0	0	108,100	142,200	157,900	106,500	53,500	127,700	110,420	113,598	-133,471	113,606	123,988	137,403	133,028	126,974	114,057	78,349	98,124	91,360	203,391	153,539	36,014	-7,876	81,544	567,460	82,379	65,776	66,126	56,869	69,213	51,637	59,570	56,813	68,677	58,013	40,926	47,099	42,639	46,407	349,029	36,608	46,450	445,632	84,624	29,866	111,681	29,771	31,456	145,331	36,822	35,162	31,824	31,096	53,768	22,256	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	285,500	276,300	-182,700	297,000	455,800	144,900	151,248	109,786	-178,575	147,941	-232,924	111,989	156,251	214,412	-8,531	124,858	124,792	5,199	110,143	71,384	127,227	32,829	123,254	19,496	91,541	-47,178	65,220	-1,008	-646	0	68,245	0	0	0	-61,452	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	59,000	42,100	41,400	38,800	38,400	36,700	37,300	35,900	33,832	31,696	31,238	28,834	29,355	26,642	26,697	26,821	26,256	25,847	27,698	27,140	18,826	19,192	18,059	16,343	16,432	15,225	14,890	14,850	15,451	14,569	14,963	16,415	15,747	16,168	14,065	16,363	16,336	16,961	14,172	15,788	17,631	9,489	10,554	10,691	12,373	8,593	8,665	8,560	9,724	7,750	8,709	8,858	8,205	6,758	7,912	7,584	8,383	6,815	7,745	7,164	8,575	7,953	8,170	7,498	7,451	6,835	6,852	6,321	6,875	5,934	6,809	6,250	6,889	7,029	6,531	6,840	8,023	7,208	7,284	7,125	5,821	2,906	7,462	7,249	7,297	6,572	6,281	5,724	5,724	6,658	3,059	2,523	2,696	2,314	2,110	1,975	2,000	1,700	1,400	1,200	1,400	1,100	1,100	900	1,000	1,000	800	800	700	800	900	800	1,000	1,000	700	1,000	1,000	700	900	900	1,100	900	1,100	800	700	700	800	600	500	400
Dividends Paid	0	15,400	58,600	0	0	36,600	0	33,700	57,336	0	0	3,632	150,648	0	0	5,833	9,044	0	1,002	0	7,857	3,417	0	9,566	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	10,372,300	11,116,600	10,153,400	9,295,600	10,512,000	9,177,000	8,704,100	7,604,000	6,800,100	6,280,213	6,071,068	6,312,907	5,988,845	5,360,985	4,835,700	3,601,964	3,120,681	3,404,591	3,301,646	2,901,532	2,658,253	2,487,051	2,154,068	2,005,728	1,665,412	1,384,966	1,223,130	1,003,679	1,183,945	719,692	605,866	604,245	714,768	756,250	870,543	664,879	625,259	718,563	420,558	424,045	569,299	583,181	531,247	379,099	489,407	436,886	454,061	267,923	475,320	542,545	458,195	446,536	243,197	569,901	337,608	396,547	446,658	559,133	408,949	602,199	389,115	542,876	549,632	490,696	355,663	253,979	168,718	354,328	213,171	483,431	41,430	81,827	78,045	101,619	194,695	37,371	55,006	37,037	63,692	53,007	98,159	77,449	133,410	180,773	108,098	103,594	125,268	189,205	189,205	195,951	168,527	222,662	322,090	471,429	183,208	191,750	31,500	22,400	400	24,800	100	1,500	1,300	72,800	1,600	1,100	12,000	185,000	2,600	78,100	6,000	28,800	700	-4,600	600	72,000	14,900	-300	-200	86,100	-400	-500	2,900	11,200	-300	-300	-300	27,300	25,300	26,000
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-6,182	0	0	0	801	1,501	2,112	1,388	-4,401	-175	-2,710	2,620	-575	-953	1,290	-2,596	-1,695	-2,126	1,146	499	5,507	0	0	-799	-31	-58	84	-136	-132	-60	34	372	-353	202	-173	-53	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	118,500	1,227,800	1,074,800	857,800	1,044,800	901,300	1,086,500	892,600	933,200	874,800	-249,600	850,100	443,836	732,953	1,020,663	796,248	429,247	310,498	447,391	306,743	298,857	360,436	292,091	223,378	184,527	142,126	164,275	254,593	129,936	51,773	24,942	-27,111	16,616	-70,870	-123,686	-232,794	-196,459	-96,945	-139,621	-191,288	14,384	-32,234	-2,728	-82,385	12,513	84,565	102,862	-3,239	494,334	32,910	-286,626	-191,478	-180,531	-174,820	-118,573	-199,572	-109,905	-26,388	-122,651	-192,138	-103,837	-137,986	94,190	-111,029	-57,891	-71,570	-81,489	-73,941	-11,475	94,505	-69,761	-68,161	-12,145	-60,745	-58,054	-58,069	-27,446	-45,506	-26,955	-54,748	-32,551	-47,151	-48,261	-57,011	-24,038	-30,685	-25,942	30,529	30,529	-61,028	-12,904	-18,570	-19,634	-11,919	21,199	-18,203	6,500	-19,200	-17,900	-17,400	-13,000	-200	-11,400	-14,400	-5,400	-3,900	-1,100	-5,000	-5,200	-7,500	-22,700	-8,900	-3,400	-5,100	-7,400	-5,500	-5,800	-2,900	-3,100	-4,800	10,000	-300	200	-3,100	-2,700	-1,000	-800	-2,300	-1,000	-700
Investments	-886,500	-117,700	-334,400	-1,766,600	209,200	3,700	1,800	12,600	4,717	-430	-14,804	-3,383	310,763	-73,142	89,776	51,116	67,477	21,116	-33,832	-21,097	66,109	-28,977	-86,686	34,212	21,137	24,281	-58,905	-149,880	222,183	36,515	-44,310	-93,451	-108,051	-103,617	370,302	245,768	-2,862	39,399	101,634	-4,405	-35,687	0	0	-28,436	29,828	-92,314	-56,224	-219,192	-377,539	19,114	241,554	411,366	-155,174	8,372	54,637	142,252	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	-11,000	-10,600	-10,400	-49,500	-12,700	-12,900	-2,455	-11,035	-2,309	-8,601	-3,547	-8,787	-11,356	-5,334	-2,812	-11,446	1,002	-10,770	-277	-2,314	-4,864	369	25,359	1,387	-6,055	-304,820	2,129	-3,909	-3,603	-4,144	52,275	-17,220	-25,090	-6,257	-4,368	289,052	-9,262	5,428	-6,119	0	0	-10,096	-207	-31,480	29,072	0	-200,000	0	0	-50,000	0	391,645	0	-22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	968,800	1,035,300	915,700	699,800	818,900	930,500	810,500	762,100	770,110	851,928	66,924	653,138	604,190	667,434	837,270	602,753	583,234	57,518	267,427	268,631	1,525,096	128,456	206,250	227,301	102,185	-291,267	31,169	249,548	27,759	-39,537	-36,151	-36,102	-74,669	-93,816	-220,992	-198,704	-180,846	-170,060	-159,382	-232,457	-184,549	-128,662	-61,712	-312,627	-78,076	-26,467	-34,468	87,876	188,141	228,452	-199,318	-176,096	-180,392	-208,957	-200,006	-165,271	-158,644	-149,565	-171,297	-162,672	-142,332	-130,044	-91,321	-96,154	-85,751	-107,033	-117,767	-80,728	-27,344	-51,802	-77,658	-50,087	-38,131	-79,578	-40,988	-44,720	-42,769	-38,771	-44,269	-40,438	-41,029	-86,421	-89,928	20,611	-32,083	-33,452	-21,019	-3,260	-3,260	-41,996	-12,107	-8,870	-11,254	-24,858	12,613	-16,159	1,700	-14,300	-10,800	-17,600	-12,600	-2,300	-9,800	-8,400	-6,800	-5,800	-1,400	-5,800	-3,900	-6,300	-22,300	-7,500	-800	-7,000	-9,000	-4,700	-4,900	-3,900	-5,600	-3,200	8,700	-2,600	-800	-3,300	-2,700	-2,200	-2,000	-1,600	-1,300	-1,200
Other Cashflows From Financing Activities	-4,700	16,500	59,700	1,100	-133,600	37,300	64,800	35,000	1,361	16,228	47,376	8,744	2,603	18,499	133,548	13,286	18,219	-125	3,066	3,615	15,007	7,181	2,255	19,316	31,332	6,112	1,450	4,006	156,040	2,030	-57,782	-102,708	93,512	-100,935	278,443	13,386	2,020	294,383	89,882	8,050	-1,252	49,536	-4,691	-37,596	874	-117	987	227	900	21,446	172,790	405,952	-169,695	391,645	-7,664	-22	27,685	122,217	-85	-290,557	-70,515	607	-19,997	278,000	143,735	-42,102	-4	-49	-280,301	48	-57	-161	165,296	-45	42,012	36,705	-83	-1,801	-12,510	-2,974	13,670	4,557	-551	7,833	3,855	-984	-1,010	-20,042	-20,042	-2,552	-503	-538	-562	333,731	-635	169,059	-600	-700	-700	-700	-700	1,000	700	400	300	-100	100	-400	1,600	100	400	-500	200	-100	300	200	-400	-400	-400	-700	-500	-600	-400	-100	-300	-300	-300	-300	-300	26,000
Other Cashflows From Investing Activities	0	0	90,100	-24,900	0	-333,700	-10,000	0	-77,000	15,000	-15,000	-15,000	-19,327	67,750	140,892	51,116	-947,707	-245,824	-54,929	-21,097	-91,292	-22,821	-22,821	-22,821	370	-158,786	-19,735	3,258	22,773	12,159	2,446	2,717	-2,112	11,479	-78,439	-21,172	-8,523	444	-51	-476	53,939	32,901	32,226	7,447	5,374	-17,518	1,724	-6,355	-908	12,317	-58,333	-564	-93	44	-4,303	-380	624	0	365	172	0	0	0	0	0	0	0	0	29,766	4,311	0	0	8,306	3,291	888	750	0	0	0	0	98,780	94,489	93,244	92,788	200	0	0	0	0	0	0	0	0	0	182	126	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-31,900	-13,300	-10,800	13,400	52,400	-45,800	23,800	73,000	-20,295	-36,077	-155	50,727	-144,110	-37,886	-94,147	56,138	-106,269	24,145	-48,090	-45,982	124,448	68,007	-46,422	-86,012	6,142	493,690	9,797	-3,206	7,044	-4,340	7,271	-3,835	14,924	-8,921	5,416	629	-1,456	-15	195	-173	316,045	9,776	10,238	414,357	65,932	-434	78,112	18	7,726	-978	11,531	5,394	-34,424	5,670	27,234	1,489	21,812	157	12,314	2,056	15,116	15,215	18,189	14,017	13,789	13,868	23,002	13,166	15,030	3,253	12,775	8,791	14,191	37,980	2,329	1,647	1,121	2,162	845	3,060	477	295	5,336	-69,346	706	1,654	848	944	0	-1,280	-345	-214	3,388	349	265	128	1,400	-300	200	100	-600	100	-200	100	0	-100	-100	100	-200	0	-100	100	-200	-300	500	-100	-100	100	100	-100	100	-100	100	-100	0	0	100	-100	0	0
Sale Purchase Of Stock	-149,500	-170,200	-31,400	-299,400	-2,100	-48,000	-4,400	-117,500	-369,852	-660,832	-3,524	-527,092	-151,599	-148,535	-3,080	-436,193	-36,062	-104	-56,010	-99,839	-143,005	-92,005	-105,033	-10,000	46,635	150,318	136,638	11,249	17,065	17,463	24,856	8,846	45,903	51,839	46,234	41,616	73,341	83,327	57,813	60,134	244,208	0	0	21,670	16,771	16,947	136,705	21,298	16,120	20,069	55,030	33,643	9,447	6,850	9,473	7,664	0	0	0	290,557	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	208,600	130,900	119,300	122,400	111,500	135,600	113,900	130,300	118,608	102,996	104,622	115,174	97,027	99,539	117,189	115,706	91,591	85,420	89,687	93,791	78,943	85,532	82,436	78,136	75,402	73,770	72,582	68,982	59,082	61,209	61,942	55,472	44,646	65,734	63,261	57,384	42,382	46,136	42,444	46,580	23,370	31,308	41,350	31,275	19,566	30,183	34,556	29,980	31,183	31,402	34,602	29,564	25,212	25,185	26,534	20,745	13,141	21,408	28,726	23,447	57,985	0	0	13,072	0	0	7,724	12,320	39,137	0	0	8,125	7,530	915	0	1,435	0	0	0	778	0	0	0	799	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-119,800	-165,000	17,300	-294,700	40,200	-60,200	47,700	-95,400	-336,235	-656,661	33,550	-518,654	-125,192	-140,684	120,025	-359,430	161,421	20,356	-13,015	-41,989	-101,046	2,079	-51,208	78,956	73,231	152,705	132,033	-289,565	93,762	13,554	21,253	4,702	97,797	34,619	21,144	35,359	56,322	357,233	33,405	50,416	16,525	13,006	157,488	-6,135	4,837	8,150	137,692	21,525	-182,980	20,069	55,030	-16,357	9,447	398,495	9,473	7,642	538,664	130,593	11,081	318,668	13,715	224,962	-9,918	391,979	10,727	-32,397	8,136	3,344	14,302	319,854	9,549	22,160	15,641	11,769	169,474	572	3,478	-1,094	-10,949	-61	16,680	8,974	804	11,010	6,648	833	4,778	-16,618	-16,618	2,365	2,680	7,591	10,598	345,490	9,884	178,059	900	900	400	600	100	1,500	1,300	1,300	1,600	1,100	12,000	150,100	2,600	78,100	6,000	400	700	100	600	400	14,900	-300	-200	57,500	-400	-500	2,900	-400	-300	-300	-300	-300	25,300	26,000
Total Cash From Operating Activities	234,600	1,268,400	1,134,400	899,900	1,078,400	955,500	1,139,800	956,200	994,993	927,219	-199,767	921,055	491,532	907,748	1,038,527	815,698	446,008	334,789	463,749	324,784	314,578	381,348	321,703	252,657	227,511	170,086	181,653	265,692	144,724	65,656	40,860	-15,137	-16,014	-47,024	-95,213	-207,181	-121,870	-87,647	-127,920	-175,762	28,855	-13,720	-927	-65,778	40,559	105,961	118,405	2,916	503,663	42,895	-216,195	-186,628	-166,103	-163,990	-108,887	-196,462	-102,327	-21,635	-118,065	-185,559	-97,225	-127,480	103,758	-105,535	-52,692	-63,641	-68,335	-67,808	-4,287	101,502	-58,982	-60,708	-7,003	-56,311	-53,910	-54,830	-23,642	-43,675	-22,971	-51,872	-28,701	-48,532	-40,318	-50,072	-13,476	-18,286	-17,496	42,257	42,257	-39,060	-2,747	-8,524	-13,823	-10,249	22,977	-15,549	9,200	-13,500	-12,600	-14,900	-10,800	1,000	-9,100	-12,200	-3,500	-2,800	-400	-2,700	-2,900	-6,900	-22,200	-8,300	300	-4,400	-6,900	-5,000	-5,400	-2,600	-3,200	-3,500	10,300	100	100	-1,900	-1,500	-1,400	-1,000	-1,400	-400	-700
Total Cashflows From Investing Activities	0	0	-303,900	-1,833,600	175,600	-384,200	-61,500	-51,000	-133,998	-52,952	-79,641	-74,309	243,747	-247,937	71,912	31,666	-896,991	-248,999	-50,190	-39,138	-40,904	-49,889	-116,298	4,933	-21,097	-162,456	-96,347	-157,781	230,168	34,791	-57,782	-102,708	-122,690	-100,935	278,443	214,038	-26,061	30,545	89,882	-20,407	-16,534	7,249	-42,287	-37,596	7,156	-131,228	-70,043	-231,702	-387,776	21,446	172,790	405,952	-169,695	-2,414	40,648	138,762	0	39,045	0	80,177	0	0	0	0	405,166	261,431	80,170	205,665	0	71,830	51,118	42,288	0	30,332	78,717	36,705	107,428	69,537	51,395	6,638	119,585	87,301	103,660	111,836	0	0	15,873	15,873	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31	1993-12-31	1992-12-31	1991-12-31	1990-12-31
Cost Of Revenue	1,262,200	1,080,300	904,200	736,300	547,758	409,539	275,119	210,460	125,542	60,987	130,277	279,885	80,505	12,730	14,202	15,686	13,904	12,170	10,098	5,649	3,126	28,281	39,629	4,082	-3,400	-4,500	-3,600	-3,200	-3,700	-3,500	-3,900	-2,800	-1,800	-
Depreciation And Amortization	181,300	37,800	6,700	331,759	260,314	72,420	61,397	61,398	62,343	63,257	48,365	38,191	35,041	30,459	30,107	32,196	27,459	25,868	27,289	29,640	23,438	25,432	17,964	9,095	6,300	4,500	3,600	3,200	3,700	3,500	3,900	2,800	1,800	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	-912	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Ebit	3,750,200	4,307,400	2,782,100	2,856,290	1,197,566	590,756	250,050	-46,070	-535,512	-674,344	456,229	-34,015	186,653	-692,621	-572,799	-489,113	-405,554	-227,768	-118,220	-133,535	-89,881	-119,549	-42,062	-23,757	-38,900	-32,400	-19,200	-20,100	-32,000	-24,300	-200	-12,000	-6,400	-4,100
Ebitda	3,931,500	4,345,200	2,788,800	3,188,049	1,457,880	663,176	311,447	15,328	-473,169	-611,087	504,594	4,176	221,694	-662,162	-542,692	-456,917	-378,095	-201,900	-90,931	-103,895	-66,443	-94,117	-24,098	-14,662	-32,600	-27,900	-15,600	-16,900	-28,300	-20,800	3,700	-9,200	-4,600	-4,100
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Extraordinary Items	0	0	0	0	0	1,560,000	0	0	0	0	0	0	0	0	0	0	0	1,046	0	0	0	0	2,188	0	0	0	0	0	0	0	0	0	0	-
Gross Profit	8,576,800	7,850,400	6,670,200	5,469,383	3,615,063	2,638,058	2,213,533	1,491,717	906,794	519,428	1,081,698	1,247,157	1,330,121	130,640	87,847	159,818	185,108	204,186	150,792	97,068	66,015	132,804	127,861	74,045	65,000	48,900	47,400	16,500	25,800	23,100	31,800	6,600	5,000	2,300
Income Before Tax	4,379,800	4,232,400	2,730,400	3,116,798	1,394,919	600,241	-15,689	-67,366	-559,581	-734,875	-976,117	-12,381	60,445	-754,626	-642,178	-464,175	-426,911	-206,891	-173,390	-158,505	-347,349	-119,659	-117,890	-53,607	-40,300	0	0	-39,500	-21,000	-17,100	2,100	-8,000	-4,800	-
Income Tax Expense	760,200	910,400	388,300	405,151	218,109	-1,486,862	-107,324	16,665	30,381	6,958	-288,567	38,754	19,266	19,275	19,336	-30,729	-21,394	-18,496	61,679	29,014	24,064	-10,983	-1,916	976	1,400	700	600	10,200	-5,000	-3,100	100	-1,500	-500	4,300
Interest Expense	44,100	54,800	61,500	58,151	58,502	34,119	57,550	81,432	84,206	72,863	22,730	14,713	36,574	19,275	13,192	13,471	0	7,955	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Interest Income	614,700	144,600	4,900	22,239	63,678	33,496	57,550	81,432	84,206	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Minority Interest	0	0	0	0	0	-9,793	-171,849	-28,021	31,847	4,190	-242,522	55,897	11,605	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income	3,619,600	3,322,000	2,342,100	2,711,700	1,176,810	2,096,896	263,484	-112,052	-558,115	-738,555	-445,028	-107,032	29,574	-754,626	-641,578	-459,851	-391,279	-206,891	-203,417	-166,247	-196,767	-108,621	-66,233	-39,658	-41,000	-33,100	-19,800	-40,000	-21,500	-17,600	2,000	-8,500	-5,100	-4,300
Net Income Applicable To Common Shares	0	3,322,000	2,342,100	2,711,647	1,176,810	2,096,896	263,484	-112,052	-556,334	-738,555	-445,028	-107,032	29,574	-754,626	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income From Continuing Ops	3,619,600	3,322,000	2,342,100	2,711,647	1,176,810	2,087,103	91,635	-84,031	-588,181	-741,833	-687,550	-51,135	41,179	-754,626	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Interest Income	570,600	89,800	-56,600	-35,912	5,176	-34,119	-57,550	-81,432	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Operating Income Net Other	0	-20,200	9,800	318,659	255,855	-790	-81,382	4,130	-6,715	30,400	-49,939	1,940	-14,923	-39,274	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Recurring	0	115,500	0	0	0	28,816	269,586	1,262	2,206	50,925	704,021	1,844	107,874	1,501	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Operating Income	3,750,200	4,307,400	2,782,100	2,856,290	1,197,566	635,150	123,243	9,936	-468,662	-692,412	-903,448	2,332	113,820	-696,077	-613,412	-462,708	-419,792	-229,038	-149,872	-154,807	-264,527	-119,604	-91,803	-38,682	-39,600	-32,400	-19,200	-29,800	-26,500	-20,700	1,200	-10,000	-5,600	-4,100
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Operating Expenses	6,088,800	4,565,300	4,795,400	3,336,293	2,960,796	2,383,631	2,095,823	1,690,979	1,498,792	1,221,902	1,411,402	1,522,866	1,188,932	837,946	694,184	633,888	611,685	441,743	302,628	239,950	241,844	280,689	235,639	116,809	101,200	76,800	63,000	43,100	48,600	40,300	26,700	13,800	8,800	6,400
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Reconciled Depreciation	181,300	148,300	125,600	109,515	106,941	72,420	61,397	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Research Development	3,690,000	2,540,300	3,051,100	1,829,537	1,754,540	1,416,476	1,324,625	1,047,690	996,170	855,506	918,783	806,185	707,706	637,416	550,685	516,292	513,054	371,713	248,540	192,162	199,636	203,018	148,673	84,921	72,200	58,700	51,600	35,200	41,500	0	0	0	0	-
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Selling General Administrative	1,136,600	887,200	840,100	770,456	658,498	557,616	496,079	432,829	376,575	305,409	362,342	436,796	400,721	187,800	130,192	101,910	84,727	57,860	43,990	42,139	39,082	49,390	47,337	27,806	26,100	18,100	11,400	7,900	0	0	0	0	0	-
Tax Provision	760,200	910,400	388,300	405,151	218,109	-1,486,862	-107,324	16,665	30,381	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Operating Expenses	4,826,600	3,485,000	3,891,200	2,599,993	2,413,038	1,974,092	1,820,704	1,480,519	1,373,250	1,160,915	1,281,125	1,242,981	1,108,427	825,216	679,982	618,202	597,781	429,573	292,530	234,301	238,718	252,408	196,010	112,727	104,600	81,300	66,600	46,300	52,300	43,800	30,600	16,600	10,600	6,400
Total Other Income Expense Net	629,600	-75,000	-51,700	260,508	197,353	-29,606	-350,968	2,868	-8,919	-20,525	-776,690	-1,844	-124,675	-42,730	-49,443	-1,467	-7,119	2,381	-23,518	-3,698	-82,822	-55	-26,087	-14,925	-700	0	0	-9,700	5,500	3,600	1,400	2,000	800	-
Total Revenue	9,839,000	8,930,700	7,574,400	6,205,683	4,162,821	3,047,597	2,488,652	1,702,177	1,032,336	580,415	1,211,975	1,527,042	1,410,626	143,370	102,049	175,504	199,012	216,356	160,890	102,717	69,141	161,085	167,490	78,127	61,600	44,400	43,800	13,300	22,100	19,600	27,900	3,800	3,200	2,300

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31	1993-12-31	1993-09-30	1993-06-30	1993-03-31	1992-12-31	1992-09-30	1992-06-30	1992-03-31	1991-12-31	1991-09-30	1991-06-30	1991-03-31	1990-12-31	1990-09-30	1990-06-30	1990-03-31
Cost Of Revenue	368,000	318,700	308,600	266,900	283,300	289,400	261,800	245,800	247,400	236,512	227,972	192,329	203,101	186,182	184,520	162,497	185,012	131,914	135,740	95,092	122,289	111,255	104,382	71,613	84,052	72,874	71,205	46,988	60,482	54,077	45,252	50,649	64,415	31,960	16,860	12,307	14,027	14,184	17,300	15,476	22,264	27,339	37,931	42,743	87,715	38,536	114,423	39,211	30,127	38,406	9,306	2,666	3,049	3,228	3,086	3,367	3,647	3,712	3,267	3,576	4,215	4,194	3,701	3,576	3,672	3,562	3,401	3,269	3,177	3,113	2,885	2,995	2,783	2,796	2,489	2,030	2,009	1,466	1,328	846	-4,230	1,651	1,538	3,515	6,601	6,577	6,462	9,670	9,670	10,663	921	837	7,362	-1,167	-1,010	-1,103	-1,000	-1,000	-200	-1,200	-1,400	-1,100	-1,100	-900	-1,000	-1,000	-800	-800	-700	-800	-900	-800	-1,000	-1,000	-700	-1,000	-1,000	-800	-900	-900	-1,100	-900	-900	-800	-700	-700	2,000	-600	-500	-400	-500	-	-	-	-	-
Depreciation And Amortization	59,000	204,900	256,200	469,100	79,300	89,800	-54,600	-78,700	33,832	31,696	31,238	28,834	29,355	26,642	26,697	26,821	26,256	25,847	27,698	27,140	18,826	19,192	18,059	16,343	16,432	15,225	14,890	14,850	15,451	14,569	14,963	16,415	15,747	16,168	14,065	16,363	16,336	16,961	14,172	15,788	17,631	9,489	10,554	10,691	12,373	8,593	8,665	8,560	9,724	7,750	8,709	8,858	8,205	6,758	7,912	7,584	8,383	6,815	7,745	7,164	8,575	7,953	8,170	7,498	7,451	6,835	6,852	6,321	6,875	5,934	6,809	6,250	6,889	7,029	6,531	6,840	8,023	7,208	7,284	7,125	5,821	2,906	7,462	7,249	7,297	6,572	6,281	5,724	5,724	6,658	3,059	2,523	2,696	2,314	2,110	1,975	2,000	1,700	1,400	1,200	1,400	1,100	1,100	900	1,000	1,000	800	800	700	800	900	800	1,000	1,000	700	1,000	1,000	700	900	900	1,100	900	1,100	800	700	700	800	600	500	400	500	-	-	-	-	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-848	-64	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Ebit	958,800	1,038,100	1,026,400	779,000	1,033,500	1,126,700	1,106,300	1,040,900	850,168	1,067,500	-58,415	803,904	876,056	734,885	821,144	646,449	666,443	62,326	314,277	307,893	47,448	125,288	208,700	209,320	108,944	-163,144	38,803	265,447	25,518	-36,455	-12,486	-25,647	-71,398	-85,694	-181,687	-196,733	-169,589	-122,311	-157,546	-225,537	264,723	-119,451	-65,935	376,899	-89,655	-8,968	-18,841	83,449	225,091	313,338	-170,897	-161,639	-205,328	-198,703	-146,027	-164,817	-120,715	-152,168	-148,568	-141,503	-138,581	-128,858	-89,145	-97,476	-91,196	-112,031	-123,808	-78,519	-32,151	-66,059	-78,336	-51,222	-34,538	-3,028	-42,082	-38,572	-33,042	-31,474	-38,560	-33,041	-45,994	-914	-89,007	-45,475	-33,650	-35,851	-24,026	-9,163	-13,163	-4,279	-17,448	-15,395	-14,244	-380	9,447	-18,580	2,200	-13,800	-10,100	-23,500	-12,300	-2,100	-9,600	-16,300	-6,500	-5,700	-1,200	-5,600	-7,300	-8,600	5,700	-9,900	-3,900	-9,200	-11,700	-7,200	-8,400	-3,700	-5,400	-3,200	8,200	-3,200	-1,400	-3,800	-3,300	-3,100	-2,800	-2,700	-2,100	-1,700	-1,400	-	-	-	-	-
Ebitda	1,017,800	1,243,000	1,282,600	1,248,100	1,112,800	1,216,500	1,051,700	962,200	884,000	1,099,196	-27,177	832,738	905,411	761,527	847,841	673,270	692,699	88,173	341,975	335,033	66,274	144,480	226,759	225,663	125,376	-147,919	53,693	280,297	40,969	-21,886	2,477	-9,232	-55,651	-69,526	-167,622	-180,370	-153,253	-105,350	-143,374	-209,749	282,354	-109,962	-55,381	387,590	-77,282	-375	-10,176	92,009	234,815	321,088	-162,188	-152,781	-197,123	-191,945	-138,115	-157,233	-112,332	-145,353	-140,823	-134,339	-130,006	-120,905	-80,975	-89,978	-83,745	-105,196	-116,956	-72,198	-25,276	-60,125	-71,527	-44,972	-27,649	4,001	-35,551	-31,732	-25,019	-24,266	-31,276	-25,916	-40,173	1,992	-81,545	-38,226	-26,353	-29,279	-17,745	-3,439	-7,439	2,379	-14,389	-12,872	-11,548	1,934	11,557	-16,605	4,200	-12,100	-8,700	-22,300	-10,900	-1,000	-8,500	-15,400	-5,500	-4,700	-400	-4,800	-6,600	-7,800	6,600	-9,100	-2,900	-8,200	-11,000	-6,200	-7,400	-3,000	-4,500	-2,300	9,300	-2,300	-300	-3,000	-2,600	-2,400	-2,000	-2,100	-1,600	-1,300	-900	800	-5,800	600	600	500
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,560,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,046	0	-1,046	1,046	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,340	17,749	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Gross Profit	2,149,700	2,164,800	2,184,600	2,107,900	2,019,400	2,044,900	1,934,400	1,851,700	1,825,200	1,747,652	1,565,398	1,531,976	1,424,719	1,352,089	1,339,965	1,352,610	1,228,253	817,914	805,553	763,343	747,817	673,280	647,775	569,186	567,582	505,291	472,930	667,730	398,224	359,706	386,356	347,431	353,520	277,856	149,216	126,202	130,529	164,803	121,121	102,975	328,893	194,361	272,819	285,625	246,279	297,470	303,882	399,526	533,213	620,794	105,118	70,996	62,475	20,567	28,536	19,062	30,242	21,245	15,797	20,403	28,596	27,415	65,708	38,099	47,320	37,452	34,795	65,541	91,077	50,176	26,841	36,092	60,973	33,411	29,832	26,576	37,826	25,362	17,213	16,667	14,834	16,701	16,038	19,094	37,183	27,699	35,868	41,855	41,855	29,705	20,522	18,220	12,342	15,033	38,044	8,626	30,600	10,600	15,500	5,200	13,100	19,500	8,300	4,100	12,200	14,500	13,000	7,700	5,500	3,700	4,000	3,300	9,200	3,300	7,200	6,100	3,700	7,300	5,700	6,500	19,100	5,300	5,500	1,700	1,700	1,700	-1,000	1,500	1,300	1,200	1,300	800	600	600	600	500
Income Before Tax	1,147,600	1,179,200	1,161,500	891,500	1,076,800	1,176,400	1,024,400	954,800	870,900	1,082,741	-44,255	820,960	888,623	745,871	824,770	657,534	676,950	70,666	327,138	320,165	32,497	136,511	216,591	214,642	112,442	-417,170	35,506	253,533	20,306	-42,034	-18,021	-30,617	-77,829	-92,486	-190,861	-198,405	-178,594	-166,577	-158,689	-231,654	-340,253	-129,406	-63,511	-442,940	-80,772	-5,112	-14,405	87,908	210,801	200,610	-174,870	-176,096	-170,972	-208,957	-200,006	-165,271	-642,178	-149,565	-171,297	-162,672	-143,504	-130,044	-91,321	-96,154	-92,024	-107,033	-117,767	-80,728	-206,891	-51,802	-77,658	-50,087	165,286	-79,578	-40,988	-44,720	-35,472	-38,771	-44,269	-40,438	111,607	-86,421	-89,928	20,611	33,452	-33,452	0	-19,524	0	-29,229	-12,107	0	-14,558	-29,964	9,457	-18,542	2,000	-14,000	-10,700	-17,300	0	0	0	-8,300	0	0	0	0	-3,700	-6,200	-22,300	-7,300	-700	-6,800	-8,900	-4,600	0	0	0	0	9,000	-2,600	-600	-3,200	-2,500	-2,100	-1,800	-1,500	-1,300	-1,100	-1,200	-	-	-	-	-
Income Tax Expense	178,800	143,900	245,800	191,700	257,900	245,900	213,900	192,700	100,800	230,813	-111,179	167,822	284,433	78,437	-12,500	54,781	93,716	13,148	59,711	51,534	-1,492,599	8,055	10,341	-12,659	10,257	-125,903	4,337	3,985	-7,453	503	18,130	5,485	-1,379	1,330	30,131	299	2,043	3,419	693	803	-155,704	-751	-1,799	-130,313	-2,696	21,355	20,063	32	22,660	-27,842	24,448	8,099	-29,274	3,477	24,633	-1,815	-483,534	-4,709	7,492	10,974	2,110	301	1,008	-1,952	-5,721	-5,880	-6,947	-2,846	-179,547	-8,910	-1,121	-1,902	18,135	38,661	649	4,234	14,691	4,743	3,872	5,708	-67,046	43,564	-44,131	-1,405	-43,086	0	-3,007	-9,903	0	26,576	-5,667	-6,525	-3,147	9,686	-3,161	-2,402	400	400	400	-2,800	300	200	200	-3,900	300	200	200	200	-1,600	-1,100	14,000	-1,100	-1,500	-1,100	-1,300	-1,200	-3,500	200	100	0	-100	-200	-200	-200	-200	-400	-400	-500	-400	-200	100	-	-	-	-	-
Interest Expense	10,600	10,900	11,200	11,400	11,600	13,700	14,600	14,900	15,100	15,255	15,478	15,678	16,288	13,856	13,871	14,136	14,249	14,548	14,837	14,868	4,773	8,143	10,106	11,097	12,547	13,574	14,664	16,765	20,439	20,140	20,155	20,698	20,654	21,134	21,111	21,307	21,177	20,384	15,585	15,717	26,730	286	6,549	4,000	3,296	4,041	3,635	3,741	12,430	6,982	6,962	10,599	7,686	3,458	3,199	3,500	4,562	1,927	3,325	3,378	3,912	3,812	3,833	1,914	1,791	494	570	1,221	7,955	1,767	2,357	2,357	3,543	4,505	4,639	4,639	4,675	4,634	4,581	4,427	4,259	4,334	4,342	4,363	4,391	4,412	4,419	4,462	4,615	4,927	9,882	0	10,569	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Interest Income	179,500	167,900	144,700	122,600	86,000	46,200	10,800	1,600	1,200	1,116	1,133	1,465	2,320	3,100	4,243	12,576	12,359	17,628	18,076	3,898	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-25,431	-290	-1,110	17,038	1,501	-188,315	13,173	1,792	-61,228	-696	28,374	5,529	62,756	1,333	-32,144	-98	4,190	0	0	0	-228,834	-4,611	-4,547	-4,611	-1,928	31,076	30,463	-3,714	29,512	7,342	-25,249	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Income	968,800	1,035,300	915,700	699,800	818,900	930,500	810,500	762,100	770,100	851,928	66,924	653,138	604,190	667,434	837,270	602,753	583,234	57,518	267,427	268,631	1,550,527	128,746	207,360	210,263	100,684	-102,952	17,996	247,756	32,945	-41,841	-64,525	-41,631	-75,512	-95,149	-188,848	-198,606	-176,656	-170,060	-159,382	-232,457	44,285	-124,125	-57,165	-308,016	-76,148	-57,543	-64,931	91,590	158,629	221,110	-174,069	-176,096	-180,392	-208,957	-200,006	-165,271	-158,644	-149,565	-171,297	-162,672	-142,332	-130,044	-91,321	-96,154	-85,751	-107,033	-117,767	-80,728	-27,344	-51,802	-77,658	-50,087	-38,131	-79,578	-40,988	-44,720	-42,769	-38,771	-44,269	-40,438	-41,029	-86,421	-45,797	20,611	-32,083	-33,452	-21,019	-3,260	-3,260	-46,978	-12,107	-8,870	-11,254	-24,858	12,613	-16,159	1,700	-14,300	-10,800	-17,600	-12,600	-2,300	-9,800	-8,400	-6,800	-5,900	-1,400	-5,800	-3,900	-6,300	-22,300	-7,500	-800	-6,900	-9,000	-4,700	-4,900	-3,900	-5,500	-3,200	8,700	-2,700	-800	-3,300	-2,700	-2,200	-1,900	-1,600	-1,300	-1,200	-1,400	-	-	-	-	-
Net Income Applicable To Common Shares	0	0	915,700	699,800	818,900	930,500	810,500	762,100	770,100	851,928	66,924	653,138	604,190	667,434	837,270	602,753	583,234	57,518	267,427	268,631	1,550,527	128,746	207,360	210,263	100,684	-102,952	17,996	247,756	32,945	-38,841	-64,525	-41,631	-73,731	-95,149	-188,848	-198,606	-176,656	-170,060	-159,382	-232,457	44,285	-124,132	-57,165	-308,016	-76,148	-57,543	-64,931	91,590	158,629	221,110	-174,069	-176,096	-180,392	-208,957	-200,006	-165,271	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Income From Continuing Ops	968,800	1,035,300	915,700	699,800	818,900	930,500	810,500	762,100	770,100	851,928	66,924	653,138	604,190	667,434	837,270	602,753	583,234	57,518	267,427	268,631	1,525,059	128,411	206,291	227,342	102,148	-291,267	31,206	249,548	27,759	-39,537	-36,151	-36,102	-74,669	-93,816	-220,992	-198,704	-179,998	-169,996	-159,382	-232,457	-184,549	-128,662	-61,712	-312,627	-78,076	-26,467	-34,468	87,876	188,141	228,452	-199,318	-176,096	-180,392	-208,957	-200,006	-165,271	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Net Interest Income	168,900	157,000	133,500	111,200	74,400	32,500	-3,800	-13,300	-13,900	-14,139	-14,345	-14,213	-13,968	-10,756	-9,628	-1,560	-1,890	3,080	3,239	747	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Non Operating Income Net Other	0	0	146,300	123,900	54,900	63,400	-67,300	-71,200	8,320	43,484	9,184	-51,188	159,119	87,486	120,608	-48,554	139,734	-14,119	72,015	58,225	-90,452	-60,995	53,819	96,838	-748	-77,553	-2,537	-544	1,105	-167	-1,219	4,411	-1,690	-1,326	1,414	-5,113	-3,792	-3,990	37,731	451	-43,361	4,652	-6,578	-4,652	497	519	560	364	-671	-8,038	-2,018	-4,196	-6,072	-5,418	-26,750	-1,034	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Non Recurring	0	0	110,500	347,100	24,600	29,000	61,900	0	0	0	0	0	0	0	0	0	0	0	0	0	29,004	-174	62	-76	387	255,677	3,523	9,999	224	8	343	687	1,524	1,826	2,128	-3,272	4,164	40,843	-270	6,188	278,258	12,048	776	412,939	194	696	594	360	992	105,381	741	760	-2,257	866	2,112	780	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Operating Income	958,800	1,038,100	1,026,400	779,000	1,033,500	1,126,700	1,106,300	1,040,900	877,700	1,054,512	-37,961	887,826	745,792	672,241	718,033	720,224	551,465	99,333	269,960	276,808	127,722	205,649	172,878	128,901	125,737	-326,043	52,707	270,842	39,640	-21,727	3,353	-14,330	-55,487	-70,026	-171,164	-171,985	-153,625	-142,203	-180,835	-216,388	-274,162	-134,058	-56,933	-438,288	-77,476	-1,071	-10,770	91,649	223,902	215,707	-165,890	-159,899	-166,634	-199,588	-169,573	-160,282	-146,719	-148,233	-157,167	-161,893	-141,863	-130,628	-91,481	-98,736	-91,748	-113,795	-125,620	-88,629	-34,933	-62,127	-79,222	-52,756	-26,394	-42,482	-38,596	-42,400	-40,436	-35,589	-42,234	-36,548	-109,475	-85,251	-89,007	19,206	-33,664	-35,851	-24,026	-15,524	-13,163	-36,153	-17,448	-15,395	-14,401	-15,172	9,452	-18,561	2,100	-13,900	-10,400	-20,400	-12,300	-2,100	-9,600	-12,300	-6,500	-5,700	-1,200	-5,600	-5,500	-7,400	-8,300	-8,600	-2,300	-8,000	-10,300	-5,900	-8,400	-3,800	-5,400	-3,200	8,600	-2,900	-1,000	-3,500	-2,900	-2,600	-2,300	-2,100	-1,700	-1,400	-1,300	800	-5,800	600	600	500
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Operating Expenses	1,558,900	1,392,500	1,356,900	1,250,600	1,244,800	1,181,200	1,077,200	1,064,100	1,196,900	928,452	1,829,731	840,379	881,528	864,230	797,252	793,283	860,300	847,536	671,333	581,627	713,380	579,060	579,217	511,974	525,510	648,531	487,905	433,877	418,842	435,502	427,912	411,723	471,898	378,016	335,112	313,766	294,017	280,347	319,526	328,651	347,061	343,710	366,907	353,717	411,276	336,381	428,481	346,728	338,446	338,112	279,573	232,801	234,415	222,517	199,083	181,931	171,451	172,416	175,124	175,677	173,033	161,352	159,722	139,781	142,464	153,927	162,910	152,384	128,161	114,001	108,505	91,076	83,752	77,124	72,660	69,092	67,913	60,856	58,938	52,243	118,679	61,209	106,583	3,403	77,448	70,127	66,356	64,688	64,688	60,770	38,891	34,452	34,105	29,038	27,582	26,084	27,500	23,500	25,700	24,400	24,000	20,500	16,800	15,500	17,700	19,200	13,400	12,500	10,300	10,300	11,400	11,100	10,500	10,300	16,800	11,000	11,100	10,300	10,200	8,800	9,400	7,300	5,600	4,400	3,900	3,600	3,300	3,000	2,500	2,200	2,100	-	6,400	-	-	-
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Reconciled Depreciation	59,000	42,100	41,400	38,800	38,400	36,700	37,300	35,900	33,832	31,696	31,238	28,834	29,355	26,642	26,697	26,821	26,256	25,847	27,698	27,140	18,826	19,192	18,059	16,343	16,432	15,225	14,890	14,850	15,451	14,569	14,963	16,415	15,747	16,168	14,065	16,363	16,336	16,961	14,172	15,788	17,631	9,489	10,554	10,691	12,373	8,593	8,665	8,560	9,724	7,750	8,709	8,858	8,205	6,758	7,912	7,584	8,383	6,815	7,745	7,164	8,575	7,953	8,170	7,498	7,451	6,835	6,852	6,321	6,875	5,934	6,809	6,250	6,889	7,029	6,531	6,840	8,023	7,208	7,284	7,125	5,821	2,906	7,462	7,249	7,297	6,572	6,281	5,724	5,724	6,658	3,059	2,523	2,696	2,314	2,110	1,975	2,000	1,700	1,400	1,200	1,400	1,100	1,100	900	1,000	1,000	800	800	700	800	900	800	1,000	1,000	700	1,000	1,000	700	900	900	1,100	900	1,100	800	700	700	800	600	500	400	500	-	-	-	-	-
Research Development	821,800	810,000	785,700	742,600	694,100	645,000	600,100	603,100	694,300	493,751	1,407,090	455,973	466,584	493,497	420,928	448,528	480,011	555,948	379,091	339,490	437,881	330,510	337,532	310,553	306,664	454,947	289,451	273,563	248,452	275,370	271,008	255,860	310,429	246,284	223,858	215,599	201,463	190,939	224,780	238,963	249,609	228,567	222,455	218,095	213,109	200,161	196,544	196,371	186,438	189,052	172,796	158,612	168,888	170,434	155,082	143,012	135,230	132,132	139,331	143,581	144,610	129,968	127,132	114,582	115,340	128,949	136,187	132,578	109,146	96,115	91,250	75,202	68,158	63,590	59,357	57,435	54,247	48,790	47,450	41,675	45,772	50,035	50,712	53,117	58,828	50,622	46,546	44,625	44,625	38,116	27,794	26,119	25,145	21,348	19,824	18,604	18,100	16,400	19,000	18,600	18,100	15,700	12,600	12,200	14,000	16,400	10,800	10,300	7,900	8,500	9,500	9,300	8,400	8,600	15,100	9,400	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Selling General Administrative	369,100	263,800	262,000	239,200	269,200	244,200	166,100	207,700	255,200	199,389	194,669	192,077	211,843	184,551	191,804	182,258	195,277	159,674	156,502	147,045	153,210	137,295	137,303	129,808	134,794	120,710	127,249	113,326	109,908	106,055	111,652	105,214	96,549	99,772	94,394	85,860	78,527	75,224	77,446	74,212	75,188	87,754	106,521	92,879	110,452	97,684	117,514	111,146	121,881	110,654	96,663	71,523	62,478	48,855	40,915	35,552	32,574	36,572	32,526	28,520	24,208	27,190	28,889	21,623	23,452	21,416	23,322	16,537	15,838	14,773	14,370	12,879	12,811	10,738	10,814	9,627	11,657	10,600	10,160	9,722	7,454	9,974	10,202	11,452	12,019	12,928	13,348	10,393	10,393	11,991	10,176	7,496	7,997	6,543	6,658	6,608	8,400	6,400	5,500	5,800	5,900	4,800	4,200	3,300	3,700	2,800	2,600	2,200	2,400	1,800	1,900	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Tax Provision	178,800	143,900	245,800	191,700	257,900	245,900	213,900	192,700	100,800	230,813	-111,179	167,822	284,433	78,437	-12,500	54,781	93,716	13,148	59,711	51,534	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Operating Expenses	1,190,900	1,073,800	1,048,300	983,700	961,500	891,800	815,400	818,300	949,500	691,940	1,601,759	648,050	678,427	678,048	612,732	630,786	675,288	715,622	535,593	486,535	591,091	467,805	474,835	440,361	441,458	575,657	416,700	386,889	358,360	381,425	382,660	361,074	407,483	346,056	318,252	301,459	279,990	266,163	302,226	313,175	324,797	316,371	328,976	310,974	323,561	297,845	314,058	307,517	308,319	299,706	270,267	230,135	231,366	219,289	195,997	178,564	167,804	168,704	171,857	172,101	168,818	157,158	156,021	136,205	138,792	150,365	159,509	149,115	124,984	110,888	105,620	88,081	80,969	74,328	70,171	67,062	65,904	59,390	57,610	51,397	122,909	59,558	105,045	-112	70,847	63,550	59,894	55,018	55,018	50,107	37,970	33,615	26,743	30,205	28,592	27,187	28,500	24,500	25,900	25,600	25,400	21,600	17,900	16,400	18,700	20,200	14,200	13,300	11,000	11,100	12,300	11,900	11,500	11,300	17,500	12,000	12,100	11,100	11,100	9,700	10,500	8,200	6,500	5,200	4,600	4,300	1,300	3,600	3,000	2,600	2,600	-	-6,400	-	-	-
Total Other Income Expense Net	188,800	-68,800	-108,300	112,500	43,300	49,700	-81,900	-86,100	9,100	41,168	6,451	-48,753	156,299	82,586	107,165	-62,730	125,875	-34,706	53,939	42,610	-119,456	-60,821	53,757	96,914	-1,135	-333,230	-6,060	-10,543	881	-175	-1,562	3,724	-3,212	-3,152	-714	-1,841	-7,956	-44,833	38,001	-5,737	-344,349	-7,396	-7,354	-417,591	-194	-696	-594	-360	-1,860	-113,496	-2,961	-6,358	-4,338	-6,777	-29,346	-2,269	-16,847	-2,106	-15,237	-10,195	-1,641	-885	-1,168	-630	-276	-882	-906	-5,055	-1,756	5,347	-443	-767	14,542	-37,889	1,743	-1,914	4,964	-2,554	-1,837	-1,689	-62,081	-41,943	-921	64,681	-14	2,399	0	-4,000	-4,000	-16,123	-326	0	-157	-14,792	5	19	-100	-100	-300	3,100	0	0	0	4,000	0	0	0	0	1,800	1,200	-14,000	1,300	1,600	1,200	1,400	1,300	0	0	0	0	400	300	400	300	400	500	500	600	400	300	100	-	-	-	-	-
Total Revenue	2,517,700	2,483,500	2,493,200	2,374,800	2,302,700	2,334,300	2,196,200	2,097,500	2,072,600	1,984,164	1,793,370	1,724,305	1,627,820	1,538,271	1,524,485	1,515,107	1,413,265	949,828	941,293	858,435	870,106	784,535	752,157	640,799	651,634	578,165	544,135	714,718	458,706	413,783	431,608	398,080	417,935	309,816	166,076	138,509	144,556	178,987	138,421	118,451	351,157	221,700	310,750	328,368	333,994	336,006	418,305	438,737	563,340	659,200	114,424	73,662	65,524	23,795	31,622	22,429	33,889	24,957	19,064	23,979	32,811	31,609	69,409	41,675	50,992	41,014	38,196	68,810	94,254	53,289	29,726	39,087	63,756	36,207	32,321	28,606	39,835	26,828	18,541	17,513	10,604	18,352	17,576	22,609	43,784	34,276	42,330	51,525	51,525	40,368	21,443	19,057	19,704	13,866	37,034	7,523	29,600	9,600	15,300	4,000	11,700	18,400	7,200	3,200	11,200	13,500	12,200	6,900	4,800	2,900	3,100	2,500	8,200	2,300	6,500	5,100	2,700	6,500	4,800	5,600	18,000	4,400	4,600	900	1,000	1,000	1,000	900	800	800	800	800	600	600	600	500

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	9,839,000
Cost of Revenue	-1,262,200
Gross Profit	8,576,800	8,576,800

Operating Income (+$)
Gross Profit	8,576,800
Operating Expense	-4,826,600
Operating Income	3,750,200	3,750,200

Operating Expense (+$)
Research Development	3,690,000
Selling General Administrative	1,136,600
Selling And Marketing Expenses	0
Operating Expense	4,826,600	4,826,600

Net Interest Income (+$)
Interest Income	614,700
Interest Expense	-44,100
Other Finance Cost	-0
Net Interest Income	570,600

Pretax Income (+$)
Operating Income	3,750,200
Net Interest Income	570,600
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	4,379,800	3,120,600 EBIT - interestExpense = 3,706,100 4,379,800 3,663,700
Interest Expense	44,100
Earnings Before Interest and Taxes (EBIT)	3,750,200	4,423,900
Earnings Before Interest and Taxes (EBITDA)	3,931,500

After tax Income (+$)
Income Before Tax	4,379,800
Tax Provision	-760,200
Net Income From Continuing Ops	3,619,600	3,619,600
Net Income	3,619,600
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	6,088,800
Total Other Income/Expenses Net	629,600	-570,600

Technical Analysis of Vertex Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vertex Pharmaceuticals Inc. The general trend of Vertex Pharmaceuticals Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vertex Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (0.0%)		Bearish trend (0.0%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Vertex Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 406.97 < 421.45 < 437.00.

The bearish price targets are: 387.42 > 356.71 > 346.29.

Tweet this

Vertex Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vertex Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Vertex Pharmaceuticals Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vertex Pharmaceuticals Inc. The current macd is -5.52327391.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vertex Pharmaceuticals Inc price going down in the near term. -2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vertex Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vertex Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

Vertex Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Vertex Pharmaceuticals Inc. The current adx is 28.73.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vertex Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2

Vertex Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vertex Pharmaceuticals Inc. The current sar is 391.02.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1

Vertex Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vertex Pharmaceuticals Inc. The current rsi is 43.24. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Trending up: The RSI is trending up. +1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Vertex Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vertex Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vertex Pharmaceuticals Inc price going up in the near term. +2
Trending up: The STOCH %K is trending up. +1

Vertex Pharmaceuticals Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vertex Pharmaceuticals Inc. The current cci is -37.44811368.

Vertex Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vertex Pharmaceuticals Inc. The current cmo is -6.71027519.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Vertex Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Vertex Pharmaceuticals Inc. The current willr is -62.82372598.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vertex Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

Vertex Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vertex Pharmaceuticals Inc. The current atr is 7.39145926.

Vertex Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vertex Pharmaceuticals Inc. The current obv is 82,426,445.

Vertex Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vertex Pharmaceuticals Inc. The current mfi is 42.38.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

MFI < 50: -1

Vertex Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Vertex Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-11-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-01	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-07	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2023-12-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-12	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-13	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-20	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2023-12-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-29	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-03	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-09	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-01-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-01-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-16	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-17	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-18	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-23	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-24	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-30	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-31	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-02	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-06	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-09	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-12	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-13	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-15	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-16	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-20	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-22	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-23	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-26	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-02-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-29	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-01	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-03-04	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-05	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-06	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-14	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-21	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-22	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-03-26	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-03-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-28	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-04-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-02	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-03	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-04-04	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-10	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-22	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.

6.3. Candlestick Patterns

Vertex Pharmaceuticals Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Vertex Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	43.237
Ma 20	Greater than	Ma 50	404.729
Ma 50	Greater than	Ma 100	413.251
Ma 100	Greater than	Ma 200	409.604
Open	Greater than	Close	397.730
Total			2/5 (40.0%)

Create your own Symbol Scanner

Get notifications about Vertex Pharmaceuticals Inc

I send you an email if I find something interesting about Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc Buy, Hold or Sell?

Let's analyse Vertex Pharmaceuticals Inc together

Get notifications about Vertex Pharmaceuticals Inc

Quick analysis of Vertex Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Vertex Pharmaceuticals Inc (5 min.)

$399.92

$67.38

$-13.63 - $113.08

$53.76 - $180.47

2. Growth of Vertex Pharmaceuticals Inc (5 min.)

Is Vertex Pharmaceuticals Inc growing?

How much money is Vertex Pharmaceuticals Inc making?

How much money comes from the company's main activities?

3. Financial Health of Vertex Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc? (5 min.)

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Vertex Pharmaceuticals Inc

About Vertex Pharmaceuticals Inc

Financial Health

Valuation

1.1. Profitability of Vertex Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Vertex Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Vertex Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Vertex Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Vertex Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Vertex Pharmaceuticals Inc
Buy, Hold or Sell?